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Abstract 
 
Introduction 
Ulcerative colitis (UC) which is a form of inflammatory bowel disease (IBD) is characterised 
by a relapsing and remitting disease course. Clinical disease activity indices (DAIs) are used 
to assess the severity of the disease activity relying solely on the clinical symptomatology of 
the patients. Non-invasive biomarkers help in assessment and possibly predicting the 
disease relapse. Although faecal calprotectin (FCP) is one such biomarker that is extensively 
researched, its accuracy in assessment and prediction of relapse is only modest. Similarly 
endoscopy in IBD with white light examination (WLE) alone is not accurate in either the 
assessment of disease activity or the prediction of disease course. Narrow band imaging 
(NBI) allows examination of the vasculature and pit pattern of the mucosa in greater detail 
than WLE. Patients with colonic IBD also have a higher risk of developing dysplasia or 
colorectal cancer (CRC). Chromoendoscopy (CE) provides a contrast enhancement and 
aids in highlighting the dysplastic areas.   
Aims 
Primary aim of the research is to assess the role of advanced endoscopy, NBI and 
Chromoendoscopy (CE) in assessment of disease activity and dysplasia detection 
respectively in UC. The secondary aim is to assess the role of DAIs in assessment of 
disease activity, their correlation with endoscopic & histological markers and overall 
outcomes during the follow up period.  
Methods 
We performed two different experiments using advanced endoscopic techniques for this 
research project; one is in assessment of inflammatory activity and second is in detection of 
dysplasia in UC.  
We performed retrospective analysis of our practice to identify if white light alone predicts 
relapse in patients with quiescent UC. Based on our findings we devised a prospective 
observational study to look at the effect of adding NBI to WLE in assessment of disease 
activity in patients with UC of varying grades of severity. As newer generation of NBI (H290 
series of Olympus KeyMed®) endoscopes were being introduced into the UK market at the 
time of the study, we compared the effect of NBI in three generations of endoscope (Q240, 
H260 and H290 series). We also assessed the use of Raman spectroscopy in endoscopic 
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and histological assessment of inflammation in UC.  
In another retrospective study we looked at the uptake of chromoendoscopy in surveillance 
colonoscopies in UC. A randomised controlled study (RCT) was also designed to compare 
high definition WLE (HDWLE) to high definition CE (HDCE) in detecting dysplasia in UC 
surveillance. As part of relapse-prediction work we also conducted a meta-analysis of 
published RCTs on FCP to analyse its predictive capability in IBD. 
Results  
In the retrospective analysis, we found that the presence of either Mayo Endoscopic 
Subscore >1 or Geboes score ≥2.1, increases the risk of relapse up to 6 times in the 
subsequent twelve months period. In our comparative study of NBI in three different 
generations of endoscopes, we demonstrated that NBI is superior to WLE in the assessment 
of the presence of blood. We also noticed a significant improvement in NBI in the newer 
generation of endoscopes (H290 and H260) compared to the earlier endoscopes (Q240). 
From the meta-analysis of RCTs we found that the FCP can predict disease flare with an 
accuracy of up to 75% only. In the observational study we determined that addition of NBI to 
WLE did not provide additional value in either assessment of disease activity or predicting 
relapse. Among the clinical disease activity indices (DAIs), the simple clinical colitis index or 
Walmsley index with score of ≥3 correlated well with endoscopy and histological findings. 
From the Raman spectroscopy study we identified the intensities of peaks (carotenoid and 
the phospholipids) that were statistically significantly different between the Raman spectra of 
the inflamed and quiescent colonic tissue. 
In our second retrospective analysis CE was found to be superior to WLE in detecting all 
dysplastic lesions and the detection of endoscopically visible flat non-polypoid lesions. 
However CE was performed only in one third of the study population. In the RCT we found 
that HDCE has an incremental yield of about 12.7% with a NNT of about 8, suggesting that 
HDCE would detect one additional patient with a dysplastic lesion for every 8 patients on 
whom this procedure is done. 
Conclusion 
The thesis has shown that endoscopic biomarkers and FCP do not reliably predict relapse in 
UC. Addition of NBI does not confer added benefit in assessment of disease activity. HDCE 
is superior to HDWLE and should be adapted as a standard practice in surveillance of 
dysplasia in UC.  
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1 Introduction 
 
Ulcerative colitis 
Ulcerative colitis (UC) is a chronic inflammatory condition of unknown aetiology, 
characterized by diffuse and confluent mucosal inflammation of the colon starting from the 
rectum with a characteristic relapsing and remitting course(1). Conventional endoscopy was 
thought to be a reliable parameter for assessment of disease activity(2), but microscopic 
inflammation can persist despite normal mucosal findings(3). Histologically detectable 
inflammation is thought to be associated with a greater risk of subsequent relapse(4, 5). A 
flare in UC activity is difficult to predict, but a simple, easily measured biological marker of 
relapse would be important in guiding the most appropriate and cost-effective therapy.  
Approximately 25% of patients with UC experience acute exacerbation of their disease 
activity during the course of their disease(6). Colectomy rate increases with more than one 
hospital admissions with acute severe UC, reaching up to 40% after two admissions (7). 
Therefore the treatment goals in UC must focus on keeping the disease in remission and a 
colectomy-free survival. 
 
Mucosal healing in UC 
Although there is no consensus definition of mucosal healing, ‘International Organisation of 
Inflammatory Bowel Disease’ proposed the following criteria to define mucosal healing: 
absence of friability, blood, erosions and ulcers in all visualised segments of the gut 
mucosa(8). Essentially disappearance of endoscopic lesions such as erosions and ulcers is 
called as mucosal healing. Drugs such as 5-aminosalicylates (5 ASA) (delayed release and 
multimatrix mesalamine), Immunomodulators like azathioprine, methotrexate and infliximab 
are used in induction and maintenance of MH in UC (9-15). MH is associated with favourable 
short and long-term clinical outcomes like reduced hospitalisation due to flares decreased 
colectomy rates and lower incidence of colorectal cancers(16-20). MH is increasingly 
recognised as a therapeutic endpoint not only in clinical trials but also in routine clinical 
practice. 
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Assessment of disease activity in UC 
 
Assessment of disease activity in UC is performed by clinical, biochemical and endoscopic 
measures. Each of these parameters is described in detail below.  
Clinical assessment of disease activity 
Clinical activity indices help physicians to assess the severity of the disease to optimise the 
treatment based on patients’ symptoms alone. Various assessment tools are available in 
clinical practice; some use clinical variables alone and others include a combination of 
clinical and biochemical markers.  Truelove and Witts severity index (TWSI)(21) described in 
1955 as a clinical assessment tool for disease activity in UC has been the widely used in 
clinical trials. The variables used are discriminative enough to assess the severity of disease 
and to be used in clinical practice. However, the major limitation of this scoring system is that 
it has never been validated externally. Stool frequency and presence of blood in the stools 
are the variables along with temperature, pulse rate and Erythrocyte sedimentation rate 
(ESR). A score of <4 is mild disease and >6 is considered as a severe disease. The 
variables are less clear for a moderate disease which is something in between mild and 
severe disease scores, and fulminant colitis is diagnosed if there is continuous blood in the 
stools necessitating blood transfusion. 
Clinical activity index (CAI) also known as Rachmilewitz index(22)  includes biochemical 
markers along with clinical parameters in the assessment tool. Additional subjective 
assessment of patient’s symptoms by the physician was allowed along with incorporating 
extra-intestinal manifestations of UC. This was subsequently validated in one study(23) in 
which a CAI score of ≤4 corresponded to clinical remission.  
Physician global assessment (PGA)(8)  is another non-validated, arbitrary measure of 
disease activity which ranges from 1 to 6. It is helpful in assessing response to therapeutic 
interventions from the baseline but lacks objective evidence to the scores described. One 
similar measure is Investigator global evaluation which allows physicians to rate patients’ 
symptoms on their objective assessment. 
Lichtiger et al(24) described a modified Truelove and Witts index for assessment of severity. 
This was an 8 point scoring system as opposed to 5 in TWSI, incorporating subjective 
assessment scores of the treating physician. Clinical remission was defined as a score less 
than ≤3 and clinical response to treatment was defined as a reduction of ≤10 points. 
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Walmsley et al(25) described a scoring system which was termed as ‘Simple clinical colitis 
index’ (SCCI). This score was an adaptation of clinical features from the Powell-Tuck index 
of severity and the general wellbeing component from the Harvey-Bradshaw index for 
Crohn’s’ colitis. The score was derived using various regression analyses; however, the 
original paper does not describe any cut off values for remission or relapse. This score has 
not been validated in clinical trials. Higgins et al in a prospective study described in 2005 that 
a score of <2.5 corresponds to patient defined clinical remission(26).  
More recently an ‘Ulcerative Colitis Clinical Score’ was proposed by Feagan et al(27). Stool 
frequency and rectal bleeding were the markers for objective evidence of disease activity. 
Symptoms such as abdominal pain, nocturnal diarrhoea were not considered in the score; 
however, subjective assessments and overall scores from both physician’s and patient’s 
perspective were included  
In an attempt to standardise the available clinical and endoscopic scores for UC, a study 
conducted by Japanese researchers evaluated the use of these scores in the previous one 
hundred clinical trials(28). They found that Rachmilewitz score, Sutherland index (also 
known as disease activity index-DAI), TLWSI, Mayo clinical score and Lichtiger score were 
the commonly used clinical indices in decreasing order of frequency.  These representative 
scores were then used to grade the disease prospectively before and after the treatment 
over 2, 4 and 8 weeks on the seventy-four recruited patients. Their results suggested that 
these scores were equally effective in assessing disease activity. However, this claim has 
not been verified by further studies. 
Endoscopic assessment of disease activity: 
Endoscopy is essential to establish a diagnosis of inflammatory bowel disease and also to 
distinguish UC from Crohn’s disease. Direct mucosal visualisation and obtaining biopsies for 
histological analysis is the advantage of endoscopy over other modes of assessment of 
disease activity. Endoscopic examination helps physicians to assess the extent & severity of 
the disease. In addition to this, it is a useful tool to identify and resect dysplastic lesions 
during surveillance for colorectal cancer and dysplasia.  
There are at least ten endoscopic scores designed to assess the disease activity in UC since 
the development of first such score by Baron et al in 1964(29) (Tables 1-5). Table 1 contains 
the different disease activity indices with only endoscopic variables and Table 2 contains the 
indices with non-endoscopic variables. These scores use clinical, biochemical and 
endoscopic components in an attempt to grade the disease activity. Endoscopic parameters 
of assessment include mucosal vascular pattern (MVP), friability and mucosal damage. 
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Mayo endoscopic subscore is an endoscopic component of full Mayo score(30). Both 
Modified Baron score and Mayo endoscopic subscore have been used in clinical trials; 
however, these scores have not been validated rigorously(8). 
 
Table 1 Disease activity indices with endoscopic component alone. 
Disease activity index Endoscopic variables  
Baron score(29) 
1964 
Bleeding  
MVP 
Rachmilewitz endoscopic index(22) 
1989 
Granulation 
MVP 
Mucosal vulnerability 
Mucosal damage 
UC colonoscopic index of severity 
(UCCIS)(31) 
2013 
MVP 
Granularity 
Ulceration 
Bleeding 
Segmental assessment of endoscopic severity 
Global assessment of endoscopic severity 
UC endoscopic index of severity 
(UCEIS)(32) 
2013 
MVP 
Bleeding 
Erosions  
Ulcers 
MVP= mucosal vascular pattern 
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Table 2 Disease activity indices with endoscopic and non-endoscopic components 
Disease activity index Endoscopic variables  Non-endoscopic variable 
Powell-Tuck score(2)  
1982 
Bleeding Wellbeing 
Abdominal pain 
Stool frequency & consistency 
Bleeding 
Anorexia 
nausea & vomiting 
EIM 
Temperature  
Sutherland index(33) 
1987 
Friability 
Bleeding 
Stool frequency 
Bleeding 
Physician’s rating of disease 
activity 
Mayo score(30) 
1987 
Erythema 
MVP 
Friability  
Erosions 
Ulcers 
spontaneous bleeding 
Stool frequency 
Bleeding 
PGA 
Improvement based on 
individual symptom 
scores(34) 
2002 
Mucosal oedema 
MVP 
Granularity 
Friability 
Petechiae 
Ulceration 
Spontaneous bleeding 
Rectal bleeding 
Stool frequency 
Abdominal pain 
PFA 
PGA 
EIM=Extra-intestinal manifestations, PFA=Patient functional assessment, PGA=Physicians global assessment. 
Mayo endoscopic subscore is widely used in the endoscopic assessment of the inflamed 
colon. Osada et al compared four endoscopic indices between expert and non-expert 
endoscopists (28). In the inter-observer analysis, kappa values for expert-endoscopist was 
found to be very good for Mayo endoscopic subscore. It is easy to use and intuitive to grade 
the inflammation; however, we felt there is little manoeuvrability in Grade 3 for grading 
superficial and deep ulcerations (Table 3). This was later addressed by the UCEIS which 
further categorises the endoscopic markers of severity in details. Whether this grading of 
inflammation will correlate with the disease outcomes is not known.    
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Table 3 Mayo Endoscopic subscore 
Score Description 
0 Normal / inactive disease 
1 Mild disease (Erythema, Decreased vascular pattern, Mild 
friability) 
2 Moderate disease (Marked erythema, absent vascular pattern, 
friability, erosions) 
3 Severe disease (Spontaneous bleeding, Ulceration) 
 
Assessment of inflammation using Baron Score included scores from 0-3; 0 was normal 
appearance and 3 was severely inflamed mucosa. The inflammation was graded 
predominantly using haemorrhage alone as the variable. It did not include mucosal friability, 
erosions or ulcerations. For the purposes of simplifying and including other endoscopic 
variables, a Modified Baron Score was proposed (Table 4)   
Table 4 Modified Barons index 
Score Description 
0 Normal, smooth, glistening mucosa with visible vascular pattern. No friability 
1 Granular mucosa, Obscure vascular pattern, erythema; no friability 
2 Score 1 + friability of mucosa. No spontaneous bleeding 
3 Score 2 but with spontaneous bleeding 
4 Score 3 but with ulceration and denuded mucosa 
 
Recently Travis et al designed and validated a new scoring system using endoscopic 
‘descriptors’ called ulcerative colitis endoscopic index of severity (UCEIS) (32, 35) (Table 5). 
Ten Inflammatory bowel disease (IBD) experts evaluated sigmoidoscopic videos of varying 
degree of endoscopic inflammation seen in UC. Inter and intra-investigator reliability was 
tested using Kappa statistics. In the validation phase, they report kappa values ranged from 
0.34 to 0.65 and 0.30 to 0.45 for inter and intra-investigator reliability respectively. No 
significant difference was observed when investigators were tested with or without the 
knowledge of clinical details of subjects. Whether this score can be used as a reliable 
endoscopic assessment tool in clinical trials and in general practice remains to be 
established. 
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Table 5 Ulcerative colitis endoscopic index of severity (UCEIS) 
Descriptor Descriptor 
Vascular pattern Normal (0)  
Patchy obliteration (1) 
Obliterated (2) 
Bleeding None (0)                                                                   
Mucosal (1)                                                             
Luminal mild (2)                                                
Luminal moderate or severe (3) 
Erosions and ulcers None (0)                                                    
Erosions (1)                                               
Superficial ulcer (2)                                                  
Deep ulcer (3) 
 
1.1.1.1 White light endoscopy (WLE) 
Endoscopic examination is commonly performed under white light for assessment of disease 
activity. Mucosal visualisation is improved greatly due to the advent of high definition 
endoscopes. However, mucosal evaluation varies among endoscopists owing to the lack of 
hard objective endpoints for variables such as mucosal friability, vulnerability and healing. 
Another factor such as relative lack of experience among endoscopists in grading the 
severity of the disease is also common. Moreover, it is known that inflammation persists 
despite the normal appearance of the mucosa under the white light which may result in 
subsequent relapse (2, 5, 38). Although white light examination is easy to perform for a quick 
assessment during relapse, factors such as lack of objective endpoints, variability among 
assessors and lack of predictive capacity for a relapse necessitates the search for an 
alternative, more advanced methods of mucosal assessment in IBD. 
1.1.1.2 Advanced endoscopic techniques 
Data on use of advanced imaging modalities such as autofluorescence imaging (AFI), NBI 
and magnification chromoendoscopy in the assessment of inflammatory activity in IBD are 
rare (36-41). Osada et al reported a close correlation between the green component of AFI 
with endoscopic (Mayo endoscopic subscore) and histological inflammation among UC 
patients(41). They also noted that as the inflammatory activity increased in the colon the 
green colour component of AFI decreased. Magnification chromoendoscopy involves topical 
application of dye onto the mucosa and visualisation of abnormal pit pattern using the zoom 
feature of the colonoscope. It is time-consuming, involves a steep learning curve and is 
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cumbersome which has resulted in low uptake despite superior diagnostic yield compared to 
WLI. Data available from a limited number of studies is encouraging in both detections of 
inflammation and prediction of relapse (42-45). NBI, in couple of small studies has shown 
improved diagnostic yield in the assessment of inflammation compared to white light 
examination alone(38, 46). NBI is easy to use and intuitive to the endoscopist; a button 
mounted on the endoscope handle is used to switch between WLI and NBI.  
 Advanced imaging techniques like high-resolution endoscopy, Narrow band imaging, Zoom 
endoscopy, chromoendoscopy helps in detailed assessment of mucosa and submucosal 
vasculature; however, the studies are rare and involved a small number of subjects and 
results are conflicting. The applicability of these techniques into routine clinical practice and 
value in predicting relapse needs further work. 
Biomarkers in the assessment of disease activity 
Biomarkers are measurable characteristics that reflect the presence of disease state or its 
severity. These could be specific cells, molecules, genes, gene products, enzymes, 
hormones or organ function. They must indicate a change in expression or state of a protein 
that correlates with the risk or progression of a disease.  
An ideal biomarker must be helpful in diagnosing plus monitoring the disease activity and 
also predicting a relapse. It must also correlate with the susceptibility of the disease to a 
given treatment. It must be non-invasive, ideal to be used for all age group of patients, quick 
and easy to perform. Desired characteristics of a biomarker include reliability (high sensitivity 
and specificity), stability from degradation factors, and independent of physiological, 
molecular or diurnal changes.  
Biomarkers can be serological such as C reactive protein (CRP), erythrocyte sedimentation 
rate (ESR), white blood cell count (WBC), platelet count, 1-acid glycoprotein, serum amyloid 
A-protein, 2-globulin, lactoferrin, orosomucoid and thrombopoietin; or they could be faecal 
markers such as Faecal calprotectin (FCP), Lactoferrin, DNA excretion, Myeloperoxidase, 
Faecal immunohistochemistry testing (FIT). Commonly used biomarkers in UC include WBC, 
Platelet count, CRP, ESR and FCP.  
The primary application of biomarkers in IBD is to reliably differentiate it from irritable bowel 
syndrome; others include disease monitoring and reliably predicting a flare. Flare-ups in UC 
are unpredictable, a real health economic burden, and have a devastating impact on quality 
of life (QOL) of patients. In this era where physician’s therapeutic armamentarium is 
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strengthened by the availability of potent drugs like biologic therapies, prediction of flares 
could help to escalate medications to prevent flare and its implications.  
1.1.1.3 C reactive protein (CRP): 
C reactive protein (CRP) was first discovered by Tillett and Francis in 1930(47). It was seen 
reacting to C-polysaccharide of Pneumococcus and hence the name CRP. It is synthesized 
in the liver in response to macrophages and adipocytes. It is detected in serum from 6 hours 
of inflammation which peaks at 48 hours (half-life around 19 hours). CRP acts as bactericidal 
protein by activating complement system and in phagocytosis of bacterial nuclei(48). 
CRP has been extensively investigated in diagnosing, monitoring and predicting the disease 
flare in IBD. In a prospective study to evaluate the usefulness of CRP in adult patients with 
chronic abdominal pain (n=82), Shine et al(49) found that all the patients subsequently 
diagnosed as Crohn’s disease (19/19) and half the patients with UC (11/22) had elevated 
CRP. Interestingly none of the 41 patients with functional abdominal pain had elevated CRP. 
Similar results were found in the paediatric population(50). Moreover, CRP elevation was 
found to correlate well with clinical, endoscopic and histological inflammation in IBD(51). 
CRP is commonly used in monitoring disease activity and to evaluate the response to 
treatment. A significant correlation between CRP and simple clinical colitis index was noted 
in prospective studies while monitoring the disease activity in patients with acute flare-up of 
UC requiring hospitalisation (52, 53). However, the evidence for CRP as a tool to predict 
flares is conflicting (See 1.1.4.2). CRP is easy to perform, inexpensive, and a reliable test to 
differentiate patients with IBD from functional gastrointestinal disorders. It is hence widely 
used as a screening tool both in primary and secondary care services. 
1.1.1.4 Faecal calprotectin 
Faecal calprotectin (FCP) was first described in 1980. Calprotectin is a calcium and zinc 
binding protein belonging to the SA100 group of proteins. It is found predominantly in the 
cytosol of neutrophils and to a lesser extent in monocytes and reactive macrophages. It is 
available in abundance in body fluids which is resistant to bacterial or enzymatic 
degradation. Calprotectin constitutes about 60% of the cytosolic protein in the granulocytes 
and about 5% of total body protein(54). Intestinal inflammation is marked by the influx of 
inflammatory cell infiltrates in the mucosal lining. Breakdown of cytosolic protein liberates 
calprotectin in the faeces the concentration of which is found to be proportional to the 
intestinal inflammation(55) and white cell scanning (56). A spot test of <5gm of faeces is 
shown to be as reliable as 24-hour stool collection and can remain stable for up to 7 days in 
room temperature (54). It can be readily quantified using enzyme-linked immunoassay 
testing (ELISA). FCP is hence classed as a ‘damage-associated molecular pattern’ protein 
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and seems to fulfil the desirable qualities of a non-invasive surrogate marker of intestinal 
inflammation. Elevated FCP levels are seen in patients with non-steroidal anti-inflammatory 
drug (NSAID) intake, and other non-IBD causes such as infective enteritis, untreated coeliac 
disease, diverticulitis, intestinal bleeding and malignancies(57-59). Other drugs which could 
potentially influence FCP levels, but lacks evidence, are proton pump inhibitors (PPIs) and 
Nicorandil (which is known to cause mucosal ulcerations in the gastrointestinal tract).   
1.1.1.5 Role of faecal calprotectin in IBD: 
FCP levels are used in discriminating between irritable bowel syndrome (IBS) from IBD with 
a specificity of 97-100% and a negative predictive value of 100% (Table 6).  There is no 
convincing evidence that FCP levels can differentiate between subtypes of IBD; however, 
their levels correlate well significantly with endoscopic disease activity in IBD(60). This 
simple test appears useful in clinical practice for non-invasive assessment of disease in 
activity and in remission. In a meta-analysis of thirty prospective trials including 5983 
subjects, FCP levels were found to be elevated in IBD population compared to normal 
subjects with a sensitivity of 95% and specificity of 91%. In the same study, a non-significant 
elevation of FCP was observed with a sensitivity and specificity of 36 % and 41% 
respectively. This makes FCP unreliable tool for colorectal cancer screening(59). Another 
meta-analysis of 13 prospective studies including 670 subjects evaluated the diagnostic 
accuracy of FCP. In these studies FCP when used as a screening tool resulted in reduction 
of 67% of endoscopic examinations(61).  
Table 6 Studies on role of Calprotectin in differentiating IBD from IBS 
Study design Study characteristics Findings 
Tibble et al(62) 
Prospective study 
220 subjects with abdominal symptoms. 
Radiological/Histological diagnosis of CD. 
IBS-ROME criteria (CD / IBS. UC 
excluded) 
FCP >30mg/L was 100% 
sensitive and 97% specific 
in discriminating IBS v/s 
IBD 
Dolwani et al(63) 
Prospective 
73 patients undergoing SMFT for   ? IBD.  
25 IBS & 25 normal controls. 
FCP >60mcg/gm predicted 
abnormal small bowel 
radiology. 100% NPV. 
Sydora et al(64) 
Prospective 
50 participants. 
Diagnosed UC, CD, IBS and normal 
volunteers.  
FCP levels were high in 
CD/UC compared to IBS & 
normal volunteers. 
100% specific for IBD pts. 
IBS= Irritable bowel syndrome, IBD=Inflammatory bowel disease, NPV=Negative predictive value, UC=Ulcerative 
colitis, CD=Crohn’s disease 
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1.1.1.6 Calprotectin in disease monitoring  
FCP is used in monitoring response to treatment in acute severe colitis and in those on 
maintenance therapy. Significantly high levels of FCP were found in patients admitted with 
acute severe colitis requiring colectomy and in those who were non-responders to 
corticosteroid or infliximab therapy(65). Normalisation of FCP levels correlated well with 
disease remission (clinical, endoscopic and histological) in a small study where the 
maintenance therapy was either with 5-aminosalicylates (5ASA) or azathioprine (66). 
However results from studies looking at monitoring disease activity with FCP in patients on 
Infliximab therapy vary widely. Tursi et al(67) reported that FCP is better at predicting 
persistence of inflammation than complete remission (Positive predictive value of 96.2% 
versus 41.8%). On the other hand de Vos et al reported that rapid decline in FCP levels 
induced by infliximab resulted in lasting disease remission(68). The data on FCP levels in 
post-operative patients with Crohn’s disease and risk of recurrence is conflicting (69-71). 
Histological assessment of disease activity 
Histology is the gold standard in the assessment of the mucosal activity in UC. Various 
histological indices are available for grading the inflammatory activity (3, 20, 21, 72-77). 
There are at least 18 scoring systems available for histological assessment in UC, however 
none of these are validated externally(78).  
Researchers have tried to compare the endoscopic findings to the histological inflammation 
seen(74, 75), however to the best of our knowledge there is no study comparing these score 
head-to-head in accuracy of assessment. A recent study has shown some correlation 
between the endoscopic findings and histological activity only in the extremes of the 
disease(79).  
Histological findings have also been used to predict clinical outcomes. Bitton et al in 2001 
demonstrated histological markers of predicting a flare in quiescent UC. There are growing 
numbers of publications exploring this further. These are discussed in detail in subsequent 
chapters.  
The three scores used in our research studies are as below 
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Riley index 
Acute inflammatory cell infiltrates (Polymorphonuclear cells in Lamina propria)                                                                                                     
1-None, 2-Mild, 3-Moderate, 4-Severe 
Crypt Abscesses:                                                                                                                                                                                     
1-None, 2-Mild, 3-Moderate, 4-Severe 
Mucin Depletion:                                                                                                                                                                                    
1-None, 2-Mild, 3-Moderate, 4-Severe 
Surface epithelial Integrity:                                                                                                                                                                   
1-None, 2-Mild, 3-Moderate, 4-Severe 
Chronic inflammatory infiltrate:                                                                                                                                                                          
1-None, 2-Mild, 3-Moderate, 4-Severe 
Crypt architectural irregularities:                                                                                                                                                                        
1-None, 2-Mild, 3-Moderate, 4-Severe 
 
 
Histologic Inflammatory activity (HIA) Score: (Rubin Score) 
 
Scores & description. 
 
0 Normal (completely uninvolved, no architectural distortion, no infiltrates 
1 Quiescent (architectural distortion, increased lamina propria lymphocytes, but no activity)                                         
2 Increased lamina propria granulocytes without definite intraepithelial granulocytes                                          
3 Intraepithelial granulocytes (e.g. cryptitis) without crypt abscesses                                                                                  
4 Crypt abscesses in less than 50% of crypts                                                                                               
5 Crypt abscesses in greater than 50% of crypts, or erosion/ulceration 
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Geboes score 
Grade 0 Structural (architectural change) 
0.0 No abnormality  
0.1 Mild abnormality 
0.2 Mild or moderate diffuse or multifocal abnormalities 
0.3 Severe diffuse or multifocal abnormalities  
Grade 1 Chronic inflammatory infiltrate 
1.0 No increase  
1.1 Mild but unequivocal increase  
1.2 Moderate increase  
1.3 Marked increase  
Grade 2 Lamina propria neutrophils and eosinophils 
2A Eosinophils                                                             2B Neutrophils 
2A. 0 No increase.                                                         2B.0 None  
2A.1 Mild but unequivocal increase                               2B.1 Mild but unequivocal increase 
2A.2 Moderate increase                                                 2B.2 Moderate increase  
2A.3 Marked increase                                                    2B.3 Marked increase  
Grade 3 Neutrophils in epithelium 
3.0 None  
3.1 < 5% crypts involved  
3.2 < 50% crypts involved 
3.3 > 50% crypts involved 
Grade 4 Crypt destruction 
4.0 None 
4.1 Probable—local excess of neutrophils in part of crypt 
4.2 Probable—marked attenuation 
4.3 Unequivocal crypt destruction 
Grade 5 Erosion or ulceration 
5.0 No erosion, ulceration, or granulation tissue 
5.1 Recovering epithelium and adjacent inflammation 
5.2 Probable erosion—focally stripped 
5.3 Unequivocal erosion 
5.4 Ulcer or granulation tissue 
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Prediction of relapse in UC 
Various clinical activity indices, serum, faecal, endoscopic and histological markers have all 
been used in the clinical trial to predict short and long-term outcomes in IBD(4, 40, 71, 80-
83).  The results are conflicting and at times confusing owing to the use of differences in 
activity indices, biomarkers and definitions of relapse used in these studies. 
Can disease activity indices predict relapse in UC? 
Approximately ten disease activity indices are available for use in UC as mentioned above. 
Some have been more commonly used than the others in clinical trials. Studies looking at 
the outcomes in using clinical activity indices alone are rare. They are usually used in 
conjunction with other parameters such as serum/faecal biomarkers, endoscopic or 
histological variables(80, 84).  Data from these studies suggest that clinical activity indices 
have a reasonable role to play in the assessment of inflammatory activity but have little in 
the way of predicting outcomes.  
Can biomarkers predict relapse? 
1.1.1.7 C-Reactive Protein (CRP) 
Bitton et al(4) evaluated the clinical, biochemical, endoscopic and histological predictors of 
relapse in UC patients. 74 adult patients with quiescent colitis were followed up for a year or 
until an episode of relapse. Younger age, multiple relapses and histological finding of basal 
plasmacytosis were found to be predictors of relapse within 12 months but not CRP. On the 
other hand, Consigny et al(85) reported a CRP>20 in association with ESR >15 mm/hour 
predicted flare up within 12-18 months in patients with IBD in clinical remission (sensitivity 
89% and specificity 43%).  
1.1.1.8 Faecal calprotectin 
Extension of the role of FCP in the prediction of a flare-up in IBD has drawn a lot of attention 
recently. The results in the published literature are variable. A meta-analysis involving six 
studies and 672 IBD patients found that elevated FCP levels predicted flare-up of disease in 
the following twelve months with a sensitivity of 78% and a specificity of 73%(86).  Whilst 
FCP seems to have a role in predicting the course of IBD the sensitivity and specificity found 
in this meta-analysis were not as high as expected. Serial measurements of FCP are found 
to be more helpful than a baseline reading to improve the accuracy of prediction. Further 
research is required to substantiate this finding.  
1.1.1.9 Histological markers 
Acute inflammatory infiltrates, crypt abscesses, mucin depletion are associated with 
increased risk of relapse of up to two to three-fold in subsequent twelve months (5). 
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Presence of increased amount of plasma cells in the lower third of the mucosa is termed as 
‘basal Plasmacytosis’-which was the feature associated with up to 4.5 fold increased risk of 
flare-up within 12 months’ time (4, 82). Feagin et al noted that basal lymphoplasmacytosis, 
basally located lymphoid aggregates and markers of more severe inflammation such as 
erosions and ulcerations were all associated with risk of relapse(16). On the other hand 
complete mucosal healing is associated with lesser relapse rates and lower colectomy rates 
(87). 
Can advanced endoscopy predict relapse? 
Advances in endoscopy such as High definition white light endoscopy (HD-WLE), Narrow 
Band Imaging (NBI), Autofluorescence imaging (AFI), Chromoendoscopy (CE), and 
Magnification Chromoendoscopy have all been investigated to assess the accuracy in 
assessment and prediction of clinical outcomes. Kudo et al(38) included 30 patients with 
quiescent colitis in their study in which they examined the mucosal vascular pattern of colon 
with standard white light endoscopy (WLE) and NBI. For assessment of disease activity the 
examination was performed by arbitrarily dividing the colon into segments. They reported 
that with the use of NBI the segments that were identified as ‘abnormal’ by the WLE, were 
further characterised into either ‘clear’ or ‘obscure’ (WLE- 60 normal & 97 abnormal 
segments, NBI-60 normal & 44-clear, 53-obscure). This was further corroborated with 
histological findings where the obscure segments showed raised acute inflammatory 
infiltrates, goblet cells and basal plasmacytosis. In another study Jauregui-Amezaga et 
al(40) reported that use of NBI did predict flare up in quiescent UC patients in 12 months 
follow up period. 
Magnification colonoscopy with chromoendoscopy in one study from Japan(42) has shown 
similar benefits when they examined the pit pattern of rectal mucosa of quiescent patients. 
They found that the grade of pit-pattern irregularity/disruption correlated with the severity of 
histological inflammation and also predicted the flare.  
Unfortunately all these studies are limited by the low number of recruits. The other limitation 
is that the endoscopies were performed by expert and hence results might not equate to 
findings by endoscopists with no such advanced skills. There is also a steep learning curve 
to master the techniques of optical diagnosis.   
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Narrow Band Imaging  
Narrow band imaging (NBI) is also called ‘virtual chromoendoscopy’. By digitally enhancing 
the optical image NBI helps better visualisation of the blood vessels and mucosal surface 
pattern. This is developed to help endoscopist identify lesions by live contrast enhancement. 
In addition to the components of the conventional endoscopes, NBI system has a special 
image processor and an image filter. The system is activated and deactivated by pressing a 
button placed on the handle of an endoscope.  
Principles of Narrow Band Imaging 
Light is an electromagnetic wave, and the peak to peak distance is called as “wavelength” 
which is measured in nanometres (nm). Wavelengths of light visible to the human eye as 
white colour are between 400-700nm, in which 400nm is seen as blue, 550nm is seen as 
green and 700 is seen as red colour. Light when illuminated on objects undergoes 
absorption, reflection and scattering. Light with a wavelength between 400-550nm gets 
absorbed more as it has less penetration and scatter. And the light between 550-700nm 
penetrates deeper and gets reflected more. The reflected light helps us to perceive the 
colour of the given object. Narrow band imaging is the technology which relies on the 
principle of depth of penetration of the light to visualise the tissue in wavelengths between 
400-550 nm. NBI filters decrease the wavelengths of the lights illuminated; the blue light is 
centred at 415nm and the green lights at 540 nm. The blue filter is designed to correspond to 
the spectrum at which haemoglobin absorption is at its peak. Submucosal vessel vascular 
structures are enhanced by light at 540nm. Therefore these dual wavelengths of light have 
less penetration and scatter into the deep submucosal tissue. These, in turn, are absorbed 
strongly by the haemoglobin and hence capillaries on the mucosa are optically enhanced on 
NBI. The reflected image is captured by a charged coupled device chip (CCD). The resultant 
merged image displayed on the screen thus highlights mucosal vascular pattern with greater 
enhancement than with white light. Figures 1 and 2 describe these principles schematically 
(see below). 
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Figure 1 Schematic diagram of NBI filters to decrease wavelengths  
The wavelengths of blue and green lights filtered through the RGB filter are centred to 415 and 540 nm.  
Image courtesy Olympus Keymed®  
 
 
 
Figure 2 Schematic diagram showing the dispersion of light 
This diagram shows the mechanism of penetrance, reflection and absorption of blue and green light. The blue 
light penetrates and scatters less than the others as a result of which superficial mucosa is visualised in great 
detail. Capillaries on the mucosal surface are highlighted as brown colour as the blue light is readily absorbed by 
haemoglobin. 
Image courtesy Olympus Keymed®  
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Narrow Band imaging in colorectal diseases. 
NBI is extensively studied to assess the accuracy of diagnosing and characterising 
gastrointestinal lesions. When used with magnification, NBI has high diagnostic yield for 
high-grade dysplasia and specialised intestinal metaplasia in Barrett’s mucosa with 
sensitivity, specificity and diagnostic odd’s ratio of 95%, 65% and 37.53 respectively(88). 
NBI has the highest diagnostic yield and inter-observer agreement compared to WLE and 
Autofluorescence imaging (AFI) when used for characterisation of colonic polyps. 
Furthermore, NBI with magnification is highly accurate in characterising colonic polyps 
<10mm with a detailed assessment of mucosal pit pattern and vascular pattern. Combination 
of these factors increases the diagnosis as opposed to using pit pattern alone (sensitivity of 
98% p=0.006)(89). NBI International Colorectal Endoscopic (NICE) classification is simple 
and well-established methods for characterisation of polyps(90). It utilises colour, mucosal 
pit pattern and vascular architecture to classify colorectal polyps. Advantages of using this in 
clinical practice include that it does not require magnification colonoscopes, has a high 
diagnostic accuracy, sensitivity and negative predictive value in differentiating neoplastic 
from non-neoplastic lesions (89%, 98% and 95% respectively)(91). Whilst use of NBI has 
clear advantages in the characterisation of polyps in colorectum, the results on adenoma 
detection are disappointing. NBI did not improve detection of adenomas compared to high 
definition WLE in a randomised controlled trial in patients at risk of developing colonic 
adenomas(92). Cochrane review of eleven randomised controlled trials involving 3673 
participants did not find evidence to support NBI is superior to WLE in improving colorectal 
polyp or adenoma detection(93). Use of NBI in long-standing colitis for detection of 
dysplastic lesions has not been encouraging either. Randomised controlled trials comparing 
NBI with WLE and CE did not show improvement in detection of dysplastic lesions(94, 95).  
Figures 3 shows an area of the colon examined under white light and NBI. The superficial 
mucosal vasculature looks brown under NBI as the haemoglobin in the capillaries readily 
absorb the blue light; whereas the submucosal veins appear cyan owing to lesser 
haemoglobin concentration. Furthermore, the pit pattern on the mucosa looks more 
prominent under NBI compared to white light (Figures 4) 
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Figure 3 Normal colonic mucosa in white light (left) and in Narrow band imaging (right) 
White light and narrow band examination of the normal colonic mucosa. NBI enhances 
mucosal capillary network (brown). Submucosal vessels are seen with cyan tinge.  
 
 
Figure 4 A sessile polyp seen with white light (left) and Narrow band imaging (right) 
A sessile polyp in the rectum is examined under white light and narrow band imaging. NBI 
enhances the surface pit pattern and improves the characterisation of the polyp. 
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Chromoendoscopy  
Adenoma detection at colonoscopy is one of the established quality indicators of 
colonoscopy outcomes. Dye spraying or ‘conventional chromoendoscopy’ (CE) is the 
application of dyes like indigo carmine or methylene blue to the colonic mucosa to improve 
identification of mucosal abnormalities.  Early adenoma detection and resection reduces the 
development of colorectal cancer (CRC) and related mortality(96, 97). National Institute for 
clinical excellence (NICE) has recommended routine use of CE in surveillance 
colonoscopies for long standing Ulcerative colitis and colonic IBD. 
Cancer risk in long-standing IBD 
Duration, extent, the involvement of terminal ileum (backwash ileitis), primary sclerosing 
cholangitis, the presence of endoscopic and histological inflammation, family history of CRC 
are well-known risk factors for the development of colorectal cancer (CRC) in UC 
patients(20, 98-102). Risk of CRC increases with the extent of the disease ranging from 1.7 
fold for proctitis to 14.8 fold rise for pancolitis, compared to the general population(103). The 
absolute risk of developing CRC in patients with pancolitis after 35 years of the disease is 
calculated at 30% in the same study. Owing to this risk, surveillance colonoscopy is 
recommended to detect early dysplastic lesions in long-standing UC patients.  
Endoscopic surveillance for dysplasia 
Various advanced endoscopic imaging techniques were tried to improve detection of 
dysplasia in surveillance colonoscopies. First generation NBI did not improve diagnostic 
ability compared to WLE in an RCT conducted by Dekker et al(104).  HDWLE was found 
equivalent to NBI in detecting dysplastic lesions in two subsequent RCTs. (94, 105). In a 
randomised cross-over trial, NBI when compared with chromoendoscopy marginally 
improved withdrawal time (26.87 ± 9.89 minutes vs 15.74 ± 5.62 minutes, P < .01) and 
showed significantly low false positive and false negative rates for dysplasia detection on 
targeted biopsies (p<0.001); however, missed rates for intraepithelial neoplasia were higher 
with NBI(95). These results questioned the use of NBI in UC surveillance (Table 7).  
AFI has been used extensively in the detection of dysplasia in UC. In a randomised trial of 
tandem colonoscopies, WLE, NBI and AFI (tri-modal imaging) were used for detection and 
characterisation of dysplastic lesions. In this small study involving 50 patients, AFI was found 
to improve detection and predict neoplasia in histology(106). In a large multi-centre 
randomised controlled study, AFI was compared with chromoendoscopy in detecting 
dysplasia in patients with long standing UC(107). The results suggested that the AFI did not 
meet the criteria for a larger non-inferiority study and that the technology should not be 
offered as an alternative in dysplasia surveillance in UC.  
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Confocal laser endocytoscopy (CLE) is a novel imaging technique which allows in vivo 
analysis of the tissue histology with high accuracy in distinguishing normal, regenerative and 
neoplastic tissues(108, 109). In a randomised controlled trial, conventional colonoscopy with 
random biopsies was compared with chromoendoscopy with CLE and targeted biopsies. A 
4.75 fold increase in detection of neoplastic lesions was noted in CE+CLE group (p=0.005), 
although 50% fewer biopsies were required (p=0.008)(110). Although CLE with 
chromoendoscopy guided targeted biopsy has excellent outcomes, routine use of this 
technique is not only time consuming and tedious but involves a steep learning curve. Table 
7 provides a summary of the studies using advanced endoscopic modalities to improve the 
detection of dysplasia in long-standing UC. 
Role of chromoendoscopy in UC 
Due to the increased risk of cancer in long-standing UC population(111) endoscopic follow 
up is recommended for early detection of dysplastic lesions. Random colonic biopsies (up to 
30-40 per patient) have been the mainstay of detecting dysplasia. Chromoendoscopy 
improves adenoma detection in UC patients by contrast enhancement of dysplastic lesions. 
Meta-analysis of six randomised controlled studies including 1277 patients comparing the 
diagnostic yield of dysplastic lesions between WLE and CE clearly demonstrated the 
superiority of CE. In this study 44% more dysplastic lesions on targeted biopsies [95% 
Confidence interval (CI) 28.6-59.1] and 27% more flat lesions (95% CI 11.2-41.9) were 
diagnosed with CE(112). Available data unequivocally demonstrated the usefulness of CE 
over WLE.  The newer generation of colonoscopes equipped with high definition image 
quality has improved detection of colonic polyps(113). When used in surveillance 
colonoscopies in long-standing UC similar results were found(114).  However, there is no 
data available comparing HD colonoscopy with or without CE. The British Society of 
Gastroenterology guidelines recommend using CE for surveillance colonoscopies in patients 
with colonic IBD(115)   
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Table 7 Diagnostic value of advanced endoscopic imaging methods in UC.   
Author (year) Study design Endoscopic 
modalities 
Total 
number 
of 
patients 
Number of patients 
with dysplasia 
Kiesslich et 
al(116). 
(2003) 
Randomized 
controlled trial 
 
CE v/s WLE 165 32with CE  vs 10 with 
WLE 
Hlavaty et 
al(117). 
(2011) 
 
Tandem 
colonoscopy 
 
CE vs WLE 20 7with CE vs  
0 with WLE 
Dekker et 
al(104). 
(2007) 
 
Randomized 
controlled trial 
 
NBI vs WLE 42 9 with NBI vs 
12 with WLE 
van den Broek 
et al(105). 
(2011) 
 
Randomized 
controlled trial 
 
NBI vs HDWLE 48 13 with NBI vs 11with 
HDWLE 
van den Broek 
et al(106) 
(2008) 
Randomised 
controlled trial 
AFI vs WLE. 
Detected lesions 
analysed by NBI 
50 AFI-first:  
10 with AFI  
0 additional lesion 
detected by WLE 
WLE-first:  
3 with WLE  v/s 6 
additional lesions 
detected by AFI 
Kiesslich et 
al(110) 
(2007) 
 
Randomised 
controlled trial 
CE+CLE 
targeted 
biopsies VS 
WLE with 
random biopsies  
153 19 with CE+CLE vs 
4 with WLE  
Vleugels et 
al(107) (2018) 
Randomised 
controlled trial 
AFI versus CE 
in surveillance 
of long standing 
UC 
210 Dysplasia was detected 
in 12% (13 patients) in 
AFI arm and 19% (20 
patients) in the CE arm 
 
CE-chromoendoscopy, NBI-Narrow Band Imaging, WLE-White light endoscopy, HDWLE-High definition white 
light examination, CLE-Confocal Laser Endomicroscopy, VS-versus, AFI-Autofluorescence Imaging.  
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Uptake of chromoendoscopy in clinical practice 
Chromoendoscopy refers to the application of diluted indigo carmine or methylene blue to 
the colonic mucosa to highlight subtle mucosal abnormalities. By providing a rim of contrast 
around the lesions, CE helps in detection, delineation, and characterisation of dysplastic 
tissue. There is growing evidence to suggest CE is superior in detecting dysplasia in UC 
surveillance compared with the standard white light examination (WLE). A Meta-analysis 
including 665 patients from 6 studies in 2013 confirmed that CE detects more dysplastic 
lesions compared to random biopsies obtained from standard WLE(118). CE is 
recommended by British Society of Gastroenterology(119) and European Crohn’s and Colitis 
Organisation(120) as a preferred method of surveillance in colonic IBD. Similar to the studies 
from the UK, a recent physician survey from Canada looked at the practice of surveillance 
colonoscopy in patients with UC among the academic gastroenterologists (121). This study 
showed that only 26.5 % of Canadian Gastroenterologists routinely use CE, despite the fact 
that the majority (71%) of the participants were physicians with IBD as their subspecialty.  
The uptake of CE among the colonoscopists has been variable. This may be due to the 
steep learning curve involved, time constraints on endoscopy lists and the common 
perception that this is a ‘messy’ time-consuming procedure. 
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Aims and Hypothesis 
Hypothesis to be tested 
• NBI confer additional benefit over standard endoscopic evaluation in the 
assessment of disease activity and prediction of short and long-term outcomes in 
UC. 
• Spectroscopic assessment of inflamed and non-inflamed tissue in UC correlated 
well with histological staging.  
• High definition chromoendoscopy detects more dysplastic lesions than high 
definition white light endoscopy alone. 
Aim  
The main aim of the research project was to assess the role of image-enhanced endoscopy 
in the assessment of disease activity, prediction of relapse and improvement in detecting 
dysplastic lesions in patients with Ulcerative colitis.  
The objectives of the studies performed are: 
• a) To establish if addition of NBI in endoscopic assessment of patients with UC 
improves the staging of disease activity.  
• To examine if NBI predicts short as well as long-term outcomes in UC. 
• To compare the findings of spectroscopy of inflamed and non-inflamed mucosa 
with histology and endoscopic findings and identify potential metabolic correlates 
of inflammation. 
To compare the rate of detection of dysplasia in patients with long-standing UC 
with HD-WLE compared to HD-CE. 
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Methods and results of each study 
2 Can standard white light endoscopy predict a flare? 
Introduction 
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) with a characteristic relapsing 
and remitting disease course. Inflammation in UC is continuous, starts from the rectum and 
extends proximally. Genetic, immunological and environmental factors have been linked to 
the mucosal inflammation seen in the UC; however, the exact etiopathogenesis is unknown. 
Similarly, the pathophysiology of flare-ups is not well understood.  
Relapse in UC has associated consequences related to health, social & psychological well-
being. It is also a considerable economic burden to patients and the healthcare provider. The 
aim of treatment in UC is to achieve mucosal healing (MH) and maintain remission. MH is 
used as a treatment endpoint in clinical trials and has shown to reduce flare related hospital 
admission and the need for surgical interventions. (87) 
Serum biomarkers are widely used to assess and monitor disease activity in UC. In one of 
the landmark studies, Bitton et al (4) report the predictors of clinical relapse in patients with 
quiescent disease.  74 patients in clinical and endoscopic remission underwent serum 
biomarkers and a colonoscopy at induction. They were prospectively followed up every three 
months for a year, or shorter if they had a relapse. They observed that younger age, multiple 
previous relapses (in women) and basal plasmacytosis were independent predictors of 
relapse. However, they found no evidence that serum levels of CRP, ESR and IL-1β, IL-6 
and IL-15 predict relapse in UC. However this has been refuted in subsequent studies; in 
one study an elevated CRP and ESR correlated well with right colonic inflammation(122), 
and in another study, an eight-fold elevation of a predictive biologic score increased the rate 
of relapse (85).  
Calprotectin (FCP) is a commonly used faecal biomarker with promising results in clinical 
trials. However, a meta-analysis of six prospective studies in patients with quiescent disease 
showed that the FCP only predicts flare within 12 months with a sensitivity and specificity of 
78% and 73% respectively (123).  
Endoscopic assessment is the key to evaluating the extent and severity of the disease 
activity. However histological inflammation is known to persist despite the normal 
endoscopic appearance of the mucosa at endoscopy(3, 124). White light endoscopy 
although routinely used in the assessment of severity of disease, has not shown any value in 
predicting disease course. Furthermore, results from studies evaluating disease outcomes 
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using advanced endoscopic features such as high definition endoscopy, narrow band 
imaging and magnification endoscopy have been conflicting (38, 40, 42, 44).  
Presence of histological inflammation is the driving force behind relapses in the short term 
and dysplasia in the long-standing UC (20). Various histological scores are available to 
grade inflammation in UC (3, 72, 73). The correlation between the presence of inflammation 
and subsequent relapse has been suggested by a number of studies (4, 16, 82, 125); 
however, a recent prospective study did not show any correlation (40) 
The available biomarkers are not reliable in predicting flare-ups of the disease. Despite the 
invasiveness of the endoscopic assessment and its subjective interpretation, there is no 
substantive replacement available with a reliable non-invasive biomarker. Our retrospective 
cohort study aimed at assessing the association between endoscopic disease activity 
assessed with Mayo endoscopic subscore (MES), histological inflammation (Geboes score) 
and combined endoscopic and histologic disease activity in predicting disease course 
(clinical relapse in 12 months) in quiescent UC patients.  
Methods 
We conducted a retrospective review of adult patients in clinical remission who underwent 
surveillance colonoscopies in our institution from January 2008 to December 2011. This 
study was conducted as an audit on local practice of surveillance procedure. The study 
protocol conforms to the ethical guidelines of the World Medical Association Declaration of 
Helsinki- Ethical Principles for Medical Research Involving Human Subjects" adopted by the 
18th WMA General Assembly, Helsinki, Finland, June 1964, as revised in Tokyo 2004. All 
procedures were done as a part of patient care and no extra tests or procedures were done 
as a part of the study. Data was collected using electronic records for endoscopy reports and 
the subsequent clinical care. Demographic details of the patients were recorded along with 
duration and extent of the disease, medications (current and past), use of oral steroids in the 
last 6 months, endoscopic assessment of inflammation using MES and follow up data for 
any disease relapse in the next 12 months. An expert gastrointestinal pathologist (OR) 
independently assessed the histology and graded the inflammation using Geboes score 
(72). The pathologist was blinded to the patient’s clinical outcomes (occurrence of relapse).  
Patients were deemed to have had a relapse if they required steroids or an increase in their 
medication dose for symptom control in the subsequent 12 months following index 
colonoscopy.  
Inclusion criteria: All adult patients (Age ≥18 years) with histologically confirmed UC on 
surveillance colonoscopy program were included.  
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Exclusion criteria: Patients were excluded from the study if they had been diagnosed to have 
a flare at colonoscopy, underwent colonic resection in the follow up period for 
dysplasia/cancer, had a diagnosis changed to Crohn’s disease either at the colonoscopy or 
in the follow-on period, failed procedure either due to poor prep or incomplete colonoscopy 
or with missing information in records/lost to follow up. 
Statistical analysis:  
The main aims of the study were to assess the association between white light endoscopic 
disease activity, histological inflammation and combined endoscopic/histological disease 
activity with the risk of clinical relapse in the next 12 months of follow-up. Results are 
expressed as means ± standard deviations for continuous variables and as frequencies for 
categorical variables. P values from ANOVA or chi-square tests were considered statistically 
significant if ≤ 0.05. Binary Logistic regression analysis was performed using the Enter 
method to calculate odds ratios (OR) and their 95% confidence intervals. All variables were 
analysed by univariate analysis and included in the multivariate regression model was used 
if p<0.3. Correlation matrices were used to identity collinearity. When collinearity was 
detected (rho >0.6) this was minimized by inputting the variable separately in the multivariate 
analysis. Hosmer-Lemeshow’s test was used to test the null hypothesis that there is a linear 
relationship between the predictor variable and the log odds of the outcome variable. All 
statistical tests were done using PASW version 20 (IBM Corp, NY).  
Results 
 
A total of 406 patients were identified to have undergone surveillance colonoscopy during 
the study period of which 295 were included in the study. The flow chart of patient selections 
is shown in Figure 5. 295 patients were included in the final analysis and their demographic 
characteristics are outlined in Table 8. The mean age of patients was 56.3 years and the 
mean duration of disease after histological diagnosis was 22.3 years. 181 (61.3%) patients 
were diagnosed with Pancolitis and 114 (38.6%) with the left sided disease. 95 (32.2%) 
patients were on various disease-modifying agents such as Azathioprine, Methotrexate, 
Infliximab or Adalimumab. The rest (n=183, 62%) were on oral 5-Aminosalicylic acid (5-ASA) 
maintenance therapy alone. 17 patients were not taking any regular treatment for their 
ulcerative colitis.  None of the patients were on topical therapy alone (5-ASA or steroids).  
65 (22%) of the 295 patients had a clinical relapse documented in the 12 months following 
their colonoscopy. The results of the univariate analysis are outlined in Table 9. Factors 
significantly associated with a greater risk of clinical relapse in the next 12 months included 
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younger age, shorter disease duration, not on immunomodulator/biologic drugs, endoscopic 
inflammation (MES>1), histologic inflammation (Geboes > 2.1) and both MES > 1 and 
Geboes score > 2.1 (Combined Both) and either MES > 1 or Geboes score > 2.1 (Combined 
Any). On multivariate analysis, every unit increase in age (in years) was significantly 
associated with a 0.96 fold (95% CI 0.93-0.99) reduction in risk of relapse and 
immunomodulator/biologic use with a 0.30 fold (014-0.66) reduction in risk of relapse. An 
MES of > 1 and a Geboes score of > 2.1 was associated with a 4.63 (95% CI 2.39-9.00) fold 
and 4.90 (2.61-9.18) fold increase in the risk of clinical relapse. Table 10 outlines the results 
from the binary logistic regression analysis. Table 11 lists the sensitivity, specificity, positive 
predictive value, negative predictive value and overall accuracy of the MES, Geboes score 
and combinations of these 2 scores in predicting the risk of relapse in the next 12 months. 
The diagnostic accuracy parameters for these scores are modest with sensitivities ranging 
from 49.2 to 73.8% and specificity from 68.7 to 83%.  
 
Table 8 Baseline characteristics of the patients included in the study. 
 Total number of patients 295 
Gender: Male (%) Female (%) 157 (53%), 138 (47%) 
Age (mean ±SD in years) 56.3 ± 13.2 
Duration (mean ±SD in years) 22.3 ± 10.6 
Disease extent: Pancolitis (%), Left sided 
colitis (%) 
181 (61.3), 114 (38.7%) 
Immunomodulator/biologic drug use (%) 95 (32.2) 
5-ASA (aminosalicylate) use (%) 183 (62) 
Recent steroid use (within 6 months) n (%) 20 (6.7) 
Geboes score >2.1 n (%) 95(32.2) 
Mayo score >1 n (%) 96 (32.5) 
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Figure 5 Flowchart of patients included in the study 1 
 
 
 
 
406 patients 
underwent 
surveillance 
colonoscopy (2008-
2011 inclusive)                               
295 patients recruited 
 
111 excluded 
65 patients relapsed 
within 12 months 
 
*Missing data/lost to 
follow up -58  
*Flare diagnosed at 
endoscopy -15                                              
*Change in diagnosis 
to Crohn’s disease-13                            
*Surgery- 6                                                    
*Failed procedure-12                                      
*No biopsies taken -2                                
*Histology slides 
unavailable-5 
No relapse in 230 patients within 12 
months  
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Table 9 Univariate analysis of baseline parameters 
 Relapsers 
(n=65) 
Non-relapsers 
(n=230) 
P value 
Age (Mean ± SD) 50.8 ± 14.4 57.89 ± 12.4 0.001 
Duration of disease 
(years) (Mean ±SD) 
20 ± 11 23 ± 11 0.043 
Gender (male/female) 33/32 124/106 0.67 
Extent (left 
sided/pancolitis) 
30/35 84/146 0.19 
Immunomodulator or 
biologic  use (yes/no) 
13/52 82/148 0.017 
Recent steroid use 
(within 6 months) 
(yes/no) 
8/57 12/218 0.048 
 
Geboes score  
       ≤2.1 
        >2.1                          
 
 
24 
41 
 
176 
54 
 
   
         <0.001 
MES 
         0 
        ≥1 
 
26 
39 
 
173 
57 
       
       
         <0.001 
Combined Both 
       Either Geboes 
Score ≤2.1 or MES =0 
      Geboes Score > 2.1 
and MES  ≥1 
 
32 
 
33     
 
191 
 
39 
 
 
 
       <0.001 
Combined Any 
      Both Geboes Score 
≤2.1 and MES =0 
      Either Geboes 
Score > 2.1 or MES ≥1 
 
48 
 
17 
 
158 
 
72 
        
 
        <0.001 
MES-Mayo endoscopic subscore  
Univariate analysis of Mayo endoscopic score (MES) > 1, Geboes histopathological score > 
2.1, both MES > 1 and Geboes score > 2.1 (Combined Both) and either MES > 1 or Geboes 
score > 2.1 (Combined Any) in predicting risk of a clinical flare in the next 12 months 
adjusted for age, duration of disease, extent of disease, immunomodulator/biologic use and 
steroid use in the last 6 months. 
 
       
<
0
.
0
0
1 
       
<
0
.
0
0
1 
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Table 10 Binary logistic regression analysis 
 Odds ratio 95% CI 
Age 0.96 0.93-0.99 
Duration of disease 1.00 0.97-1.03 
Extent (Left sided vs 
Pancolitis) 
0.97 0.51-1.83 
Immunomodulator/Biologic 
use (Yes vs no) 
0.30 0.14-0.66 
Recent steroid use (Yes vs 
No) 
1.46 0.45-4.73 
Geboes score >2.1 4.90 2.61-9.18 
MES>1 4.63 2.39-9.00 
Combined Both 4.15 2.11-8.14 
Combined Any 6.19 3.19-12.00 
Binary logistic regression analysis of Mayo endoscopic score (MES) > 1, Geboes 
histopathological score > 2.1, both MES > 1 and Geboes score > 2.1 (Combined Both) and 
either MES > 1 or Geboes score > 2.1 (Combined Any) in predicting risk of a clinical flare in 
the next 12 months adjusted for age, duration of disease, extent of disease, 
immunomodulator/biologic use and steroid use in the last 6 months.
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Table 11 Results  
Score Sensitivity 
(95%CI) 
Specificity 
(95% CI) 
Negative 
predictive 
value 
Positive 
predictive 
value 
Overall 
accuracy 
(95%CI) 
MES > 1 60.0% (48.8-
70.3) 
75.2% (72.0-
78.1) 
0.87 (0.83-
0.90) 
0.41 (0.33-
0.48) 
71.9% 
(66.9-76.4) 
Geboes 
score > 2.1 
63.1 % 
(51.9-73.2) 
76.5% (73.4-
79.4) 
0.88 (0.84-
0.91) 
0.44 (0.36-
0.50) 
73.6% 
(68.6-78.0) 
Combined 
Both 
49.2% (38.5-
59.5) 
83% (80.0-
86.0) 
0.85 (0.82-
0.88) 
0.45 (0.35-
0.55) 
75.6%(70.9-
80.1) 
Combined 
Any 
73.8% (62.7-
83.0) 
68.7% (65.6-
71.3%) 
0.90 (0.86-
0.94) 
0.40 (0.34-
0.45) 
69.8% 
(64.9-73.9) 
Sensitivity, Specificity, negative likelihood ratio, positive likelihood ratio and overall accuracy 
of Mayo endoscopic score (MES) > 1, Geboes histopathological score > 2.1, both MES > 1 
and Geboes score > 2.1 (Combined Both) and either MES > 1 or Geboes score > 2.1 
(Combined Any) in predicting risk of a clinical flare in the next 12 months. 
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Discussion 
Our study demonstrates that MES ≥1 and Geboes score ≥2.1, both individually and 
combined are predictors of disease relapse in patients with UC undergoing surveillance 
endoscopy. MES ≥1 indicates the macroscopic inflammation seen at endoscopy. Geboes 
score >2.1 is the presence of acute inflammation (increased eosinophils and neutrophil 
count in lamina propria), whereas scores 0, 1 and 2.0 does not include acute inflammatory 
infiltrates (hence in our results we report Geboes >2.1 and not 2.0). Some of the studies in 
published literature assessed clinical outcomes using endoscopic scores such as MES and 
Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (126-129), and others used 
histological scores like Geboes score or Riley index (3, 4, 82, 125, 130) individually. To the 
best of our knowledge, ours is the only study in which both endoscopic and histologic 
disease activity indices are used to predict disease recurrence/relapse. In our study cohort, 
we found that the presence of either of these markers (MES>1 or Geboes ≥2.1) increases 
the risk of relapse up to 6 times in the subsequent twelve months period.  
In a recent prospective study involving 187 patients with quiescent UC (MES 0=126 and 
MES 1= 61), Acosta et al(126) observed that in total 26% (n=49) of patients had relapsed in 
12 months of follow up period. 41% of patients with MES 1 and 19.3% of MES 0 had 
relapsed at the end of 12 months. They noted a much stronger association of MES with 
relapse in the first 6 months period (9.6% of MES 0 and 36.6% of MES 1). Similar results 
were noted by Carvalho and colleagues(127) where patients with Mayo 1 relapsed 
significantly more than patients with Mayo 0 disease. In their subgroup analysis, they found 
that the findings were not dissimilar to patients with either extensive or left sided colitis (but 
not proctitis).   
In another recent study, Arai et al(128) found that UCEIS correlated well with MES. The 
severity of disease activity noted at endoscopy with UCEIS had a linear correlation with the 
percentage of patients who had a relapse at the end of study period (5% of patients with 
UCEIS 0 relapsed compared to 75% of those with UCEIS 4-5).  
Histology is the gold standard in the assessment of disease activity in UC. Various scoring 
systems are available in the literature (3, 72, 73) but none seems to have been rigorously 
validated externally. Presence of basal plasmacytosis in rectal specimens is reported to be 
an independent predictor of disease relapse(4, 82). However, opinion among the 
gastrointestinal histopathologists differs on this. Recently Feagins et al (16) in a 
retrospective review noted that presence of any of the histological markers of inflammation 
such as basal lymphoplasmacytosis, basal lymphoid aggregates, erosions/ulcers in the 
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epithelium, moderate/marked architectural distortion were independently associated with 
significant relapse risk in patients with clinical remission.  
Bessissow and colleagues also reported that a Geboes score of >3.1 (Neutrophils in 
epithelium and crypt involvement of <5%) was significantly associated predicting a relapse 
within 12 months. Interestingly Jauregui-Amezaga et al in their prospective study involving 
70 inactive UC patients found that only 7/38 patients who had basal plasmacytosis in 
biopsies relapsed whereas 10/24 patients with no basal plasmacytosis relapsed (p=0.78). In 
our study, we did not aim to look at the basal plasmacytosis as it was felt that the histological 
slides needed to be re-processed for accurate assessment.  
In a recent systematic review and meta-analysis of 15 studies, Park et al(130) found that the 
absence of histological inflammation compared to its presence was associated with less risk 
of flare up [RR 0.48 (95%CI 0.39-0.60)]. They also reported similar outcomes for the specific 
histological subset with absence v/s presence of eosinophils and neutrophils in epithelium 
and lamina propria, Crypt abscesses, Basal plasmacytosis and basal lymphoid aggregates. 
Similar to our study, they noted that the presence of Eosinophils and neutrophils (graded as 
2.1 on the Geboes score) is associated with increased risk of relapse. Interestingly they also 
found that absence of basal plasmacytosis was not associated with decreased risk of 
relapse.  
The accuracy of CE and magnification endoscopy with or without CE in the prediction of 
disease flare is poor (37, 42, 44). Watanabe et al(44) studied the use of magnification 
chromoendoscopy in their prospective study. 57 patients with long standing UC were 
included, of whom 12 of 17 (70%) patients with ‘frank mucosal defects’ had a disease flare 
within 12 months of follow up. On the other hand only 10 of 22 (45%) patients with ‘some 
mucosal irregularity’ and 1 of 18 patients with ‘no mucosal abnormalities’ had a flare within 
the same period. Although there seems to be a linear relationship with the degree of 
inflammation to the risk of relapse, the diagnostic accuracy of this endoscopic modality was 
poor.  
 Jauregui-Amezaga et al(40) studied the use of high-resolution chromoendoscopy and NBI in 
predicting flare-up in patients with sustained clinical remission. In this study, neither 
advanced endoscopic techniques nor the histology was predictive of relapse within 12 
months period. Unfortunately, uses of advanced imaging modalities have their own 
limitations. Only small areas can be assessed in detail, it is labour intensive, time-consuming 
and needs considerable expertise.  
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Our study had similar relapse rates to the published literature. Using both endoscopic and 
histological markers to predict disease relapse, we observed that presence of either will 
increase the probability of disease flare-up by six times [OR 6.19 (95% confidence interval 
(CI) 3.19-12.00)]. When used in combination or individually the parameters were significant 
in predicting disease flare (Table 3). However, the overall diagnostic accuracy of these 
parameters was low with low sensitivity, specificity, negative and positive predictive values. 
Overall diagnostic accuracy for MES>1 was 72%, and that of Geboes score >2.1 was 74%. 
When used both in combination (Mayo>1 and Geboes score >2.1) there was a minimal rise 
in overall diagnostic accuracy (76%) whereas when any combination (Mayo>1 or Geboes 
score >2.1) was used, the accuracy fell to 70%. One possible explanation for such low 
figures is the low pick up rate due to sampling error. It is possible that the biopsies were not 
adequately targeted. 
Limitations of our study 
One of the limitations of our study is the retrospective design. However, we have a robust 
electronic patient records system which is integrated with the General practitioners and 
Hospitals locally. All hospital episodes or GP reviews are pulled through to our system 
bound by the data-share agreement. Despite this, the data on smoking status and 
psychological stress ‘at the time of procedure’ was not complete and hence excluded. We 
also chose to exclude the serological markers of inflammation in our analysis as there was a 
considerable degree of variability in the timing of blood tests and the procedure in the initial 
100 patients assessed.  
The other limitation of our study is that we included only surveillance patients and patients in 
the early years of the diagnosis were excluded. However, the relapse rate in our study is 
similar to studies that were conducted in non-surveillance patients. Hence we believe that 
the data can be extrapolated to the non-surveillance population too.     
The endoscopic scores for our study were provided by analysing the archived images in the 
reporting software. Although this is an accepted method of retrospective assessment in 
publications, we appreciate that it could potentially introduce bias. 
Despite the above limitations, we believe that our data is robust in capturing all the relevant 
information surrounding a relapse, and we have taken appropriate steps to avoid potential 
bias.  
Conclusion 
Endoscopic and histological activity is an important driving force of inflammation in UC with 
the risk of subsequent relapse.  However, only 60-70% of patients with risk of relapse are 
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identified using both. Further studies looking at combining endoscopic and histological 
markers are required.  
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3 Can Faecal Calprotectin predict a flare in IBD: A Meta-
analysis  
Introduction 
Ulcerative colitis (UC) and Crohn’s disease (CD) are the two major types of inflammatory 
bowel diseases (IBD) with characteristic relapsing and remitting disease course. Mucosal 
inflammation is associated with relapse. There are significant physical, mental and financial 
consequences associated with relapse. Deep remission with complete mucosal healing is 
the aim of treatment in IBD. Commonly used biomarkers such as C-reactive protein (CRP) 
and erythrocyte sedimentation rate (ESR) are used conventionally to monitor the disease 
activity; however, they have not been found useful to identify patients with high risk of 
relapse(4). Levels of CRP and ESR vary with the systemic illnesses making their 
interpretation difficult in IBD. The ability to predict relapse using biomarkers may be helpful 
to physicians in tailoring the treatment and preventing future relapses and its consequences.  
Calprotectin is a calcium and zinc binding protein belonging to the SA100 group of proteins. 
It is found predominantly in the cytosol of neutrophils and to a lesser extent in monocytes 
and reactive macrophages. It is available in abundance in body fluids and is resistant to 
bacterial or enzymatic degradation. Calprotectin constitutes about 60% of the cytosolic 
protein in the granulocytes and about 5% of total body protein(54). Intestinal inflammation is 
marked by the influx of inflammatory cell infiltrates in the mucosal lining. Breakdown of 
cytosolic protein liberates calprotectin in the faeces, the concentration of which is found to be 
proportional to the intestinal inflammation(55) and on white cell scanning (56). A spot test of 
<5gm of faeces is shown to be as reliable as 24-hour stool collection and can remain stable 
for up to 7 days in room temperature (54). It can be readily quantified using enzyme-linked 
immunoassay testing (ELISA). Faecal calprotectin (FCP) is hence classed as a ‘damage-
associated molecular pattern’ protein and fulfils desirable qualities of a non-invasive 
surrogate marker for intestinal inflammation. New generation FCP kits make it even easier 
with ‘on table’ testing. All these features make FCP an attractive alternative for the serum 
biomarkers. 
Tibble et al (62) have demonstrated that FCP can be used to discriminate Crohn’s disease 
from irritable bowel disease in adult patients with 100% sensitivity. FCP has been shown to 
correlate well with the endoscopic and histological inflammation (131-133). A growing body 
of evidence suggests that this can be used effectively to monitor disease activity and tailor 
treatment modalities to prevent relapses (134-136). More recently the role of FCP in 
predicting relapses in UC and CD has drawn interest from researchers. The results in the 
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published literature on this subject are variable. This meta-analysis aims at assessing the 
predictive capabilities of FCP in UC and CD population from prospective trials involving adult 
patients with no surgical history or biologic therapy.  
Material and Methods 
3.1.1.1 Literature search  
Multiple electronic databases were searched including Pubmed, Embase and Ovid looking 
for studies providing data on relapse prediction in IBD using FCP up to July 2018. Search 
terms used included ‘Calprotectin’, ‘Faecal calprotectin’, Fecal calprotectin’. These terms 
were further intermixed with ‘Crohn’s disease’, ‘Ulcerative colitis’, ‘relapse prediction’, and 
‘prediction of flare’ respectively. Our search results were not restricted to English language 
literature alone. Only prospective studies satisfying the inclusion criteriae were included in 
the final analysis. Further details were requested from the authors, where felt appropriate, 
prior to inclusion/exclusion. Articles were first screened by all three investigators (NM, ET 
and VS) using the title and abstract. Full text of shortlisted articles was independently 
assessed and data extracted by NM and ET. Disagreements were resolved by discussions 
with the senior author (VS). 
3.1.1.2 Study selection 
A study was included if it met the following criteria as follows 1) the study prospectively 
evaluated the capability of FCP in predicting flare-up in adult patients with UC or CD, 2) the 
criteria for diagnosing a relapse was clearly mentioned and 3) the study provided deducible 
information or the authors provided further information to carry out the required statistical 
tests. Studies looking at the outcomes in paediatric/teenage population and post-operative 
patients were excluded, as were the studies looking at the predictive value of FCP in 
patients on anti-TNF therapy.  
3.1.1.3 Data extraction  
Data was collected independently  (NM and ET) on author, year of publication, study design, 
type of Calprotectin kit, definition of relapse and cut off level used, along with the diagnostic 
accuracy tests including sensitivity, specificity, true positive (TP), true negative (TN),  false 
positive (FP) and false negatives (FN) were calculated for each study. A 2X2 table was 
created to extract the information when it was not available from the papers. Where the 
published data was not sufficient the authors were contacted for further input. Differences 
were resolved by discussion with senior author (VS). 
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3.1.1.4 Quality assessment 
Quality assessments of the included studies were conducted using QUADAS-2 (Quality 
Assessment of Studies of Diagnostic Accuracy included in Systematic reviews) which is a 
revised version of a previously used QUADAS tool(137). Answering terms ‘yes’, ‘no’ or 
‘unclear’ were used in four different domains such as ‘patient selection’, ‘Index test’, 
‘reference standard’ and ‘flow and timing’. Assessment of bias and concerns regarding 
applicability was marked as ‘low’, ‘high’, or ‘unclear’. Disagreements were resolved by 
discussions among the authors.  
 
3.1.1.5 Statistical analysis 
All standard methods for performing meta-analysis were used. Statistical analyses were 
performed using Meta-Disc version 1.4(138).  
For each study, sensitivity, specificity, positive likelihood ratio (LR+), negative likelihood ratio 
(LR-) of baseline FCP level. A 2X2 table was created for calculations. A random-effect model 
was used to create pooled estimates with 95% confidence intervals. Summary receiver 
operating characteristic curve (SROC) was created to assess the relationship between true 
and false positive rates. Study differences were calculated using the I2 statistics (25% - low 
inconsistency, 50-moderate inconsistency and 75% - high inconsistency)(139).
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Figure 6 Flow chart of study selection (FCP Meta-analysis) 
  
 
 
 
 
 
 
 
 
 
 
 
Papers from initial 
database search 
(n=839) 
Potentially eligible 
studies after reading 
abstract (n=123) 
Excluded on 
basis of title and 
abstract (n=716) 
Included in final 
analysis (n=13) 
Excluded papers: 
>Paediatric studies     
> Studies involving 
post-operative 
patients and 
biological treatment  
>Reviews & others 
>Retrospective 
studies                 
>Meta-analysis 
>Insufficient data 
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Table 12 Characteristics of included studies. 
Study number Author/year Country Calprotectin 
assay 
Cut off level 
(UC/CD/IBD) 
No. of 
Patients 
(UC/CD/IBD) 
Age (years) Definition of relapse FU duration 
(months) 
1 Tibble et al 
(2000) 
UK Roseth 50 mg/l 
(Adjusted 
value 250 
µg/g) 
37/43/80 16-77 CDAI>150 with >100 
increase from baseline 
(CD), HBI >2 increase 
from baseline 
(UC)+change in 
treatment 
12 
2 Costa et al (2005) Italy Calprest 150 µg/g  41/38/79 24-54 CDAI>150 (CD), UCAI>4 
(UC), plus change in 
treatment 
12 
3 D’Incà et al 
(2008) 
Italy Calprest 130 mg/kg 
Adjusted 
value 130  
µg/g) 
97/65/162 15-80 CDAI>150 or increase 
>50 or 75 from 
baseline (CD), or TW 
score≥4 (UC) 
12 
4 García-Sánchez 
et al (2009) 
Spain Calprest 150 µg/g  
 
69/66/135 27-54 CDAI>150 (CD) or 
modified TW>11 (UC) 
plus change in 
treatment 
12 
5 Kallel et al (2009) Tunisia Calprest 340 µg/g 0/53/0 15-66 CDAI>150 or increase 
>100 from baseline 
that warranted 
treatment 
12 
6 Gisbert et al 
(2009) 
Spain Philcal 150 µg/g  
 
74/89/163 -- CDAI>150 (CD) or 
modified TW>11 (UC) 
12 
7 Lasson et al 
(2013) 
Sweden Bühlmann 169 µg/g  
 
69/0/0 18-74 Symptoms of UC 
requiring change in 
3 months 
then yearly 
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treatment for 3 years 
8 Yamamoto et al 
(2013) 
Japan Human 
Calprotectin 
ELISA Kit 
170 µg/g 
 
80/0/0 20-75 Worsening of stool 
frequency and/or 
rectal bleeding with an 
endoscopic score of 2 
or 3. 
12 
9 Naismith et al 
(2013) 
UK Bühlmann 240 µg/g 
 
0/92/0 18-83 Unplanned escalation 
of therapy, progression 
of disease (Montreal), 
or hospitalisation +/- 
emergency surgery. 
12 
10 Jauregui-
Amezaga et al 
(2014) 
Spain Philcal 250 µg/g 
 
64/0/0 -- Blood PR/Mayo≥ 1 
with Histological 
activity 
12 
11 Hosseini et al 
(2015) 
Iran Bühlmann 341 µg/g 
 
154/0/0 20-69 Elevated Seo index 
(>220), escalation of 
treatment 
12 
12 Scaioli et al 
(2015) 
Italy Calprest 193 µg/g 
 
74/0/0 16-89 SCCAI>3 12 
13 Theede et al 
(2016) 
Denmark Bühlmann 321 µg/g 
 
70/0/0 -- Escalation of treatment 12 
CD-Crohn’s disease, UC-Ulcerative colitis, CDAI-Crohn’s disease activity index, HBI-Harvey-Bradshaw Index, UCAI-Ulcerative Colitis Activity 
Index, TW-Truelove and Witts severity index, PR-Per rectum, SCCAI-Simple Clinical Colitis Activity Index, pMayo-Partial Mayo score.
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Table 13 Quality Assessment of studies of Diagnostic Accuracy included in Systematic reviews-2 (QUADAS-2) 
Domain 1 
PATIENT 
SELECTION 
 
Stud
y 1 
Stud
y 2 
Stud
y 3 
Stud
y 4 
Stud
y 5 
Stud
y 6 
Study 
 7 
Study 8 
Study 
9 
Study  
10  
Study 
11 
Study 
12 
Study 
13 
Risk of bias 
Q1 
Q2 
Q3 
Y 
N 
N 
Y 
N 
N 
Y 
N 
N 
Y 
N 
N 
Y 
N 
N 
Y 
N 
N 
Y 
N 
N 
Y 
N 
N 
Y 
N 
N 
Y 
N 
N 
Y 
N 
N 
Y 
N 
N 
Y 
N 
N 
Could the selection 
of patients have 
introduced bias? 
Risk Low Low Low Low Low Low Low Low Low Low Low Low Low 
Concerns 
regarding 
applicability 
              
Is there concern 
that the included 
patients do not 
match the review 
question? 
Concern Low Low Low Low Low Low Low Low Low Low Low Low Low 
Domain 2 
INDEX TEST 
              
Risk of bias 
Q4 
Q5 
Y  
N 
Y  
N 
Y  
N 
Y  
N 
Y  
N 
Y  
N 
Y  
N 
Y  
N 
Y  
N 
Y  
N 
Y  
N 
Y  
N 
Y  
N 
Could the conduct 
or interpretation of 
the index test have 
introduced bias? 
Risk Low Low Low Low Low Low Low Low Low Low Low Low Low 
Concerns 
regarding 
applicability  
              
Is there concern 
that the index test, 
its conduct, or 
interpretation differ 
from the review 
question? 
Concern Low Low Low Low Low Low Low Low Low Low Low Low Low 
Domain 3 
REFERENCE 
STANDARD 
 CR CR CR CR CR CR CR CR+ER CR CR+ER+
HR 
CR CR CR 
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Risk of bias 
Q6 
Q7 
Y  
U 
Y  
U 
Y  
U 
Y  
U 
Y  
U 
Y 
N 
N 
Y 
Y 
U 
Y 
N 
Y 
Y 
Y 
U 
Y 
Y 
Y 
Y 
Could the reference 
standard, its 
conduct, or its 
interpretation have 
introduced bias? 
Risk Low Low Low Low Low Low High Low Low Low Low Low High 
Concern regarding 
applicability 
              
Is there concern 
that the target 
condition as defined 
by the reference 
standard does not 
match the review 
question? 
Concern Low Low Low Low Low Low Low Low Low Low Low Low Low 
Domain 4 
FLOW AND 
TIMING 
              
Risk of bias 
Q8 
Q9 
Q10 
Q11 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Could the patient 
flow have 
introduced bias? 
Concern Low Low Low Low Low Low Low Low Low Low Low Low Low 
 
Q1- Was a consecutive or random sample of patients enrolled?  
Q2- Was a case-control design avoided?  
Q3-Did the study avoid inappropriate exclusions?  
Q4-Were the index test results interpreted without knowledge of the results of the reference standards?  
Q5-If a threshold was used, was it pre-specified? 
Q6- Is the reference standard likely to correctly classify the target condition? 
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Q7- Were the reference standard results interpreted without knowledge of the results of the index test? 
Q8- Was there an appropriate interval between index test(s) and reference standard? 
Q9- Did all patients receive a reference standard? 
Q10- Did patients receive the same reference standard? 
Q11- Were all patients included in the analysis? 
Yes-Y, No-N, Unclear-U 
CR- Clinical relapse 
ER-Endoscopic relapse 
HR-Histological relapse 
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Results 
Electronic search for the terms mentioned earlier returned 3178 related publications, of 
which 839 articles were selected for detailed review. Further selection process is shown in 
the flowchart above. Studies assessing the ability of FCP in diagnosing IBD were not 
included. Those which assess the role of FCP in predicting relapses in postoperative 
Crohn’s disease and in the paediatric/adolescent population were excluded. We also 
excluded studies including patients exclusively on biologic therapy.  
Thirteen studies were included in the meta-analysis (40, 140-152). All the included studies 
were prospective studies with either a consecutive, systematic or a random selection of 
patients. Eleven studies provided (or extractable) data on Ulcerative colitis (40, 140-143, 
145-147, 149, 150, 152) and 7 on Crohn’s disease(140-145, 148). Data on combined UC 
and CD patients was extracted from 4 studies(140, 142, 145, 151), however, one study 
provided combined data alone without separate analysis of UC and CD patients (151). The 
characteristics of each of the included studies are mentioned in Table 12 and QUADAS-2 
questionnaires in Table 13. Due to the small number of studies, it was felt that the analysis 
of combined data for UC and CD will not yield meaningful results.  
Where appropriate the authors were contacted to provide additional data on their studies. 
Studies that were excluded from analysis include, a) those studies that did not provide a 12-
month of data, b) those studies where the data was not extractable, and c)  when the 
authors failed to respond to our email requests for providing us with the data (153, 154). A 
recent study assessing the role of consecutive sampling of FCP in predicting relapse was 
not included as extractable data was not available for analysis(155). 
Diagnostic accuracy of FCP in predicting relapses in UC: 
Eleven studies with a total of 932 patients with UC were included in the analysis. The pooled 
sensitivity and specificity are 0.70 (95% CI 0.65-0.76), 0.82 (95% CI0.79-0.86) respectively 
with a pooled DOR of 10.5 (95% CI 5.74-19.23). The pooled LR+ was 3.51 (95% CI 2.48-
4.97) and LR- was 0.4 (95% CI 0.28-0.56). The AUC was 0.83 (SE 0.03) and the Q* was 
0.76 (SE 0.03) (Figures 7 and 8). The specificity of FCP for UC patients was improved 
compared to the overall IBD populations (82 versus 66%); however, the results 
demonstrated significant heterogeneity.  
Diagnostic accuracy of FCP in predicting relapses in CD: 
Seven studies involving 446 patients were included in this analysis. The pooled sensitivity 
and specificity was 0.74 (95% CI 0.65-0.82) and 0.75 (95% CI 0.71-0.80) respectively with a 
pooled DOR of 8.2 (95%CI 3.95-17.15). The pooled LR+ was 2.62 (95% CI 1.80-3.82) and 
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LR- was 0.35 (0.18-0.70). The AUC was 0.8 (SE 0.04) with a Q* of 0.74 (SE 0.03) (Figures 9 
and 10). 
The above results suggest that FCP in UC has a slight advantage in predicting a relapse 
within 12 months compared to the CD patients. 
 
Figure 7 Pooled sensitivity and specificity for UC studies  
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Figure 8Summary receiver operating characteristic curve (SROC) for UC studies 
 
Figure 9 Pooled sensitivity and specificity for CD studies 
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Figure 10 Summary receiver operating characteristic curve (SROC) for CD studies 
 
Heterogeneity testing: 
We identified three areas to test for heterogeneity among the studies; the FCP assays used, 
the cut-off levels of FCP used in studies to predict relapse, and the definition of relapse.  
FCP cut off used in the studies ranged from 130 to 341 µg/gms for predicting relapse. We 
separated studies using 200µg/gm and tested for heterogeneity among the included studies. There 
were 7 studies in UC group with FCP cut off <200 and four studies with FCP cut off >200. 
However the data available to test heterogeneity among CD studies using cut off of 200 was 
not significant (only three studies with data on FCP cut off <200 and one study with cut off 
>200), and hence the analysis was not performed in this group.  
Some studies have used clinical scoring systems to define a relapse (140-145, 149-151) 
while some used clinical symptoms (40, 146-148, 152) and others used a combination. The 
results are shown in Table 14.
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Table 14 Heterogeneity testing of the studies 
 Sensitivity 
[95% 
confidence 
interval 
9CI)] 
Specificity LR+ LR- DOR SROC 
FCP in UC 
>200  
0.72  
(0.63-0.79) 
0.87  
(0.81-0.91) 
4.66 
(2.67-
8.11) 
0.37 
(0.17-
0.78) 
13.12 
(3.69-
46.63) 
0.95 
(SE=0.02, 
Q*=0.89) 
FCP in UC 
<200 
0.69 
(0.62-0.76) 
0.80 
(0.75-0.84) 
2.94 
(2.05-
4.21) 
0.41 
(0.28-
0.60) 
8.86 
(4.60-
17.04) 
0.80 
(SE=0.03, 
Q*=0.74) 
Relapse 
defined 
with 
scores 
0.70 
(0.64-0.76) 
0.85 
(0.86-0.88) 
4.74 
(2.56-
8.76) 
0.36 
(0.20-
0.62) 
14.80 
(5.65-
38.74) 
0.87 
(SE=0.87 
Q*=0.80) 
Relapse 
determined 
clinically 
0.62 
(0.52-0.71) 
0.79 
(0.73-0.83) 
2.93 
(2.23-
3.87) 
0.53 
(0.39-
0.72) 
6.03 
(3.46-
10.51) 
0.80 
(SE=0.80, 
Q*=0.73) 
LR+ likelihood ratio positive, LR- Likelihood ratio negative, FCP, Faecal calprotectin, DOR-
Diagnostic odds ratio, SE-Standard error, SROC-Summary Receiver Operator curve 
 
Discussion 
FCP is a stable protein, resistant to degradation in room temperature for about 7 days, and 
the ability of spot testing (using stool sample of just around 5 grams) to detect the 
inflammatory burden, making it a simple, inexpensive and non-invasive biomarker. It is used 
to reliably distinguish IBD from functional bowel disease. A meta-analysis of 13 prospective 
studies including 1041 patients FCP was shown to be an effective screening tool to 
distinguish IBD from IBS with 93% sensitivity and 96% specificity (156). The study results 
also suggested that there would be a 67% reduction in endoscopic procedures if screened 
with FCP.  
Another meta-analysis of 6 prospective studies involving 672 IBD patients assessed the 
value of FCP in predicting a relapse in IBD. In this study, the authors describe a pooled 
sensitivity of 78% and specificity of 73% of the baseline FCP values to predict a relapse in 
the 12 months follow up period(123). However in this meta-analysis authors have combined 
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studies which provided only CD(144) and UC data(143) along with the ones which provided 
combined data(140-142, 145). As we know that CD and UC have different disease pattern a 
combined analysis would not be suitable for diagnostic accuracy of FCP in predicting 
relapse. In our analysis, 8 additional prospective studies involving adult IBD patients were 
included with analysis of UC, CD and combined data separately. Our results suggest that 
FCP fares better in UC than CD population. The sensitivity of 70% and specificity of 82% 
with a pooled DOR of 10.51 and AUC was 0.83 in UC population. Although this is not as 
expected of a diagnostic test, it has good overall predictive value. The LR+ and LR- were not 
as expected to be of a predictive test. Ideally one would expect LR+ to be at least >5 and 
LR- to be <0.2 to be a strong diagnostic marker.  
In three different studies, it has been noted that consecutive sampling of FCP helps predict 
relapse. The first study was conducted in patients with Crohn’s disease treated with anti-TNF 
therapy(157), and second was in patients with mesalamine treated distal UC(158). The latter 
study only had a follow-up period of up to 40 weeks and hence did not qualify for our 
analysis. Both these studies suggested using FCP every 2-3 months in predicting relapse. 
Huge variation of cut off levels was observed in these studies. In the former study, a cut off 
of >300 mg/kg in two consecutive samples predicted a relapse with 61.5% sensitivity and 
100% sensitivity. However, in the latter study, an FCP elevation of >55 µg/g was associated 
with relapse with 88% sensitivity and 80% specificity. In the third study by Zhulina et al (155), 
both UC and CD patients were included. A doubling of FCP value between two consecutive 
samples within 3 months was associated with 101% increased risk of relapse. This study 
could not be included in our study due to the lack of extractable data.  
We acknowledge that our data has limitations. Heterogeneity across the studies existed due 
to the different assays used along with different cut-offs and the criteria used to define 
relapse in the studies. We could not statistically correct this. Studies not only varied in 
defining relapse but also in the methods used to confirm and assess the severity of relapse. 
Some studies used only clinical parameters with or without scoring systems to diagnose a 
relapse; others used endoscopic and histological markers of inflammation. Most of the 
scoring systems used in the studies are generally accepted in clinical practice; however, 
they are not externally validated. The parameters used in these indices to define relapse are 
different and could introduce bias.  
Subjective interpretation of symptoms without using standard or validated scoring systems to 
define relapse could introduce inter-observer variations making the studies prone to 
bias(146, 152). In our analysis, we found that only a few studies used hard endpoints to 
define relapse like endoscopic and histological inflammation (40, 147, 151).  
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Data analysis based on the location of the disease (ileal, ileocolonic, colonic Crohn’s disease 
and in UC proctitis, left sided colitis or pancolitis) was not possible owing to the relatively 
small number of studies providing such extensive data. Finally, publication bias with positive 
studies being published more often than negative studies is an established fact.  
Conclusion 
Our results suggest that FCP has a potential role in predicting disease relapses, more so for 
UC than CD patients. Repeated measurements may be useful than one-off baseline FCP 
value in predicting disease course. More research is needed in use of repeated FCP 
measurements at regular intervals with standardised cut off values.   
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4 Do newer generations of Narrow Band Imaging 
quantitatively improve contrast enhancement of 
endoscopic images?  
Introduction 
Narrow band imaging (NBI) digitally enhances the optical image and provides contrast 
enhancement resulting in better visualisation of the blood vessels and mucosal surface 
pattern. Hence it is also referred to as ‘virtual chromoendoscopy’ or ‘Image-enhanced 
endoscopy’ (IEE). 
The Wavelengths of light visible to the human eye as white colour is between 400-700nm, in 
which 400nm is seen as blue, 550nm and 700 are seen as green and red colour 
respectively. Light undergoes degradation in three forms when illuminated on objects; 
absorption, reflection and scattering. Light with a wavelength of 400-550nm gets absorbed 
more due to less penetrance and scatter. Narrow band imaging is the technology which 
relies on the principle of depth of penetration of the light to visualise the tissue in 
wavelengths between 400-550 nm. NBI filters decrease the wavelengths of the light 
illuminated; the blue light is centred at 415nm and the green lights at 540 nm. Photons in 
light at these wavelengths are absorbed strongly by the haemoglobin and hence capillaries 
on the mucosa appear optically enhanced with NBI.  
NBI allows superior assessment of vascular pattern and the intensity of capillary networking 
compared to white light endoscopy (159-163). These features help to differentiate polyps 
into adenomatous and non-adenomatous. Sano et al proposed a classification system using 
NBI with magnification (meshed capillary pattern I -non-adenomatous and capillary pattern II 
and IIIa, IIIb -neoplastic)(164). Diagnostic accuracy of NBI with magnification in 
differentiating adenomatous from non-adenomatous is reported at 95.3% compared with the 
histology with a sensitivity of 96.4% and specificity of 92.3%(162). Recently, NBI 
International Colorectal Endoscopic (NICE) classification is designed by an international 
group of experts with interest in NBI. The proposed classification helps to characterise 
polyps using NBI without magnification (165). Studies show that effective training in the use 
of NBI has resulted in high accuracy in diagnosing lesions in the colorectum (166-168).  
There are three generations of endoscopes equipped with NBI capabilities currently 
available in the UK, the 240, 260, and the latest 290 series of Olympus endoscopes. Each 
upgrade has resulted in an improved resolution and enhanced image quality. The 240 series 
were standard definition whereas the 260 and 290s are higher definition endoscopes. 
Whether the improvement in resolutions and NBI among these successive generations of 
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endoscopes translates into the better visualisation of haemoglobin has not been studied. We 
aimed to quantitatively compare the effect of improvement in contrast enhancement among 
three generations of Olympus endoscopes using serial dilutions of haemoglobin in our in 
vitro study. 
Methods 
We compared the visibility of human blood on endoscopic still images captured in white light 
(WL) and NBI with three generations of endoscopes. 
Images of human blood diluted with distilled water were taken with each generation of 
endoscopes, first with white light followed by NBI. A 24-well transparent plastic plate was 
used with one millilitre of distilled water pipetted in each of the flat wells. Human blood was 
added to the first well to set up a 1:1 concentration (1/2 dilution). Blood was diluted in 
subsequent wells so that each step resulted in doubling dilution. We used Olympus® 
Keymed gastroscopes for capturing images; GIF Q240 and GIF H260 endoscopes were 
used with a LUCERA spectrum CV260 processor and GIF H290 endoscope was used with 
an ELITE CV 290 processor. Still images of the overview of the plate and of each well were 
taken with WL and NBI as shown in images in Figure 11 and 12. It is worth noting that the 
effect of NBI does not vary between gastroscopes or colonoscopes of the same generation. 
We did not use digital enhancement techniques available on the endoscopes, as we felt that 
by doing so the image quality would be distorted.   
Endoscopic images appear convex or curved and in order to eliminate the bias of curved 
effect on assessing the presence or absence of blood we imaged individual wells at an 
optimal distance to prevent the curving of the image. In total 150 images were taken (6 
overview and 144 individual wells) which were then mixed in random order in a PowerPoint 
presentation. Participants who entered into the study were asked to identify the least 
noticeable blood in the overview image and to answer ‘yes’ or ‘no’ for the presence of blood 
in individual wells. 
Out of 45 participants included for the study, 15 were novices with no prior endoscopic 
experience at all, 15 were endoscopist with accreditation to perform upper endoscopy 
independently but without NBI experience (NBI-Naïve) and 15 were NBI-experienced or 
experts in the field of NBI. The NBI-Naïve group had certification of upper gastrointestinal 
endoscopy skills by the Joint advisory group (JAG)-a quality improving and service 
accrediting body for endoscopy in the UK. The NBI experts included in the study are the 
endoscopists with either published record of expertise in NBI or those select consultant 
gastroenterologists who admitted to using NBI in “most of the cases” in the screening 
questionnaire.  
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Statistical analysis 
The kappa values were calculated for an inter-rater agreement for the presence or absence 
of blood using IBM SPSS version 21. A kappa value of 0.01-0.20 means that the agreement 
is slight, a value of 0.21-0.40 - fair, 0.41-0.60 - moderate, 0.61-0.80 - substantial agreement 
and 0.81-0.99 is almost perfect agreement. (169) 
 
Figure 11 Overview images of 24-well plate using three series of endoscopes 
White light and NBI images of the overview using 240 (a & b), 260 (c & d) and 290 series (e & f) 
respectively
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Results 
4.1.1.1 Analysis of overview images:  
Blood appears dark under NBI and hence more readily visible than under WLE. This pattern 
was observed in our analysis across all generations of the endoscopes. With conventional 
white light the median dilution at which all 3 groups noted the presence of haemoglobin was 
1/215 using all three generations of endoscopes. The average scores for WLE among the 
experts was 15.6, NBI naïve-15.2 and Novices-15.8. It was impossible to assess the 
presence of blood at further dilutions despite using higher resolution endoscopes under 
white light examination. The visualisation of blood improved using NBI across all three 
groups. The average score among experts was 18.9 whereas among NBI-naïve and novices 
it was 19.1 and 19.7 respectively. The kappa value for the inter-rater agreement was 
substantial for all 3 generations of endoscopes using conventional white light.  
4.1.1.2 Analysis of individual images 
The analysis of the presence of blood assessed using individual wells revealed similar 
results. Presence of blood identified with WLE was between 1/212 - 1/216 across the three 
groups with median visualisation at 1/215. There was an improvement in visualising blood 
using NBI. It was noted that using NBI with GIF Q240 series, blood was seen at 1/217. There 
was further improvement with GIF H260 series with blood seen at 1/219 and to 1/220 using 
GIF H290 series of endoscopes.  
 
240 series 
 
 
260 series 
 
 
290 series 
Visibility of 
haemoglobin in white 
light (a’s) and NBI 
(b’s) at 1/28 
  
Least visible 
concentration of 
haemoglobin in 
white light (a’s) and 
NBI (b’s)  
 
Figure 12 Comparative visibility of haemoglobin under white light and NBI with different 
dilutions of blood. 
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The kappa values for the inter-rater agreement was κ>0.7 for all 3 generations of 
endoscopes using conventional white light, while it was κ>0.5 for all 3 generations of NBI.  
The kappa value of >0.7 suggests there was substantial agreement whereas a kappa value 
of >0.5 means only moderate to fair agreement between the observers (169).  
These results suggest that there was a significant improvement in assessing the presence of 
blood using NBI over WLE. There was a greater increment seen using NBI between Q240 
series to H260 series of endoscopes than seen between H260 and H290 series of 
endoscopes.   
Discussion  
NBI is designed to allow maximum absorption of light by haemoglobin and provide contrast 
enhancement of the tissue vasculature. The vascular pattern is altered in the mucosa and 
submucosa when a tissue undergoes neoplastic change. Because of the increased uptake 
of NBI from within the vasculature, it allows characterisation and potentially assessing the 
deeper invasion of the neoplastic lesions. NBI, as discussed earlier is superior to WLE in 
assessment and characterisation of lesions in the colon and rectum.  
Introduction of higher resolution and higher definition video endoscopes systems with digital 
and optical zoom capabilities have improved image quality. The Q 240 series of endoscopes 
were normal definition endoscopes equipped with the NBI technology. Later generation of 
endoscopes, the H260 and H290 series, are the higher definition endoscopes with further 
improvement in contrast enhancement. In our study, we compared the effect of improvement 
in contrast enhancement among the three generation of endoscopes. Not surprisingly the 
visualisation of blood was better with NBI compared to WLE. Similar findings were noted in 
one previous in vitro study which demonstrated the superiority of NBI in identifying blood 
compared to WLE and FICE(170). In our study, we compared WLE and NBI in three different 
generations of endoscopes in addition to quantitatively assessing the improvement between 
the three generations of endoscopes. To the best of our knowledge, this is the only study 
looking at such a comparison. This study is clinically relevant as all three generation of 
endoscopes are still in use in endoscopy units across the UK. And we believe that the 
results of the study can be translated into clinical practice. 
We acknowledge the limitation of our study is that is an in vitro study. However since we 
aimed at visualising blood using three generation of endoscopes, an in vitro study design 
was felt appropriate. In vivo study for assessment of the presence of haemoglobin within a 
colorectal lesion with three different endoscopes would not have been feasible. It would 
require a tandem design with back to back examination of the lesion with three different 
endoscopes for such a study and recruitment would be a major problem. We also 
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considered confounding factors in an in vivo such as mucosal changes of the lesions 
impairing the true assessment of the haemoglobin such as oedema and collagen content 
within the lesion.  
Conclusion 
 In conclusion, we demonstrated that NBI is superior to WLE in the assessment of the 
presence of blood. There was a significant improvement in NBI in the newer generation of 
endoscopes (H290 and H260) compared to the earlier endoscopes (Q240). The 
improvement in NBI was not as we expected between H260 to H290 in our study. Further 
studies comparing these two generations of endoscopes in humans to demonstrate the 
clinical utility must be considered.  
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5 Use of NBI in predicting disease outcomes in UC-a 
prospective observational study  
Background 
Ulcerative colitis (UC) is a chronic inflammatory condition of unknown aetiology, 
characterized by a diffuse confluent mucosal inflammation of the colon starting from the 
rectum with a relapsing and remitting course(134). Conventional endoscopy was thought to 
be a reliable parameter of disease activity(2), but microscopic inflammation can persist 
despite normal mucosal findings with conventional endoscopy(3). Histological detectable 
inflammation is thought to be associated with a greater risk of subsequent relapse(4, 5) A 
flare in UC activity is difficult to predict, but a simple, easily measured biological marker of 
relapse would be important in guiding the most appropriate and cost-effective therapy. High 
dose maintenance therapies could reduce the risk of relapse but carry their own risks. 
Serum markers like erythrocyte sedimentation rate, C reactive protein as well as 
orosomucoid have been shown to have a relatively poor sensitivity and specificity for 
intestinal inflammation and correlate poorly with disease activity indices(55, 171). Although 
faecal calprotectin and lactoferrin have been shown to be sensitive but not very specific in 
predicting the risk of relapse(142, 145), they are still underutilized with no large prospective 
studies on a diverse patient population done to date. More recently small studies have 
shown that findings on magnifying colonoscopy modestly predict disease relapse, with 70% 
of patients having endoscopic mucosal defects relapsing in 12 months(44). A pilot study 
from Japan showed that the mucosal vascular pattern using narrow band imaging correlates 
well with histological grade of inflammation in ulcerative colitis(38).   
Recent technological advances in fibre optics, light sources, detectors, and molecular 
biology have stimulated the unprecedented development of numerous optical methods that 
promise to significantly improve our ability to visualize and evaluate human epithelium in 
vivo. These methods collectively termed “optical biopsy,” are non-destructive in situ assays 
of mucosal histopathology using light that can provide instantaneous tissue assessment. NBI 
is a novel technique that enhances the diagnostic capability of endoscopes in characterising 
tissues by using narrow-band width filters in a red-green-blue (RGB) sequential illumination 
system. In NBI, the bandwidths of the standard red, green, and blue pass filters have been 
narrowed and the relative contribution of the blue filter has been increased resulting in 
improved mucosal contrast and detail(172)  
UC always involves the rectum and activity is usually greatest distally. This makes an 
evaluation of the rectum alone an attractive marker in patients with UC. Unlike serum and 
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faecal markers, endoscopic assessment of the rectal mucosa is unlikely to be affected by 
systemic disease or inflammation in the small intestine/stomach and would be a relatively 
easy and acceptable test for patients and physicians. Utilizing magnifying colonoscopy using 
Indigo carmine dye spray (which improves surface mucosa resolution), Japanese 
researchers have shown that regular pit patterns are associated with a significantly reduced 
risk of relapse(44). Similarly, patients with the distorted mucosal vascular pattern are noted 
to have a higher grade of inflammation among UC patients in remission(38)  
The primary aims of our pilot proof of concept study was to assess the correlation between 
NBI, white light endoscopy, and histological assessment of inflammation and clinical scoring 
systems in patients with ulcerative colitis. 
 
Study design  
This was a single centre study with a sequential trial design where all patients included in the 
trial had an endoscopic assessment of their rectum and sigmoid colon by either 
sigmoidoscopy or colonoscopy with white light and narrow band imaging. National research 
ethics committee and local ‘research and development’ department approval were obtained 
for the study (NREC reference number 13/YH/0115, and R&D approval number 
UR/13/10708).  
The power calculation was for this pilot observational study was based on the estimated 
relapse rate of 20-30% among our study group. The risk of relapse in UC patients when 
followed up for 12 months was derived from the published literature (4, 40, 82). Similar 
findings were noted in our retrospective analysis mentioned in chapter 2. Hence, we 
estimated that recruitment of around 120 patients would yield the desired results in the follow 
up period of one year.   
All adult patients undergoing sigmoidoscopy/colonoscopy at the Leeds Teaching Hospitals 
Trust (LTHT) for UC related assessment or surveillance on endoscopy waiting lists or those 
from gastroenterology outpatient clinics, were invited to take part in the study. All patients 
were under the care of Gastroenterology consultants (which may include the investigators) 
at LTHT. Patients were interviewed individually and details about the study were provided 
which included a written patient information sheet. Adequate time was given (at least 2 
weeks) to consider participating in the study and to clarify any doubts before consent was 
obtained. Patients were clearly informed that they can withdraw their consent at any stage 
during the study without compromising their standard clinical care. Images or videos of all 
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endoscopic procedures were digitally recorded with no patient identifiable data included. The 
endoscopies were performed by the researchers with experience in advanced endoscopic 
imaging. Data were collected on three different activity indices for clinical, endoscopic and 
histologic findings. Walmsley, Lichtiger and Modified Mayo scores were used for clinical 
activity; Baron, Mayo endoscopic subscore and Ulcerative colitis endoscopic index of 
severity were used for endoscopic assessment. Histology slides were graded according to 
three scores, Geboes, Riley and Rubin scores.  
Endoscopic assessment of UC plays a vital role in the assessment of disease activity. It also 
helps in assessing the response to treatment. Mucosal healing (MH) is increasingly adopted 
in research studies as a clinical endpoint. Although the definition of MH is not clear, it is 
complete absence of any inflammatory activity i.e. normal appearing mucosa. Endoscopic 
indices are developed to assess the inflammatory activity and may correlate with the 
histological grade of inflammation. However endoscopic examination has the disadvantage 
of being an invasive and hence not particularly desired by the patients. The problems with 
endoscopic assessment tools are two-fold; on one hand, there is lack of uniformity in 
definitions used to define severity and on the other hand there are numerous un-validated 
endoscopic indices of severity. Some of the indices use endoscopic findings alone while 
others use various combinations of clinical, biochemical, histological findings along with 
physicians own impression of the clinical situation(22, 27, 29, 30, 33, 34). On one hand, it 
may be argued that using these parameters separately allows for an objective assessment 
and perhaps make it easier, some researchers have questioned the need for endoscopy in 
the first place for knowing severity of disease activity, when similar findings can be derived 
by using clinical disease activity indices (26, 173). In one study researchers found that the 
absence of rectal bleeding and normal stool frequency can equate to complete mucosal 
healing(174). The clinical disease activity indices are non-invasive, rely on the clinical (and in 
some, biochemical) parameters to assess disease activity and may be preferred by patients 
compared to endoscopic examinations.   
 
Histology is the gold standard in the assessment of inflammation in UC. 18 histological 
indices are available to assess disease activity in UC, however, none of them is validated 
externally nor a preferred scoring system that is used universally. We compared the disease 
activity indices to the histological scores. Three histological scores were selected for the 
purpose of the study. The process of selecting the scoring systems was purely on the basis 
of published literature and ease of use by the histopathologists. We also looked for the 
defined cut off for the active and inactive disease. We did not restrict the selection based on 
external validation of the scores as none of them would have been qualified. The three 
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selected scores are Geboes, Riley and Histological inflammatory activity (HIA) scores. For 
the ease of use, we have named the scores on the basis of the first author of the published 
article in which the scores were proposed. Hence HIA is referred as Rubin score in the 
thesis. For Geboes score the cut off for defining active disease was 3.2, and that for Riley 
was 12 and Rubin was 2. Any scores above the cut off levels were classed as an active 
disease (5, 72, 73, 82).  
All three endoscopic indices used in the study are extensively used in the clinical research. 
Mucosal healing with a complete absence of inflammation is perceived as an important 
clinical outcome in the trials. Recent research suggests that patients with Mayo endoscopic 
score of 1 have a higher risk of relapse than those with a score of ‘0’(126, 127). Ikeya et al 
and Xie et al compared MES and UCEIS to the clinical outcomes in UC. In both these 
studies, patients with acute severe colitis were included. UCEIS score of ≥7 was a predictor 
for colectomy and was found to outperform MES (175). It was also found to accurately 
predict medium and long-term outcomes when tested against MES during the treatment 
phase of acute severe colitis(176).  
In this prospective observational study, we aimed to assess the relationship of the clinical, 
endoscopic and histologic markers to the clinical outcomes of the disease. Three clinical 
disease activity indices were selected for assessment of inflammation for the purpose of our 
study. There are various scoring systems or activity indices available in the literature. The 
commonly used parameters for assessing the severity are stool frequency and rectal 
bleeding. The other clinically important factors such as urgency and incontinence were not 
commonly featured among the scoring systems.   
For the purpose of the study, we wanted the scoring systems that used only clinical 
parameters and no biochemical markers were involved. We selected Walmsley index (also 
called as Simple Clinical Colitis Index), Lichtiger index (also called as Modified Truelove and 
Witts index) and Modified Mayo score (Mayo score without the endoscopic component).  
 
Methods 
5.1.1.1 Procedural details:  
The endoscopies were performed by the researchers with experience in advanced 
endoscopic imaging. Rectum and Sigmoid colon were adequately washed and white light 
endoscopy performed followed by examination under NBI with Olympus endoscopes series 
numbers 260 and above.  
80 
 
The endoscopic findings and the biopsies (number, site, level) taken were recorded 
accurately in the patient case record form. Biopsies taken were according to the standard 
guidelines for UC surveillance.  
5.1.1.2 Timescale 
The patient’s participation in the study is for twelve months after their sigmoidoscopy or 
colonoscopy performed for clinical indications as determined by the treating physician.  
Patients with acute colitis who underwent sigmoidoscopy for assessment of disease severity 
and extent were followed up for the period of twelve months following the procedure.  
Patients with Quiescent colitis who underwent colonoscopy for surveillance of their disease 
were included in the study for twelve months following the procedure. Flare up data was 
recorded during the follow-up period.  
5.1.1.3 Primary endpoint 
The primary endpoint is the assessment of inflammation in patients with ulcerative colitis 
using NBI and its correlation with standard endoscopy, histology and clinical scoring systems 
also called as Disease activity indices (DAIs). 
5.1.1.4 Secondary endpoints 
• To assess the accuracy of clinical DAIs and endoscopic scores in predicting 
inflammatory activity. 
• To assess if DAIs, endoscopic and histological scores predict outcomes among the 
recruited patients.  
• To assess the benefit of adding NBI to WLE endoscopy in predicting disease 
outcomes. 
 
Statistical Analysis 
Results are expressed as means ± standard deviations for continuous variables and as 
frequencies for categorical variables. P values from ANOVA or chi-square tests were 
considered statistically significant if ≤ 0.05. We used varying cut-offs of endoscopic scores 
(with white light and/or NBI imaging) and histologic scores to predict disease activity based 
on patient perspective of a flare,   physician global assessment and clinical diseases actiivty 
indices.   We also   evaluated the ability of endosopic and histologic scores in prediting 
disease flare at 12 months of folow up.  We calculated sensitivity, specificity, negative and 
positive predictive values, and diagnostic accuracy for each scoring system together with 
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95% confidence intervals (CI), according to standard definitions.  All statistical tests were 
done using PASW version 20 (IBM Corp, NY).  
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Figure 13 Inactive UC assessed with white light (left) and NBI (right) 
  
Figure 14 Active UC assessed with white light (left) and NBI (right) 
  
Results 
Patients were recruited for this trial from 20th September 2013 to 17th July 2014. All patients 
with acute severe colitis were contacted to participate in the trial by the research fellow (NM) 
and research nurses. Patients who were thought to have a flare up of their disease activity 
from the out-patient’s clinic were contacted by the consulting physician. A sigmoidoscopy 
was arranged on the same day in most of the cases. Patients with quiescent disease were 
provided with the written information of the trial and were consented prior to procedure. 
Baseline characteristics 
A total of 116 patients were included in the study, 53 in acute and 61 in quiescent arm. Table 
15 demonstrates the basic demographics of the patients involved. As expected from the 
disease pattern, the duration of disease is significantly different in the quiescent compared to 
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the acute arm. The flowchart describes the process of patient selection for the study. A total 
of 124 patients were contacted for the study; 4 did not consent for the trial, 2 withdrew 
consent during the procedure and 3 patients did not attend clinic appointments.  
Table 16 describes the outcomes in the follow up period for patients in acute and quiescent 
arms. In the first year of follow up among the patients in acute arm, about 33% of patient 
flared. This is attributable to the fact that many of the patients included were newly 
diagnosed with Ulcerative colitis. 11 patients out of 53 (20.7%) were newly diagnosed colitis 
with recto-sigmoiditis diagnosed within the last 12 months. In the quiescent arm, however, 
the percentage of patients who experienced a flare up were 8.2 and 20% in first year of 
follow up respectively which is around the same in the published literature(4, 40) 
The results of this study pertaining to our primary and secondary objectives are presented in 
different subheadings as follows. 
Table 15 Characteristics of patients included in NBI prospective study 
 Acute arm (n=53) 
 
Quiescent arm (n=61) 
Mean age in years (range) 37.6 (20-80) 55.8 (24-83) 
Males 26 41 
Females 27 20 
Mean duration of disease 
in years (range) 
8.07 (1-44) 20.2 (2-54) 
Extent of disease 
(Montreal classification) 
E1 
E2 
E3 
 
 
5 
34 
14 
 
 
1 
23 
37 
Previous flare up in 
months (range) 
12.05 (1-60) 24.3 (2-60) 
 E1- Proctitis only, E2-Left sided colitis, E3-Extensive/Pan colitis
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Figure 15 Flowchart of patient recruitment for NBI study 
 
  
124 patients were contacted 
for the study 
120 patients recruited 
61 patients included in 
quiescent arm 
4 did not 
consent 
2 patients (acute arm) 
withdrew consent during 
the procedure 
1 patients was recruited 
twice for the study 
3 patients lost to follow up 
53 patients included in 
acute arm  
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Table 16 Outcome data for patients with acute and quiescent colitis at twelve months 
 Acute arm (n=53) Quiescent arm 
(n=61) 
 Outcome at  
30 days (n=53) 
Outcome at 12 
 months (n=51)* 
Outcomes at 12 
months (n=61) 
Remission attained 
(%) 
47 (88.6) 34 (66.6) 56 (91.8) 
Remission not 
attained (%) 
5 (9.4) 17 (33.3) 5 (8.2) 
Mean duration of 
relapse in months 
(range) 
n/a 5.4 (2-11) 7.2 (6-11) 
Lost to follow up 1 1 0 
Escalation of 
treatment  
5 19 3 
Escalated 
treatment 
INF alone-3 
INF+AZA-1 
Adacolum-1  
INF alone- 11 
INF+AZA- 5 
Adacolum-1 
Steroids+ AZA-1 
AZA alone-1 
Golizumab-1 
No escalation -2 
Surgery None 2 None 
INF-Infliximab, AZA-Azathioprine
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Can disease activity indices predict endoscopic activity in UC?  
 
All three DAIs were assessed against the three endoscopic indices separately to assess 
accuracy of DAIs in predicting endoscopic activity. We also checked other parameters such 
as ‘patient’s understanding of the symptoms’ (flare or no-flare), and Physicians global 
assessment (PGA) against disease activity indices.  
Statistical analysis was performed on the available cut off scores for each of the indices to 
assess quiescent and active disease. When there is more than one cut off scores available 
in the literature analyses was performed for on each of the scores. For example, a score of 2 
and 3 are reported as cut-offs for Walmsley index in the literature and hence these scores 
were individually analysed to determine the sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV), correlation and accuracy as shown in the tables 
below. Each of the three DAIs was compared to the three endoscopic indices and analysis 
was separately performed for WLE and NBI as shown in tables below. 
The results in Tables 17-20, 21-24 and 25-28 show the comparative analysis of the DAIs to 
Mayo endoscopy sub-scores, Ulcerative colitis endoscopic index of severity and Modified 
Baron’s scores with white light and Narrow band examinations respectively.  
From the analysis, it is also evident that the use of DAIs with objective point-based scoring 
systems were better in predicting the endoscopic findings in both active (MES ≥1) and 
inactive/quiescent state (MES 0) of the disease. The PGA although scored better in 
assessing the active state, compared to the patient’s interpretation of symptoms, the 
sensitivity still remained around 80%. All three DAIs faired more or less the same in 
predicting the activity, with sensitivity and accuracy around 80%. Addition of NBI to the three 
endoscopic scores does not seem to confer any added benefit in grading the severity further 
than white light examination.   
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5.1.1.5 Comparison of disease activity indices in predicting endoscopic activity using Mayo 
endoscopic sub-score. 
 
Table 17 Comparison of three DAIs and Mayo endoscopic subscore ‘0’ (with WLE) 
 MES ‘0’ 
WLE 
Sensitivity 
% (95% 
confidence 
interval) 
MES ‘0’ WLE 
Specificity 
% (95% 
confidence 
interval) 
MES ‘0’ 
WLE  
PPV 
% (95% 
confidence 
interval) 
 
MES ‘0’ 
WLE  
NPV 
% (95% 
confidence 
interval) 
MES ‘0’ 
WLE 
Accuracy 
% (95% 
confidence 
interval) 
Patient’s 
interpretation of 
symptoms 
0.53  
(0.46-0.57) 
0.92  
(0.81-0.97) 
0.90  
(0.78-0.97) 
0.58  
(0.51-0.61) 
0.69  
(0.60-0.73) 
Physicians 
global 
assessment  
0.72  
(0.65-0.77) 
0.87  
(0.77-0.94) 
0.89  
(0.80-0.95) 
0.69  
(0.60-0.74) 
0.78  
(0.70-0.84) 
Walmsley index 
≥2 
0.91  
(0.81-0.97) 
0.70  
(0.63-0.74) 
0.68  
(0.61-0.72) 
0.92  
(0.83-0.97) 
0.79  
(0.71-0.84) 
Walmsley index 
≥3 
0.93  
(0.83-0.98) 
0.67  
(0.60-0.70) 
0.67  
(0.60-0.70) 
0.93 
(0.84-0.98) 
0.78  
(0.70-0.82) 
Modified Mayo 
score ‘0’ 
0.89  
(0.74-0.92)  
0.77 
(0.70-0.83) 
0.73  
(0.64-0.79) 
0.91  
(0.79-0.94) 
0.81  
(0.72-0.87) 
Modified Mayo 
score ≥1 
0.81  
(0.79-0.96) 
0.74  
(0.67-0.78) 
0.70  
(0.62-0.75)  
0.89  
(0.82-0.96)  
0.80  
(0.72-0.85) 
Lichtiger index 
≥3 
0.91  
(0.81-0.97) 
0.67  
(0.60-0.71) 
0.66  
(0.59-0.70) 
0.92  
(0.82-0.97) 
0.78  
(0.69-0.82) 
Disease activity indices – DAIs, White light examination (WLE). ‘PPV=Positive predictive value, 
NPV=Negative predictive value. Values expressed in % and 95% confidence intervals in the bracket. 
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Table 18 Comparison of the three DAIs and Mayo endoscopic subscore ‘≥1’ (with WLE) 
 MES ‘1’  
WLE 
Sensitivity 
% (95% 
confidence 
interval) 
MES ‘1’  
WLE 
Specificity 
% (95% 
confidence 
interval) 
MES ‘1’ 
WLE  
PPV 
% (95% 
confidence 
interval) 
 
MES ‘1’ 
WLE  
NPV 
% (95% 
confidence 
interval) 
MES ‘1’ 
WLE 
Accuracy 
% (95% 
confidence 
interval) 
Patient’s 
interpretation of 
symptoms 
0.63  
(0.51-0.72) 
0.84  
(0.77-0.90) 
0.72  
(0.59-0.83) 
0.78  
(0.70-0.83) 
0.76  
(0.67-0.83) 
Physicians 
global 
assessment  
0.85  
(0.74-0.92) 
0.77   
(0.70-0.82) 
0.71  
(0.62-0.77) 
0.88  
(0.80-0.94) 
0.80  
(0.71-0.86) 
Walmsley index 
≥2 
0.78  
(0.71-0.84) 
0.80  
(0.69-0.89) 
0.86  
(0.78-0.92) 
0.71  
(0.61-0.78)  
0.79 
(0.70-0.86) 
Walmsley index 
≥3 
0.8  
(0.72-0.86) 
0.76  
(0.64-0.85) 
0.83  
(0.75 0.89) 
0.71  
(0.60-0.79) 
0.78  
(0.69-0.86) 
Modified Mayo 
score ‘0’ 
0.71  
(0.64-0.76) 
0.87  
(0.75-0.94) 
0.89  
(0.80-0.95) 
0.66  
(0.58 0.72)  
0.78  
(0.69-0.83) 
Modified Mayo 
score ≥1 
0.75  
(0.68-0.80) 
0.84  
(0.73-0.92) 
0.88  
(0.80-0.94) 
0.70  
(0.60-0.76) 
0.79  
(0.70-0.85) 
Lichtiger index 
≥3 
0.80  
(0.72-0.85) 
0.78  
(0.66-0.87) 
0.85  
(0.77-0.90) 
0.72  
(0.61-0.80) 
0.79 
 (0.70-0.86) 
Comparison of the three disease activity indices (DAIs) and Mayo endoscopic subscore ‘≥1’ using 
white light examination (WLE). Values expressed in % and 95% confidence intervals in the bracket. 
‘PPV=Positive predictive value, NPV=Negative predictive value 
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Table 19 Comparison of the three DAIs and Mayo endoscopic subscore ‘0’ (with NBI) 
 MES ‘0’  
NBI 
Sensitivity 
% (95% 
confidence 
interval) 
MES ‘0’  
NBI 
Specificity 
% (95% 
confidence 
interval) 
MES ‘0’ 
NBI 
PPV 
% (95% 
confidence 
interval) 
 
MES ‘0’ 
NBI 
NPV 
% (95% 
confidence 
interval) 
MES ‘0’ 
NBI 
Accuracy 
% (95% 
confidence 
interval) 
Patient’s 
interpretation 
of symptoms 
0.53  
(0.46-0.57) 
0.92  
(0.81-0.72) 
0.90  
(0.78-0.97) 
0.58  
(0.51-0.61) 
0.69  
(0.60-0.73) 
Physicians 
global 
assessment  
0.70  
(0.63-0.75) 
0.87  
(0.76-0.94) 
0.89  
(0.80-0.95) 
0.66  
(0.57-0.71) 
0.77  
(0.68-0.82) 
Walmsley 
index ≥2 
0.91  
(0.80-0.97) 
0.68  
(0.61-0.72) 
0.65  
(0.58-0.69) 
0.92  
(0.82-0.97) 
0.78  
(0.69-0.82) 
Walmsley 
index ≥3 
0.93  
(0.83-0.98) 
0.65  
(0.59-0.68) 
0.64  
(0.57-0.67) 
0.93  
(0.84-0.98) 
0.77  
(0.69-0.80) 
Modified Mayo 
score ‘0’ 
0.84  
(0.73-0.92) 
0.75  
(0.68-0.80) 
0.69  
(0.60-0.76) 
0.69  
(0.79-0.94) 
0.79  
(0.70-0.85) 
Modified Mayo 
score ≥1 
0.89  
(0.78-0.95) 
0.72  
(0.65-0.77) 
0.68 
(0.60-0.73) 
0.91  
(0.82-0.96) 
0.79  
(0.71-0.84) 
Lichtiger index 
≥3 
 
0.91  
(0.80-0.97) 
0.65  
(0.58-0.69) 
0.63  
(0.56-0.67) 
0.92 
(0.82-0.97) 
0.76  
(0.67-0.80) 
Comparison of the three disease activity indices (DAIs) and Mayo endoscopic subscore of ‘0’ using 
Narrow Band Imaging (NBI). Values expressed in % and 95% confidence intervals in the bracket. 
PPV=Positive predictive value, NPV=Negative predictive value 
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Table 20 Comparison of the three DAIs and Mayo endoscopic subscore ‘≥1’ (with NBI) 
 MES ‘≥1’ 
NBI 
Sensitivity 
% (95% 
confidence 
interval) 
MES ‘≥1’ 
NBI 
Specificity 
% (95% 
confidence 
interval) 
MES ‘≥1’ 
NBI 
PPV 
% (95% 
confidence 
interval) 
 
MES ‘≥1’ 
NBI 
NPV 
% (95% 
confidence 
interval) 
MES ‘≥1’ 
NBI 
Accuracy 
% (95% 
confidence 
interval) 
Patient’s 
interpretation 
of symptoms 
0.59  
(0.51-0.64) 
0.91  
(0.82-0.96) 
0.87  
(0.75-0.95) 
0.68 
(0.62-0.72) 
0.75  
(0.66-0.80) 
Physicians 
global 
assessment  
0.80  
(0.71-0.86) 
0.86  
(0.77-0.92) 
0.85  
(0.76-0.92) 
0.80  
(0.72-0.86) 
0.83  
(0.74-0.89) 
Walmsley 
index ≥2 
0.89  
(0.80-0.95) 
0.78  
(0.69-0.83) 
0.79  
(0.71-0.84) 
0.88  
(0.78-0.94) 
0.84  
(0.75-0.89) 
Walmsley 
index  ≥3 
0.91  
(0.82-0.96) 
0.74  
(0.66-0.79) 
0.77  
(0.70-0.82) 
0.89  
(0.79-0.95) 
0.83  
(0.74-0.88) 
Modified Mayo 
score ‘0’ 
0.82  
(0.73-0.88) 
0.84  
(0.76-0.91) 
0.83  
(0.74-0.90) 
0.83  
(0.74-0.89) 
0.84  
(0.75-0.90) 
Modified Mayo 
score ≥1 
0.86  
(0.77-0.92) 
0.81  
(0.72-0.87) 
0.81  
(0.73-0.87) 
0.85  
(0.76-0.92) 
0.836 (0.75-
0.90) 
Lichtiger index  
≥3 
0.89  
(0.80-0.95) 
0.74  
(0.66-0.80) 
0.77  
(0.69-0.82) 
0.88  
(0.78-0.94) 
0.82  
(0.73-0.88) 
Table 4. Comparison of the three disease activity indices (DAIs) and Mayo endoscopic subscore of 
‘≥1’ using Narrow Band Imaging (NBI). Values expressed in % and 95% confidence intervals in the 
bracket. PPV=Positive predictive value. NPV= Negative predictive value. 
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5.1.1.6 Comparison of disease activity indices in predicting endoscopic activity using 
Ulcerative colitis endoscopic index of severity (UCEIS). 
Table 21 Comparison of the three DAIs and UCEIS ‘0’ (with WLE) 
 UCEIS  
WLE 0 
Sensitivity 
UCEIS  
WLE 0 
Specificity 
UCEIS  
WLE 0  
PPV 
UCEIS  
WLE 0  
NPV 
UCEIS  
WLE 0 
Accuracy 
 
Patient’s 
interpretation of 
symptoms 
0.55  
(0.45-0.65) 
0.91  
(0.81-0.97) 
0.90  
(0.78-0.97) 
0.57  
(0.50-0.60) 
0.68  
(0.60-0.73) 
Physicians 
global 
assessment  
0.71  
(0.64-0.76) 
0.82  
(0.76-0.94) 
0.89  
(0.80-0.95) 
0.67  
(0.59-0.73) 
0.78 
(0.69-0.83) 
Walmsley index 
≥2 
0.91  
(0.81-0.97) 
0.69  
(0.62-0.73) 
0.67  
(0.59-0.71) 
0.92  
(0.82-0.97)  
0.78  
(0.70-0.83) 
Walmsley index 
≥3 
 
0.93  
(0.83-0.98) 
0.66  
(0.59-0.69) 
0.65  
(0.58-0.68) 
0.93  
(0.84-0.98) 
0.88  
(0.67-0.97) 
Modified Mayo 
score ‘0’ 
0.85  
(0.74-0.92) 
0.76  
(0.69-0.82) 
0.71  
(0.62-0.77) 
0.88  
(0.79-0.94) 
0.80  
(0.71-0.86) 
Modified Mayo 
score ≥1 
0.89 
(0.78-0.95) 
0.73  
(0.66-0.78) 
0.70  
(0.61-0.75) 
0.91  
(0.82-0.96) 
0.80  
(0.72-0.85) 
Lichtiger index 
≥3 
0.91  
(0.81-0.97) 
0.66  
(0.59-0.70) 
0.65  
(0.57-0.69) 
0.92  
(0.82-0.97) 
0.77  
(0.68-0.81) 
Comparison of the three disease activity indices (DAIs) and Ulcerative Colitis Endoscopic Index of 
Severity (UCEIS) ‘0’ using White light endoscopy (WLE). Values expressed in % and 95% confidence 
intervals in the bracket. PPV=Positive predictive value. NPV= Negative predictive value
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Table 22 Comparison of the three DAIs and UCEIS ‘≥ 1’ (with WLE). 
 UCEIS  
WLE ≥ 1 
Sensitivity 
UCEIS  
WLE ≥ 1 
Specificity 
UCEIS  
WLE ≥ 1  
PPV 
UCEIS  
WLE ≥ 1  
NPV 
UCEIS  
WLE ≥ 1 
Accuracy 
Patient’s 
interpretation 
of symptoms 
0.59  
(0.51-0.64) 
0.91  
(0.82-0.96) 
0.87  
(0.75-0.95) 
0.68  
(0.62-0.72) 
0.75  
(0.66-0.80) 
Physicians 
global 
assessment  
0.75  
(0.65-0.82) 
0.80  
(0.71-0.88) 
0.80  
(0.70-0.88) 
0.75  
(0.67-0.82) 
0.77  
(0.68-0.85) 
Walmsley index 
≥2 
0.82  
(0.73-0.89) 
0.71  
(0.62-0.78) 
0.73  
(0.65-0.79) 
0.80  
(0.70-0.88) 
0.76  
(0.67-0.84) 
Walmsley index  
≥3 
0.84  
(0.74-0.91) 
0.67  
(0.58-0.74) 
0.71  
(0.63-0.77) 
0.81  
(0.70-0.89) 
0.76  
(0.67-0.83) 
Modified Mayo 
score ‘0’ 
0.75  
(0.65-0.83) 
0.78  
(0.68-0.85) 
0.76  
(0.67-0.84) 
0.76  
(0.67-0.83) 
0.77  
(0.67-0.84) 
Modified Mayo 
score ≥1 
0.78  
(0.69-0.86) 
0.74  
(0.65-0.81) 
0.75  
(0.65-0.82) 
0.78  
(0.68-0.86) 
0.77  
(0.67-0.84) 
Lichtiger index 
≥3 
0.82  
(0.72-0.89) 
0.67  
(0.58-0.74) 
0.71  
(0.63-0.77) 
0.80  
(0.69-0.88) 
0.75  
(0.66-0.82) 
Comparison of the three disease activity indices (DAIs) and Ulcerative Colitis Endoscopic Index of 
Severity (UCEIS) of ‘≥1’ using White light endoscopy (WLE). Values expressed in % and 95% 
confidence intervals in the bracket. PPV=Positive predictive value. NPV= Negative predictive value.
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Table 23 Comparison of the three DAIs and UCEIS ‘0’ (with NBI) 
 UCEIS  
NBI 0 
Sensitivity 
UCEIS  
NBI 0 
Specificity 
UCEIS  
NBI 0  
PPV 
UCEIS 
NBI 0  
NPV 
UCEIS  
NBI 0 
Accuracy 
Patient’s 
interpretation of 
symptoms 
0.52 (0.45-
0.55) 
0.93 (0.83-
0.98) 
0.92 (0.81-
0.98) 
0.55 (0.49-
0.58) 
0.68 (0.60-
0.72) 
Physicians 
global 
assessment  
0.70 (0.63-
0.75) 
0.89 (0.78-
0.96) 
0.91 (0.82-
0.96) 
0.66 (0.57-
0.70) 
0.77 (0.69-
0.83) 
Walmsley index 
≥2 
0.91 (0.80-
0.97) 
0.67 (0.60-
0.71) 
0.64 (0.56-
0.68) 
0.92 (0.82-
0.97) 
0.77 (0.68-
0.81) 
Walmsley index 
≥3 
0.93 (0.82-
0.98) 
0.64 (95% CI 
0.58-0.67) 
0.62 (0.55-
0.66) 
0.93 (0.84-
0.98) 
0.76 (0.68-
0.78) 
Modified Mayo 
score ‘0’ 
0.84 (0.73-
0.92) 
0.74 (0.67-
0.79) 
0.67 (0.58-
0.74) 
0.88 (0.79-
0.94)  
0.78 (0.69-
0.85) 
Modified Mayo 
score ≥1 
0.88 (0.77-
0.95) 
0.71 (0.64-
0.76) 
0.66 (0.58-
0.71) 
0.91 (0.82-
0.96) 
0.78 (0.70-
0.84) 
Lichtiger index 
≥3 
0.91 (0.80-
0.97) 
0.64 (0.57-
0.68) 
0.62 (0.54-
0.66) 
0.92 (0.82-
0.97) 
0.75 (0.66-
0.80) 
Comparison of the three disease activity indices (DAIs) and Ulcerative Colitis Endoscopic Index of 
Severity (UCEIS) 0f ‘0’ using Narrow Band Imaging (NBI). Values expressed in % and 95% 
confidence intervals in the bracket. PPV=Positive predictive value. NPV= Negative predictive value
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Table 24 Comparison of the three DAIs and UCEIS ‘≥ 1’ (with NBI). 
 UCEIS  
NBI ≥ 1 
Sensitivity 
UCEIS  
NBI ≥ 1 
Specificity 
UCEIS  
NBI ≥ 1  
PPV 
UCEIS  
NBI ≥ 1  
NPV 
UCEIS  
NBI ≥ 1 
Accuracy 
Patient’s 
interpretation 
of symptoms 
0.54 (0.47-
0.59) 
0.92 (0.82-
0.97) 
0.90 (0.78-
0.97) 
0.60 (0.54-
0.64) 
0.70 (0.62-
0.75) 
Physicians 
global 
assessment  
0.71 (0.63-
0.77) 
0.84 (0.73-
0.92) 
0.91 (0.82-
0.96) 
0.66 (0.57-
0.70) 
0.78 (0.69-
0.83) 
Walmsley Index 
≥2 
0.88 (0.77-
0.94) 
0.69 (0.61-
0.74) 
0.68 (0.60-
0.74) 
0.88 (0.78-
0.94) 
0.78 (0.69-
0.83) 
Walmsley Index  
≥3 
0.84 (0.74-
0.91) 
0.67 (0.58-
0.74) 
0.71 (0.63-
0.77) 
0.81 (0.70-
0.89) 
0.77 (0.68-
0.82) 
Modified Mayo 
score ‘0’ 
0.82 (0.71-
0.89) 
0.77 (0.69-
0.83) 
0.73 (0.63-
0.80) 
0.85 (0.76-
0.91) 
0.79 (0.70-
0.86) 
Modified Mayo 
score ≥1 
0.86 (0.75-
0.93) 
0.74 (0.66-
0.79) 
0.71 (0.63-
0.77) 
0.87 (0.78-
0.93) 
0.79 (0.70-
0.85) 
Lichtiger Index 
≥3 
0.88 (0.77-
0.94) 
0.66 (0.58-
0.71) 
0.66 (0.58-
0.71) 
0.88 (0.77-
0.94) 
0.76 (0.67-
0.82) 
Comparison of the three disease activity indices (DAIs) and Ulcerative Colitis Endoscopic Index of 
Severity (UCEIS) 0f ‘≥1’ using Narrow Band Imaging (NBI). Values expressed in % and 95% 
confidence intervals in the bracket. PPV=Positive predictive value. NPV= Negative predictive value 
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5.1.1.7 Comparison of disease activity indices in predicting endoscopic activity using 
Modified Baron’s index of activity. 
 
Table 25 Comparison of the three DAIs and Modified Baron index of ‘0’ (with WLE).   
 Baron 
WLE_0 
Sensitivity 
Baron 
WLE_0 
Specificity 
Baron 
WLE_0 
PPV 
Baron 
WLE_0 
NPV 
Baron 
WLE_0 
Accuracy 
Patient’s 
interpretation of 
symptoms 
0.53 (0.457-
0.568) 
0.92 (0.81-
0.97) 
0.90 (0.78-
0.97) 
0.58 (0.51-
0.61) 
0.69 (0.60-
0.73) 
Physicians 
global 
assessment  
0.72 (0.65-
0.77) 
0.87 (0.77-
0.94) 
0.89 (0.80-
0.95) 
0.69 (0.60-
0.74) 
0.78 (0.70-
0.84) 
Walmsley index 
≥2  
0.91 (0.81-
0.97) 
0.70 (0.63-
0.74) 
0.68 (0.61-
0.72) 
0.92 (0.83-
0.97) 
0.79 (0.70-
0.84) 
Walmsley index 
≥3 
0.93 (0.83-
0.98) 
0.67 (0.60-
0.70) 
0.67 (0.60-
0.70) 
0.93 (0.84-
0.98) 
0.78 (0.70-
0.82) 
Modified Mayo 
score ‘0’ 
0.85 (0.74-
0.92) 
0.77 (0.70-
0.83) 
0.73 (0.64-
0.79) 
0.88 (0.79-
0.94) 
0.81 (0.72-
0.87) 
Modified Mayo 
score ≥1 
0.89 (0.79-
0.95) 
0.75 (0.67-
0.79) 
0.71 (0.63-
0.76) 
0.91 (0.82-
0.96) 
0.81 (0.72-
0.86) 
Lichtiger index 
≥3 
0.91 (0.81-
0.97) 
0.67 (0.60-
0.71) 
0.66 (0.59-
0.70) 
0.92 (0.82-
0.97) 
0.77 (0.69-
0.82) 
Comparison of the three disease activity indices (DAIs) and Modified Baron index of ‘0’ using White 
Light Endoscopy (WLE). Values expressed in % and 95% confidence intervals in the bracket. 
PPV=Positive predictive value. NPV= Negative predictive value. 
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Table 26 Comparison of the three DAIs and Modified Baron index of ‘≥1’ (with WLE). 
 Baron  
WLE ≥ 1 
Sensitivity 
Baron  
WLE ≥ 1 
Specificity 
Baron  
WLE ≥ 1 
PPV 
Baron  
WLE ≥ 1 
NPV 
Baron  
WLE ≥ 1 
Accuracy 
Patient’s 
interpretation of 
symptoms 
0.53 (0.46-
0.57) 
0.92 (0.81-
0.97) 
0.90 (0.78-
0.97) 
0.58 (0.51-
0.61) 
0.69 (0.60-
0.73)  
Physicians 
global 
assessment  
0.72 (0.65-
0.77) 
0.87 (0.77-
0.94) 
0.89 (0.80-
0.95) 
0.69 (0.60-
0.74) 
0.78 (0.70-
0.84) 
Walmsley index 
≥2 
0.70 (0.63-
0.74) 
0.92 (0.81-
0.97) 
0.92 (0.83-
0.97) 
0.69 (0.61-
0.73) 
0.79 (0.71-
0.84) 
Walmsley index 
≥3 
0.68 (0.61-
0.71) 
0.94 (0.84-
0.98) 
0.94 (0.84-
0.98) 
0.67 (0.60-
0.70) 
0.78 (0.70-
0.82) 
Modified Mayo 
score ‘0’ 
0.78 (0.70-
0.83) 
0.85  (0.75-
0.93) 
0.88 (0.80-
0.94) 
0.73 (0.64-
0.79) 
0.81 (0.72-
0.87) 
Modified Mayo 
score ≥1 
0.75 (0.68-
0.79) 
0.90 (0.79-
0.96) 
0.91 (0.82-
0.96) 
0.72 (0.63-
0.77) 
0.81 (0.72-
0.86) 
Lichtiger index 
≥3 
0.68 (0.60-
0.71) 
0.92 (0.81-
0.97) 
0.92 (0.82-
0.97) 
0.67 (0.59-
0.71) 
0.78 (0.69-
0.82) 
Comparison of the three disease activity indices (DAIs) and Modified Baron index of ‘≥1’ using white 
light endoscopy (WLE). Values expressed in % and 95% confidence intervals in the bracket. 
PPV=Positive predictive value. NPV= Negative predictive value 
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Table 27 Comparison of the three DAIs and Modified Baron index of ‘0’ (with NBI) 
 Baron NBI_0 
Sensitivity 
Baron NBI_0 
Specificity 
Baron 
NBI_0 
PPV 
Baron 
NBI_0  
NPV 
Baron NBI_0 
Accuracy 
Patient’s 
interpretation of 
symptoms 
0.51 (0.44-
0.55) 
0.91 (0.80-
0.97) 
0.90 (0.77-
0.96) 
0.55 (0.49-
0.59) 
0.67 (0.59-
0.72) 
Physicians 
global 
assessment  
0.70 (0.63-
0.75) 
0.87 (0.76-
0.94) 
0.89 (0.80-
0.95) 
0.66 (0.57-
0.71) 
0.77 (0.68-
0.82) 
Walmsley index 
≥2 
0.91 (0.80-
0.97) 
0.68 (0.61-
0.72) 
0.65 (0.58-
0.69) 
0.92 (0.82-
0.97) 
0.78 (0.69-
0.82) 
Walmsley index 
≥3 
0.93 (0.83-
0.98) 
0.65 (0.59-
0.68) 
0.64 (0.57-
0.67) 
0.93 (0.84-
0.98) 
0.767 (0.686-
0.805) 
Modified Mayo 
score ‘0’ 
0.84 (0.73-
0.92) 
0.75 (0.68-
0.80) 
0.69 (0.60-
0.76) 
0.88 (0.79-
0.94) 
0.79 (0.70-
0.85) 
Modified Mayo 
score ≥1 
0.89 (0.78-
0.95) 
0.72 (0.65-
0.77) 
0.68 (0.60-
0.73) 
0.91 (0.82-
0.96) 
0.79 (0.70-
0.84) 
Lichtiger index 
≥3 
0.91 (0.80-
0.97) 
0.65 (0.58-
0.69) 
0.63 (0.56-
0.67) 
0.92 (0.82-
0.97) 
0.76 (0.67-
0.80) 
Comparison of the three disease activity indices (DAIs) and Modified Baron index of ‘0’ using Narrow 
Band Imaging. Values expressed in % and 95% confidence intervals in the bracket. PPV=Positive 
predictive value. NPV= Negative predictive value 
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Table 28 Comparison of the three DAIs and Modified Baron index of ‘≥1’ (with NBI) 
 Baron  
NBI ≥1 
Sensitivity 
Baron 
NBI ≥ 1 
Specificity 
Baron  
NBI ≥ 1 
PPV 
Baron 
NBI ≥1 
NPV 
Baron 
NBI ≥1 
Accuracy 
Patient’s 
interpretation 
of symptoms 
0.51 (0.44-
0.55) 
0.91 (0.81-
0.97) 
0.90 (0.78-
0.97) 
0.55 (0.49-
0.59) 
0.67 (0.59-
0.72) 
Physicians 
global 
assessment  
0.70 (0.63-
0.75) 
0.87 (0.76-
0.94) 
0.89 (0.80-
0.95) 
0.66 (0.57-
0.71) 
0.77 (0.68-
0.82) 
Walmsley 
index ≥ 2 
0.69 (0.62-
0.72) 
0.91 (0.81-
0.97) 
0.92 (0.83-
0.97) 
0.66 (0.58-
0.70) 
0.77 (0.69-
0.82) 
Walmsley 
index ≥3 
0.66 (0.59-
0.69) 
0.93 (0.83-
0.98) 
0.94 (0.84-
0.98) 
0.64 (0.57-
0.67) 
0.77 (0.69-
0.80) 
Modified 
Mayo score 
‘0’ 
0.76 (0.68-
0.81) 
0.85 (0.74-
0.92) 
0.883 
 (0.79-0.94) 
0.70 (0.60-
0.76) 
0.79 (0.70-
0.85) 
Modified 
Mayo score 
≥1 
0.73 (0.66-
0.77) 
0.89 (0.78-
0.96) 
0.91 (0.82-
0.96) 
0.68 (0.60-
0.73) 
0.79 (0.71-
0.84) 
Lichtiger 
index ≥3 
0.66 (0.59-
0.69) 
0.91 (0.81-
0.97) 
0.92 (0.82-
0.97) 
0.64 (0.56-
0.68) 
0.76 (0.67-
0.80) 
Comparison of the three disease activity indices (DAIs) and Modified Baron index of ‘≥1’ using Narrow 
Band Imaging. Values expressed in % and 95% confidence intervals in the bracket. PPV=Positive 
predictive value. NPV= Negative predictive value 
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Can Disease Activity Indices predict histological activity? 
 
In this section we compared DAIs with the three histological scores to check their accuracy 
in predicting the histology.  
Statistical analysis was performed while comparing DAIs, patient’s interpretation of a flare 
and PGA with the histologically active disease scored as Geboes score >3.2. Data was 
recorded on the 2x2 table to attain Sensitivity, Specificity, PPV, NPV, Correlation and 
accuracy of the scores.  
The results in Tables 29-31 show the comparative analysis of the DAIs to Geboes score 
≥3.2, Riley’s score ≥12 and Rubin score ≥2 respectively.  
Among the scores used, both Walmsley (cut off 2 and 3) and Lichtiger indices predicted the 
histological inflammation better than Modified Mayo score. Although the sensitivities were 
high, the accuracy remained low at around 70%. The patient’s interpretation of the 
symptoms was poorly correlated with the histological findings ranging from 46-50% across 
the three scores.  
Table 29 Comparison of the three DAIs and histology using Geboes score  
 Geboes 
score ≥3.2 
Sensitivity 
Geboes 
score ≥3.2 
Specificity 
Geboes 
score ≥3.2 
PPV 
Geboes 
score ≥3.2 
NPV 
Geboes score ≥3.2 
Accuracy 
Patients 
perspective 
0.49  
(0.42-0.54) 
0.87  
(0.76-0.94) 
0.85  
(0.72-0.93) 
0.54  
(0.47-0.58) 
0.65  
(0.56-0.70) 
Walmsley 
index  
≥2 
0.85  
(0.74-0.93) 
0.65  
(0.58-0.70) 
0.62  
(0.54-0.68) 
0.86  
(0.76-0.93) 
0.73  
(0.64-0.79) 
Walmsley 
index  
≥3 
0.87  
(0.76-0.94) 
0.62  
(0.55-0.67) 
0.61  
(0.53-0.66) 
0.88  
(0.77-0.95) 
0.72  
(0.63-0.78) 
Modified 
Mayo score 
0 
0.77  
(0.65-0.86) 
0.71  
(0.63-0.77) 
0.64  
(0.54-0.72) 
0.82  
(0.73-0.89) 
0.73  
(0.64-0.81) 
Modified 
Mayo score 
≥ 1 
0.81  
(0.69-0.89) 
0.68  
(0.60-0.74) 
0.63  
(0.54-0.70) 
0.84  
(0.74-0.91) 
0.73  
(0.64-0.80) 
Lichtiger 
index ≥ 3 
0.85 (0.74-
0.93) 
0.62  
(0.55-0.67) 
0.60  
(0.53-0.66) 
0.86  
(0.75-0.93) 
0.72  
(0.62-0.78) 
Comparison of the three disease activity indices (DAIs) and histology using Geboes score with a cut 
off ≥3.2. Values expressed in % and 95% confidence intervals in the bracket. PPV=Positive predictive 
value. NPV= Negative predictive value 
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Table 30 Comparison of the three DAIs and histology using Riley score  
 Riley 
score_12 
Sensitivity 
Riley 
score_12 
Specificity 
Riley 
score_12  
PPV 
Riley 
score_12 
NPV 
Riley 
score_12 
Accuracy 
Patients 
perspective 
0.50  
(0.42-0.55) 
0.87  
(0.77-0.94) 
0.85  
(0.72-0.93) 
0.55  
(0.48-0.60) 
0.65  
(0.56-0.71) 
Walmsley 
index ≥2 
0.85 
(0.74-0.93) 
0.66  
(0.58-0.71) 
0.64  
(0.56-0.70) 
0.86  
(0.76-0.93) 
0.74  
(0.65-0.80) 
Walmsley 
index ≥3 
0.87  
(0.77-0.94) 
0.63  
(0.56-0.68) 
0.63  
(0.55-0.68) 
0.88  
(0.77-0.95) 
0.73  
(0.64-0.79) 
Modified  
Mayo score_0 
0.77  
(0.66-0.86) 
0.72 
(0.64-0.78) 
0.66 
(0.56-0.74) 
0.82  
(0.73-0.89) 
0.74  
(0.65-0.82) 
Modified  
Mayo score 
≥1 
0.81  
(0.70-0.90) 
0.62  
(0.61-0.75) 
0.65  
(0.56-0.72) 
0.84  
(0.74-0.91) 
0.74  
(0.65-0.81) 
Lichtiger 
index≥3 
0.85  
(0.74-0.93) 
0.63  
(0.55-0.69) 
0.62  
(0.54-0.68) 
0.86  
(0.75-0.93) 
0.72  
(0.52-0.79) 
Comparison of the three disease activity indices (DAIs) and histology using Riley score with a cut off 
≥12. Values expressed in % and 95% confidence intervals in the bracket. PPV=Positive predictive 
value. NPV= Negative predictive value 
Table 31 Comparison of the three DAIs and histology using Rubin score  
 Rubin 
score_2  
Sensitivity 
 
Rubin 
score_2  
Specificity 
Rubin 
score_2  
PPV 
Rubin 
score_2  
NPV 
Rubin 
score_2  
Accuracy 
Patients 
perspective 
0.46  
(0.40-0.48) 
0.91  
(0.78-0.98) 
0.92  
(0.81-0.91) 
0.42  
(0.36-0.45) 
0.59  
(0.51-0.63) 
Walmsley 
index ≥2 
0.89  
(0.75-0.96)  
0.59  
(0.53-0.62) 
0.48  
(0.41-0.53) 
0.92  
(0.83-0.97) 
0.68  
(0.60-0.73) 
Walmsley 
index ≥3 
0.91  
(0.78-0.98) 
0.57  
(0.51-0.59) 
0.48  
(0.41-0.51) 
0.94  
(0.84-0.98) 
0.67  
(0.59-0.71) 
Modified  
Mayo score_0 
0.83  
(0.68-0.92) 
0.67  
(0.60-0.71) 
0.52  
(0.43-0.58) 
0.90  
(0.81-0.92) 
0.72  
(0.63-0.77) 
Modified  
Mayo score 
≥1 
0.89  
(0.75-0.96) 
0.65  
(0.59-0.68) 
0.52  
(0.43-0.56) 
0.93  
(0.85-0.98) 
0.72  
(0.64-0.76) 
Lichtiger 
index≥3 
0.89  
(0.75-0.96) 
0.57  
(0.51-0.60) 
0.47  
(0.40-0.51) 
0.92  
(0.82-0.97) 
0.66  
(0.58-0.71) 
Comparison of the three disease activity indices (DAIs) and histology using Rubin score with a cut off 
≥2. Values expressed in % and 95% confidence intervals in the bracket. PPV=Positive predictive 
value. NPV= Negative predictive value 
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Can the Endoscopic scores predict histological activity? 
We performed a statistical analysis to compare the three endoscopic score to test their 
ability to predict histology. Both white light and Narrow band examinations were scored 
according to the three endoscopic indices. Tables 32-35 demonstrates the comparison 
between the three endoscopic and histological scores.  
In our analysis all three endoscopic scores were able to predict histology with sensitivities 
around 80% when assessed against the three histology scoring systems. Among the 
individual scores, MES ≥1, UCEIS ≥1 and Modified Baron ≥1 predicted the histology with 
higher sensitivities (range 85-91%), however the overall accuracy remained around 83-84%. 
The addition of NBI to WLE marginally improved sensitivities when MES 0 and Modified 
Baron’s ≥1 scores were used with Geboes and Rubin scores. When used against Riley 
index, addition of NBI was of little value. NBI seemed to play a role in upstaging the disease 
marginally with MES for inactive and with Modified Baron scores for active disease. However 
the overall correlation and accuracy remained under 90%.
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Table 32 Comparison of the EIs and histological activity using Geboes score  
 Geboes 
score _3.2 
Sensitivity 
 
Geboes score 
_3.2 
Specificity 
Geboes score 
_3.2 
PPV 
Geboes 
score _3.2 
NPV 
Geboes 
score _3.2 
Accuracy 
MES  
WLE_0 
0.81  
(0.70-0.89) 
0.85 (0.78-0.91) 0.79  
(0.69-0.87) 
0.87  
(0.79-0.92) 
0.84  
(0.75-0.90) 
MES  
NBI_0 
0.88  
(0.81-0.93) 
0.88  
(0.81-0.93) 
0.83  
(0.72-0.90) 
0.87  
(0.80-0.92) 
0.85  
(0.77-0.91) 
MES  
WLE ≥1 
0.91  
(0.81-0.97) 
0.61  
(0.54-0.65) 
0.61  
(0.54-0.65) 
0.91  
(0.81-0.97) 
0.73  
(0.65-0.78) 
MES  
NBI ≥1 
0.87  
(0.76-0.82) 
0.77  
(0.69-0.82) 
0.72  
(0.63-0.78) 
0.90  
(0.81-0.95) 
0.81  
(0.72-0.87) 
UCEIS WLE_0 0.81  
(0.70-0.88) 
0.87  
(0.80-0.92) 
0.81  
(0.70-0.88) 
0.87  
(0.80-0.92)  
0.84  
(0.76-0.91) 
UCEIS NBI_0 0.80  
(0.70-0.88) 
0.87  
(0.80-0.92) 
 
0.81  
(0.70-0.89) 
0.87  
(0.80-0.92) 
0.84  
(0.76-0.91) 
UCEIS  
WLE ≥1 
0.89  
(0.79-0.96) 
0.78  
(0.71-0.83) 
0.74  
(0.65-0.79) 
0.91  
(0.83-0.97) 
0.83  
(0.74-0.88) 
UCEIS 
NBI ≥1 
0.85 (0.75-
0.92) 
0.85  
(0.78-0.94) 
0.80   
(0.70-0.87) 
0.89  
(0.82-0.94) 
0.85  
(0.77-0.91) 
Baron score 
WLE_0 
0.81  
(0.70-0.87) 
0.85  
(0.78-0.91) 
0.79  
(0.69-0.87) 
0.87  
(0.79-0.92) 
0.84  
(0.75-0.90) 
Baron score 
NBI_0 
0.81  
(0.70-0.88) 
0.88  
(0.81-0.93) 
0.83  
(0.72-0.90) 
0.87  
(0.80-0.92) 
0.85  
(0.77-0.91) 
Baron score 
WLE ≥1 
0.85 (0.78-
0.91) 
0.81  
(0.70-0.89) 
0.87  
(0.79-0.92) 
0.79 
(0.69-0.87) 
0.84  
(0.75-0.90) 
Baron score 
NBI ≥1 
0.88  
(0.81-0.93) 
0.81 (0.70-0.88) 0.87  
(0.80-0.92) 
0.83  
(0.72-0.90) 
0.85  
(0.77-0.91) 
Comparison of the three endoscopic indices and histological inflammation (active disease) using 
Geboes score with a cut off ≥3.2. Values expressed in % and 95% confidence intervals in the bracket. 
PPV=Positive predictive value. NPV= Negative predictive value. MES=Mayo Endoscopic Sub-score, 
UCEIS= Ulcerative Colitis Endoscopic Index of Severity, WLE=White Light Examination, NBI= Narrow 
Band Imaging, EI-Endoscopic indices
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Table 33 Comparison of the EIs and histological activity using Riley’s score  
 Riley score_ 
cut off 12 
Sensitivity 
 
Riley score_ 
cut off 12 
Specificity 
Riley score_ 
cut off 12 
PPV 
Riley score_ 
cut off 12 
NPV 
Riley score_ 
cut off 12 
Accuracy 
MES  
WLE_0 
0.88  
(0.81-0.93) 
0.83  
(0.73-0.90) 
0.88  
(0.81-0.93) 
0.83  
(0.73-0.90) 
0.86  
(0.78-0.92) 
MES  
NBI_0 
0.91  
(0.84-0.96) 
0.83  
(0.73-0.90) 
0.89  
(0.82-0.93) 
0.87  
(0.77-0.94) 
0.88  
(0.80-0.93) 
MES  
WLE ≥1 
0.92  
(0.81-0.97) 
0.62  
(0.54-0.66) 
0.63  
(0.56-0.67) 
0.91  
(0.81-0.97) 
0.74  
(0.66-0.79) 
MES  
NBI ≥1 
0.85  
(0.75-0.93) 
0.76  
(0.69-0.82) 
 
0.72  
(0.63-0.78) 
0.88  
(0.79-0.94) 
0.80  
(0.71-0.86) 
UCEIS 
WLE_0 
0.83  
(0.73-0.90) 
0.90  
(0.83-0.94) 
0.85  
(0.75-0.92) 
0.88  
(0.81-0.93) 
0.87  
(0.79-0.93) 
UCEIS NBI_0 0.81  
(0.71-0.88) 
0.91  
(0.84-0.96) 
0.87  
(0.76-0.94) 
0.87  
(0.81-0.92) 
0.87  
(0.79-0.92) 
UCEIS  
WLE ≥1 
0.90  
(0.79-0.96) 
0.79  
(0.72-0.84) 
0.75  
(0.67-0.81) 
0.91  
(0.83-0.97) 
0.84  
(0.75-0.89) 
UCEIS 
NBI ≥1 
0.83  
(0.73-0.91) 
0.85  
(0.78-0.90) 
0.80  
(0.70-0.87) 
0.88  
(0.80-0.93) 
0.84  
(0.76-0.91) 
Baron score 
WLE_0 
0.83  
(0.73-0.90) 
0.88  
(0.73-0.90) 
0.83 (0.73-
0.90) 
0.88  
(0.81-0.93) 
0.86  
(0.78-0.92) 
Baron score 
NBI_0 
0.81 
(0.71-0.88) 
0.91  
(0.84-0.96) 
0.87  
(0.76-0.94) 
0.87  
(0.80-0.92) 
0.87  
(0.79-0.92) 
Baron score 
WLE ≥1 
0.88  
(0.81-0.93) 
0.83  
(0.73-0.90) 
0.88  
(0.81-0.93) 
0.83  
(0.73-0.90) 
0.86  
(0.78-0.92) 
Baron score 
NBI ≥1 
0.91  
(0.84-0.96) 
0.83  
(0.73-0.90) 
0.89  
(0.82-0.93) 
0.87 (0.77-
0.94) 
0.88  
(0.80-0.93) 
Comparison of the three endoscopic indices and histological inflammation (active disease) using Riley 
score with a cut off ≥12. Values expressed in % and 95% confidence intervals in the bracket. 
PPV=Positive predictive value. NPV= Negative predictive value. MES=Mayo Endoscopic Sub-score, 
UCEIS= Ulcerative Colitis Endoscopic Index of Severity, WLE=White Light Examination, NBI= Narrow 
Band Imaging, EI-Endoscopic indices. 
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Table 34 Comparison of the EIs and histological activity using Rubin score  
 Rubin  
Cut off_2 
Sensitivity 
 
Rubin  
Cut off_2 
Specificity 
Rubin  
Cut off_2 
PPV  
Rubin  
Cut off_2 
NPV 
Rubin  
Cut off_2 
Accuracy 
MES  
WLE_0 
0.83  
(0.78-0.84) 
0.97  
(0.85-0.99) 
0.98  
(0.92-0.99) 
0.71  
(0.62-0.73) 
0.87  
(0.80-0.89) 
MES  
NBI_0 
0.85  
(0.80-0.86) 
0.97  
(0.86-0.99) 
0.98  
(0.93-0.99) 
0.74  
(0.65-0.76) 
0.89  
(0.82-0.90) 
MES  
WLE ≥1 
0.57  
(0.52-0.57) 
1.0  
(0.89-1.0) 
1.0 (91-1.0) 0.50  
(0.44-0.50) 
0.69  
(0.63-0.70) 
MES  
NBI ≥1 
0.72  
(0.66-0.73) 
0.92  
(0.85-0.99) 
0.98 (0.91-
0.99) 
0.59  
(0.52-0.61) 
0.79  
(0.72-0.81) 
UCEIS WLE_0 0.84  
(0.79-0.85) 
0.97  
(0.86-0.99) 
0.98  
(0.93-0.99) 
0.72  
(0.64-0.74) 
0.88  
(0.81-0.90) 
UCEIS NBI_0 0.85  
(0.80-0.87) 
0.94  
(0.82-0.99) 
0.97  
(0.91-0.99) 
0.73  
(0.64-0.77) 
0.88  
(0.81-0.91) 
UCEIS  
WLE ≥1 
0.73  
(0.68-0.73) 
1.0  
(0.89-1.0) 
1.0  
(0.93-1.0) 
0.61  
(0.55-0.61) 
0.81  
(0.74-0.81) 
UCEIS 
NBI ≥1 
0.80  
(0.75-0.81) 
0.97  
(0.85-0.99) 
0.98  
(0.92-0.99) 
0.68  
(0.56-0.70) 
0.85  
(0.78-0.87) 
Baron score 
WLE_0 
0.83  
(0.78-0.84) 
0.97  
(0.85-0.99) 
0.98  
(0.92-0.99) 
0.71  
(0.62-0.73) 
0.87  
(0.80-0.89) 
Baron score 
NBI_0 
0.85  
(0.80-0.86) 
0.97  
(0.86-0.99) 
0.98  
(0.93-0.99) 
0.734 (0.65-
0.76) 
0.89  
(0.82-0.90) 
Baron score 
WLE ≥1 
0.85 (0.78-
0.91) 
0.81  
(0.70-0.89) 
0.87  
(0.79-0.92) 
0.79 
(0.69-0.87) 
0.84  
(0.75-0.90) 
Baron score 
NBI ≥1 
0.88  
(0.81-0.93) 
0.81 (0.70-
0.88) 
0.87  
(0.80-0.92) 
0.83  
(0.72-0.90) 
0.85  
(0.77-0.91) 
Comparison of the three endoscopic indices and histological inflammation (active disease) using 
Rubin score with a cut off ≥2. Values expressed in % and 95% confidence intervals in the bracket. 
PPV=Positive predictive value. NPV= Negative predictive value. MES=Mayo Endoscopic Sub-score, 
UCEIS= Ulcerative Colitis Endoscopic Index of Severity, WLE=White Light Examination, NBI= Narrow 
Band Imaging, EI-Endoscopic indices.
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Can endoscopy and histology predict outcomes of the disease? 
 
Here we compared the endoscopic and histological findings with the clinical outcomes to 
assess if they could predict disease relapse/remission or surgery. 
Although overall accuracy did not reach ≥90% using all three of the endoscopic indices for 
inflammatory activity, the accuracy of UCEIS≥1 was 85% with a sensitivity of 89%. Among 
the histological scores Geboes≥3.2 predicted outcomes with accuracy of 88% and a 
sensitivity of 89%. The data was insufficient for analysis regarding surgical outcome.   
 
Table 35 Comparison of the EIs and histological scores with the clinical outcomes  
 Relapse  
Sensitivity 
Relapse  
Specificity 
Relapse  
Correlation 
Relapse  
Accuracy 
(95%CI) 
MES ≥1 0.73  
(0.70-0.89) 
0.79  
(0.75-0.99) 
0.71  
(0.62-0.73) 
0.72  
(0.58-0.94) 
MES NBI ≥1 0.71  
(0.64-0.96) 
0.81  
(0.73-0.90) 
0.77  
(0.73-0.94) 
0.78  
(0.70-0.93) 
UCEIS ≥1 0.89  
(0.79-0.96) 
0.78  
(0.71-0.84) 
0.90  
(0.73-0.96) 
0.85  
(0.76-0.90) 
UCEIS NBI ≥1 0.83  
(0.73-0.91) 
0.85  
(0.78-0.90) 
0.88  
(0.72-0.96) 
0.84  
(0.76-0.91) 
Baron≥1 0.81  
(0.70-0.91) 
0.67  
(0.59-0.92) 
0.77  
(0.69-0.95) 
0.79  
(0.75-0.90) 
Baron NBI ≥1 0.80  
(0.70-0.88) 
0.78  
(0.61-0.90) 
0.83  
(0.72-0.90) 
0.81  
(0.71-0.91) 
Geboes≥3.2 0.89  
(0.80-0.92) 
0.78  
(0.70-0.82) 
0.88   
(0.72-0.93) 
0.88  
(0.74-0.93) 
Riley≥12 0.71 
(0.66-0.73) 
0.89 
(0.85-0.99) 
0.85  
(0.75-0.99) 
0.79  
(0.73-0.91) 
Rubin≥2 0.81  
(0.78-0.84) 
0.85  
(0.81-0.99) 
0.75  
(0.62-0.78) 
0.83  
(0.80-0.89) 
Comparison of the three endoscopic indices and three histological inflammation (all representing 
active disease) to correlate with the outcomes at 12 months. Values expressed in % and 95% 
confidence intervals in the bracket. MES=Mayo Endoscopic Sub-score, UCEIS= Ulcerative Colitis 
Endoscopic Index of Severity, WLE=White Light Examination, NBI= Narrow Band Imaging, EI-
Endoscopic indices. 
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Discussion 
In this prospective observational study we found that the DAIs predict endoscopic and 
histological inflammation better than patient’s own impression of disease activity and in most 
of the case they performed better than the PGA. Results from Walmsley index ≥3 were 
better with sensitivities consistently >90% when assessed against all three endoscopic and 
histological indices. It is simple to use in day to day clinical practice.  
In a large retrospective study of 369 patients the ‘clinical impression’ of disease activity 
under-estimated inflammatory activity in one third of study population(177). This finding is 
similar to our study in which the accuracy of PGA was at best around 80%.  
We also assessed the ability of WLE and NBI in assessment of inflammation. There was 
only marginal benefit of adding NBI to WLE. NBI assessment was of limited value in 
presence of severe inflammation as contact bleeding hampered detailed examination of the 
colon. The additional time spent on using NBI was thought to upstage the disease in 
selected population with very mild inflammation, however the results were not statistically 
significant. Although there are more descriptors in UCEIS to differentiate grades of 
inflammation, addition of NBI to the score did not contribute to upstaging of the endoscopic 
activity. Only marginal improvement was noted in MES (0) and Modified Baron (≥1) scores 
when used with NBI. As the results were unimpressive, we did not feel the need to 
investigate further to identify the predictive markers with NBI.    
Among the endoscopic and histological scores UCEIS and Geboes scores predicted the 
outcomes of the disease activity in 12 months of follow up with reasonable accuracy, albeit 
falling short of 90%. However addition of NBI to the endoscopic scores was not helpful for 
predicting the outcomes. Similar outcome was found by Jauregui-Amezaga et al, when they 
examined the role of advanced endoscopy and histological markers to predict outcomes in 
patients with UC(40). In this study 17 out of 64 patients (27%) relapsed within 12 months 
follow up period. They found that the high resolution endoscopy with or without NBI did not 
confer any benefit in prediction of relapse. In addition to this histological findings assessed 
by Matt’s grading and Riley’s index did not predict relapse with accuracy. This study 
contradicted the previously observed histological criteria, the presence of basal 
plasmacytosis, as a predictor of relapse (4, 72, 82). Presence of plasma cells in excessive 
amounts in the lower third of the biopsy specimen is classed as ‘Basal plasmacytosis’. 
Opinion among the gastrointestinal histopathologists differs on the significance of finding 
basal plasmacytosis. Recently Feagins et al (16) in a retrospective review noted that 
presence of any of the histological markers of inflammation such as basal 
lymphoplasmacytosis, basal lymphoid aggregates, erosions/ulcers in the epithelium, 
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moderate/marked architectural distortion were independently associated with significant 
relapse risk in patients with clinical remission. This study confirms that presence of any 
chronic inflammatory infiltrate predisposes to the risk of relapse, than only plasma cells.  
In another prospective study of patients who were in clinical remission, UCEIS was found to 
be predictive of relapse in medium and long term with increasing severity of scores (5.0% for 
UCEIS=0, 22.4% for UCEIS=1, 27.0% for UCEIS=2, 35.7% for UCEIS=3 and 75.0% for 
UCEIS=4–5)(128). Despite aiming at including patients with clinical remission the study had 
significant proportion of patients with endoscopically active disease (67% of patients had 
MES score>0 and 75% had UCEIS score>0). This study found a suboptimal correlation of 
clinical severity with UCEIS; however these results cannot be generalised as there were no 
patients included with acute severe colitis. In our study we have included patients with both 
quiescent and active colitis.  
 
Our findings support the recent studies in which UCEIS has outperformed MES in 
assessment and prediction of outcomes(126, 176). In another study UCEIS >7 is shown to 
predict colectomy rates(175). In our study we only had 2 patients who underwent surgery 
and hence we did not have enough of data to further analyse for predicting surgery.  
In conclusion, DAIs are useful in clinical practice for objective assessment of the disease 
activity and predicting histology. We advocate using Walmsley or Simple clinical colitis 
activity index based on our findings. Addition of NBI to WLE is not found to be helpful in 
predicting outcomes and as such additional time spent may not be useful in assessing the 
endoscopic severity either.  
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6 Raman spectroscopy of endoscopic colonic biopsies 
from patients with ulcerative colitis to identify mucosal 
inflammation and healing  
Abstract:  
Raman spectroscopy was used to differentiate between mucosally healed (or quiescent) and 
inflamed colon tissue, as assessed endoscopically, in patients with ulcerative colitis. From 
the analysis of the Raman spectra of 60 biopsy tissue samples, clear differences were 
identified between the spectra of the quiescent and inflamed tissue. Three carotenoid peaks 
were found to be approximately twice as intense in the inflamed tissue. Two phospholipid 
peaks were found to be significantly lower in the inflamed tissue. Using multivariate 
statistical analysis, we show that these five peaks can be used to discriminate between 
endoscopically quiescent and inflamed tissue. We also correlated the Raman data with a 
histological assessment of the tissue. Four of the five peaks were found to be significantly 
different between the spectra of histologically healed (or quiescent) and histologically 
inflamed tissue. These findings indicate the ability of Raman spectroscopy to accurately 
classify colon tissue as either quiescent or inflamed, irrespective of whether an endoscopic 
or histological grading scheme is followed. We thus demonstrate that Raman spectroscopy 
could potentially be used as an early diagnostic tool for assessing the presence of mucosal 
healing or inflammation in patients with ulcerative colitis.
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Introduction 
Approximately 25% of patients with UC experience acute exacerbation of their disease 
activity during the course of their disease(7). The colectomy rate increases with more than 
one hospital admission with acute severe UC reaching up to 40% after two admissions(7). 
The treatment goals in UC focus on keeping the disease in remission and a colectomy-free 
survival. Endoscopic mucosal healing (MH) is characterised by the disappearance of 
endoscopic lesions such as erosions and ulcers. If MH is achieved then the short and long-
term clinical outcomes for the patient tend to be favourable. However presence of 
histologically detectable inflammation despite normal endoscopic finding, has been shown to 
be associated with a greater risk of subsequent relapse(4, 5). That said, irrespective of 
whichever technique is used, a flare in UC activity remains difficult to predict. Therefore, a 
simple, easily measured biological marker that predicts relapse would be of great use in 
guiding the most appropriate and cost-effective therapy. Developing a complementary tool 
that can reliably and quickly identify the presence of inflammation or confirm that MH has 
occurred would help to guide patient management. 
In this respect, the molecular vibrational spectroscopic analysis is a strong candidate for 
such a tool. The molecular vibrational spectroscopic analysis is used to characterise solids, 
liquids and gases and is especially relevant when the analyte is rare to procure and small in 
size for analysis, as is the case for endoscopic biopsy specimens of typical surface area ~5 
mm2. Further, vibrational spectroscopy has huge potential in medicinal applications as it is 
Non-destructive and has the ability to reveal the biochemistry of tissue. This allows, in 
principle, differentiation between healthy and anomalous tissue. 
Raman spectroscopy was chosen as the vibrational spectroscopic technique for this study. 
In a Raman microscope, as used in this study, the incident monochromatic light of modest 
power   (< 10 mW), controlled by focussing through an objective lens is directed at the 
sample. The light scattered by the sample is collected and detected. Raman scattering is an 
inelastic scattering process for which the probability of occurrence is 1000-100,000 times 
less than that of Rayleigh scattering. Only molecular vibrations which involve changes in the 
polarizability of the molecule are Raman active. In this respect, the vast majority of 
biomolecules provide rich Raman spectra as they have complex ring-like aromatic and/or 
long-chain aliphatic structures, which may be interconnected to enhance the probability of 
inelastic scattering, and, as a result, may be more Raman active. Such extended local order 
in the structures of biomolecules limits the dispersion of energy states in the resulting 
Raman spectra. Consequently, the peaks have well-defined shapes, unlike in amorphous 
materials where the lack of medium and long-range order yields dispersed phonon energy 
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states(178). In analytes consisting of multiple constituent molecules, a spectrum of Raman 
scattered light consists of a range of peaks corresponding to the Raman active-vibrational 
modes, stimulated by the incident laser. The peak intensities are proportional to the 
concentrations of the responsible molecules. The resultant spectrum may, therefore, be 
interpreted as a qualitative and quantitative measure of the analyte biochemistry(179). 
Importantly, the OH vibrational modes of water molecules produce weak Raman signals and 
thus do not contribute significantly to Raman spectra. This is in contrast to infrared (IR) 
spectroscopy where OH- ions and free water, often present in biomolecular and tissue 
media, are highly absorptive in the mid IR range from 2.7 to 4.5 μm. The absorption peaks of 
water thus tend to overlap with those due to representative aromatic ring C-C (wavenumber 
1600-1585 cm−1, 1500-1400 cm−1), hydrocarbon C-H (2850-3100 cm−1) and C = O (1630-
1780 cm−1) stretch vibrations of biomolecules. Fluorescence spectroscopy can also be used 
to characterise tissue. Once again in complex molecules, a range of electron-phonon 
coupled states might arise during excitation which during fluorescence decay might yield a 
broad spectrum of spontaneous emission. Fluorescence spectra from tissue thus tend to be 
relatively broad and featureless(180) with fewer specific differences in the spectra from 
healthy and anomalous tissue(181). In comparison, Raman spectroscopy has the advantage 
of delivering spectra with sharp, narrow peaks in different parts of the spectrum for lipids, 
proteins and nucleic acids(182). The main disadvantages of Raman spectroscopy are that 
the scattered intensity is inherently weak and that the Raman excitation laser can induce the 
aforementioned fluorescence in tissue, which can obscure the weak Raman signal(183). 
Despite these drawbacks, Raman spectroscopy has been shown to be successful in 
providing very sensitive biochemical information about the composition of biological 
tissue(184).  
A number of vibrational spectroscopy studies have been performed on human colon tissue. 
Most of these studies have attempted to use vibrational spectroscopy to distinguish either 
between colon tissue containing polyps and healthy tissue or between cancerous and 
healthy tissue (185-189). However, very few studies have employed spectroscopy to study 
UC. Two such studies on UC and Crohn’s disease(190, 191) examined respectively, 21 and 
38 samples. 
In this study, therefore, we perform Raman spectroscopy on a large sample set (60 samples) 
of colonic biopsies, taken from patients who have been diagnosed with UC and are either in 
remission or still have the condition. We analyse the ability of Raman spectroscopy to 
differentiate between tissue that has, from an endoscopic point of view, mucosally healed 
and tissue for which endoscopic inflammation is still present. We provide insights into the 
pathogenesis of UC and put forward a biological explanation for the differences observed in 
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the levels of certain biomolecules between quiescent and inflamed tissue. In addition, we 
assessed the second set of colonic biopsies, taken from the same patients at the same sites 
at the same time as the first set, for histological activity. We assess whether Raman 
spectroscopy also provides a reliable means of discriminating between tissue that has, from 
a histological point of view, healed and tissue for which histological inflammation is still 
observable. We thus evaluate the ability of Raman spectroscopy to distinguish between 
quiescent and inflamed tissue, which has been graded by two different clinical techniques; 
endoscopy and histopathology. In this way, we aim to provide a more complete assessment 
of the utility of Raman spectroscopy as a potential, complementary tool for the assessment 
of UC.  
Experiment 
Patients, samples and tissue preparation 
All patients in the study had initially been diagnosed with UC at the IBD clinic at St James 
University Hospital, Leeds, had followed a course of treatment and returned to the IBD clinic 
for further assessment during colonoscopy. Informed consent was obtained from all patients 
and ethical approval for the study including the collection of biopsies for spectroscopy and 
histological assessment was obtained from the Yorkshire and Humber–Yorkshire Bridge 
National Research Ethics Committee (13YH-0115). During a colonoscopy the colonic tissue 
was assessed endoscopically for endoscopic MH by expert (gastrointestinal GI) 
endoscopists, using the Mayo endoscopic score (See Table 3 in chapter ‘Endoscopic 
assessment of disease activity) [34], and a score was assigned. A score of zero was taken 
to indicate that endoscopic MH had occurred and all scores greater than 0 indicated that 
endoscopic inflammation was still present (i.e. an absence of endoscopic MH). 
 
Biopsies for the purposes of the Raman spectroscopy study and the histological assessment 
were then taken from the same area assessed by endoscopy. All biopsies were targeted, 
whether taken from active or inactive/quiescent area. The sample dimensions of biopsies 
were typically of length ~3 to 4 mm, width ~1.5 to 2 mm and thickness ~1 to 2 mm. For both 
the Raman study and the histological assessment, 60 biopsies were collected from 39 
patients; 32 from the sigmoid and 28 from the rectum. Of the 60 samples for the Raman 
study, 24 were taken from areas with endoscopic MH and 36 from areas with signs of 
endoscopic inflammation. Immediately after taking the biopsies, they were snap-frozen in 
liquid nitrogen and stored at −80°C. The prompt snap-freezing of biopsies allowed the 
metabolic content of the tissue to be preserved as in the in-vivo state, as required to obtain 
Raman spectra which accurately reflect their biochemical composition at the time of 
collection of the biopsies. 60 biopsies were also taken at the same sites at the same time for 
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the histological assessment. These were fixed in formaldehyde and then later stained with 
haematoxylin and eosin. These were graded histopathologically by an expert GI 
histopathologist (O.R.), using the validated Geboes scoring system, which has been shown 
to have the best inter-observer agreement(192). A Geboes score of less than 3.1 was 
considered to indicate that the mucosa had histologically healed and a score of 3.1 or 
greater to denote histological activity (HA), when there is the presence of neutrophils in the 
epithelium(82, 125). Of these 60 samples, 27 were graded as histologically healed and 33 as 
histologically active (HA). In both the endoscopically assessed and in the histologically 
assessed groups of samples we can thus consider that there is a population of tissue 
samples with the status quiescent and another population with the status inflamed. 
 
We compared the status given to each sample during endoscopic assessment with that 
given during histological assessment. Disagreement between the endoscopic and 
histological assessments of the tissue status was observed in 5 samples out of 60. The 
assessments of the tissue status via the two techniques, as being either quiescent or 
inflamed, thus matched for 92% of the samples, as might be expected for two techniques 
that are complementary. 
Raman spectroscopy 
We used an inVia Renishaw Raman microscope to obtain the Raman spectra for the tissue 
samples. Samples were removed from the −80°C freezer and placed on to low fluorescence 
glass microscope slides on the microscope stage. Samples were not rehydrated in saline. A 
continuous wave (cw) laser of wavelength 514.5 nm and 5 mW incident power was used as 
the excitation source. The laser beam was focused by a 50x microscope objective of 
numerical aperture 0.8 and working distance 1.1 mm to form a spot of diameter ~5 μm on 
the sample surface. Single scan exposures of 10 seconds were sufficient to obtain a good 
signal to noise ratio. The values used for the incident laser power, spot size and exposure 
time lead to an energy density which is similar or slightly lower than that employed in other 
Raman spectroscopy studies on tissue(187, 193, 194). The constituency, shape and 
composition of a biopsy sample can vary significantly from one region to another on its 
surface. Hence spectra were taken at four different points per sample. Spectra were 
collected for the Raman shift range of 400 to 3000 cm−1 with a spectral resolution of 4 cm−1. 
This range and resolution are relatively favourable with respect to typical Raman 
instruments, which often provide a range of 700 to 1800 cm−1 and a resolution of 6 to 8 
cm−1, and are similar to those used in some recent Raman studies on colon tissue(195, 196). 
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Processing of Raman spectra 
For each sample, the average Raman spectrum was calculated from the four measurements 
taken. As mentioned in Section 1, the tissue may produce fluorescence when excited with a 
short wavelength visible laser for Raman spectroscopy. The measured spectrum thus 
consists of Raman scattered light, fluorescent light emitted by the tissue (the fluorescent 
background) and noise(197). Three operations were performed; i) data smoothing, ii) 
background estimation and subtraction and iii) normalisation of the background-corrected 
spectrum. Data smoothing was achieved using a Savitzky-Golay filter with a smoothing width 
of 9 and a polynomial of degree 3 in order to increase the signal-to-noise ratio(187). An 
effective method for estimating the fluorescence background is modified polynomial 
fitting(198) and this technique was found to be optimal for the spectra in this study. The 
adapted polynomial form was subtracted from the averaged, smoothed spectrum to obtain 
the uncluttered Raman spectrum consisting of a set of peaks with a relatively flat baseline. In 
a Raman microscope, the cone of light backscattered from the sample, which enters the 
objective, forms the signal measured. For a particular illuminated sample area, the signal 
measured, therefore, depends not only on the concentrations of the Raman-active molecules 
in the area but also on the shape and the reflectivity of the surface and the accuracy of 
focussing on the surface. Since the biopsies were non-uniform and uneven, these factors 
lead to large variations in the signal measured from area to area on the sample and from 
sample to sample. To correct for the variations in absolute signal intensity and thus to be 
able to compare the peak intensities between samples, each background-corrected 
spectrum was thus normalised by dividing by the total area under the curve(194). 
 
Statistical methods 
For the evaluation of diagnostic sensitivity and tissue classification, two-tailed nonparametric 
Mann-Whitney U tests to identify statistically significant differences between the peak 
intensities in the Raman spectra for different sample groups were performed. One test was 
carried out on the Raman data for the group of samples assessed endoscopically in order to 
highlight the differences between the spectra of samples taken from areas of the colon which 
showed endoscopic MH and of those taken from areas which showed endoscopic 
inflammation. A second such test was performed on the group of samples assessed 
histologically in order to quantify the spectral differences between the samples which 
showed histological healing and those which showed HA. Non-parametric tests were used 
as the distribution of the Raman spectral peak intensities did not follow a normal distribution. 
A p-Value of ≤ 0.05 was used as a cut-off of significance. Results are expressed as the 
mean ± standard deviation for continuous variables. 
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Multivariate analysis was also performed by logistic regression analysis to calculate odds 
ratios (OR) and their 95% confidence intervals. All variables with a p-value of < 0.1 in the 
Mann-Whitney U analysis were included (as planned a-priori) in the final multivariate model. 
Correlation matrices were used to identify collinearity. If collinearity was detected we 
minimised this by inputting the variable separately in the multivariate analysis. Hosmer- 
Lemeshow’s test was used to verify the null hypothesis that there is a linear relationship 
between the predictor variable and the log odds of the outcome variable. All statistical tests 
were done using PASW version 21 (IBM Corp, NY). 
 
Results and discussion 
Analysis of Raman spectra 
Figure 16 displays the average Raman spectra of the endoscopically assessed biopsy 
samples taken from areas of the colon which showed endoscopic MH and of those taken 
from areas which showed endoscopic inflammation (i.e. where endoscopic MH was absent). 
 
Figure 16 Raman shift  
The above figure shows the average background-subtracted normalised Raman spectra for 
endoscopically assessed colonic mucosa which showed either a) endoscopic MH (black) or b) 
endoscopic inflammation (red). 
 
The form of the spectra for both the colonic mucosa which showed endoscopic MH and 
those which exhibited endoscopic inflammation is similar with primary peaks observable at 
Raman shifts of 1003, 1155, 1244, 1307, 1368, 1395, 1440, 1518, 1585, 1641, 1690, 1709, 
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2762 and 2936 cm−1 and shoulder peaks at 1125, 1549, 2854, 2892 and 2969 cm−1. Strong 
peaks are found in both tissue types at 1003, 1155, 1518 (the largest peak in the 
endoscopically inflamed tissue), 2762, 2892 and 2936 cm−1 (the largest peak in the 
endoscopic MH tissue). The most striking difference between the two tissue types is in the 
intensity of the peaks at 1003, 1155 and 1518 cm−1. These are considerably higher in the 
endoscopically inflamed than in the endoscopic MH tissue. 
In terms of constituent biomolecules, both spectra contain contributions from vibrational 
modes of proteins, amino acids, lipids and nucleic acids as well as other compounds such as 
carotenoids and myoglobin. A detailed list of the peaks observed and their possible 
assignments are described in Table 36. Regarding the peaks at 1125, 1307, 1368 and 1395 
cm−1 several different assignments for each one are possible. The peak at 1125 cm−1 could 
be attributed to vibrations of phospholipids or proteins(199); the peak at 1307 cm−1 could be 
assigned to phospholipids(200) or lipids or the nucleotide, adenine(201); the peak at 1368 
cm−1 to the nucleotides, guanine or thymine or to the amino acid, tryptophan (199)and that at 
1395 cm−1 to the nucleotide, uracil(201). However, the fact that these four peaks as well as 
peaks at 1549 cm−1 (assigned to deoxy-myoglobin in colon tissue) and at 1585 cm−1 and 
1641 cm−1 (both assigned to oxy-myoglobin in colon tissue(183) are present in the spectra 
plus the experimental observation that the inflamed colonic mucosa often showed signs of 
bleeding mean that we assign the peaks at 1125, 1307, 1368 and 1395 cm−1 to haeme 
groups, in particular to the haeme core of myoglobin. In terms of the other peaks, the peak at 
1440 cm−1 is characteristic of scissoring vibrations of CH2 in phospholipids(197) and 
lipids(200). Signals characteristic of the amide bands of proteins is found at 1244 cm−1 
(amide III, β-sheet conformation) and 1690 cm−1 (amide I, β-sheet conformation(194)). The 
band at 1709 cm−1 is consistent with C = O vibrations in phospholipids and triglycerides. The 
signal at 2762 cm−1 corresponds to a CH stretch, possibly in phospholipids. Vibrations that 
are characteristic of the CH groups in lipids (fatty acids, triglycerides) are observed at: 2854 
cm−1 (symmetric stretching of the CH2 group), 2892 cm−1 (antisymmetric stretching of the 
CH2 group [43]), 2936 cm−1 (symmetric stretching of the CH3 group) and 2969 cm−1 
(antisymmetric stretching of the CH3 group). 
Considering the three sharp peaks at 1003, 1155 and 1518 cm−1, the peak at 1003 cm−1 has 
previously been considered to be due to phenylalanine. However, when peaks at 1155 cm−1 
and 1518 cm−1 are also present, forming the triplet combination seen in Fig. 1, it has become 
common to assign these three peaks to vibrations of carotenoids (193, 195, 202). In an 
attempt to improve the characterisation of the carotenoid groups, we have compared our 
data with the Raman data for a wide range of carotenoids. The most dominant phonon 
vibration is the approximate in-phase stretching vibration of C = C bonds (ν1, 1490-1540 
cm−1), followed by the C-C stretching mode (ν2, 1140-1160 cm−1), which may be mixed with 
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C-H in-plane vibrations, and, finally, the in-plane rocking mode of CH3 (ν3, ~1005 cm−1). 
This vibration is part of the carotenoid “fingerprint region” from 1100 to 1400 cm−1, which 
contains weak peaks sensitive to the terminal groups and chain conformation in the 
carotenoid. In our data, the peaks at 1003 cm−1 (in-plane rocking of CH3), 1155 cm−1 
(stretching of C-C) and 1518 cm−1 (stretching of C = C) are thus consistent both in terms of 
position and relative intensities with the data reported for carotenoids(203). 
We take the analysis of our data further by examining the relationship between π-electron 
conjugation and the wavenumber of the C-C stretching mode (ν2) for different carotenoids. 
In polyenes, such as carotenoids, as the number of C = C double bonds and, in that way, 
length of the conjugated chain increases, the space for the Π electrons to delocalise 
increases, leading to a decrease in the order of the C = C bond. This causes a reduction in 
bond strength and thus a decrease in the frequency of vibration of the C = C stretching 
mode (ν1). This can be seen in Fig. 17, where, for example, ν1 for decapreno-beta-carotene, 
which has 10 more C atoms than beta-carotene, is 25 cm−1 lower than for beta-carotene. A 
decrease in the position of the ν1 mode is usually accompanied by an increase in the 
position of the ν2 mode(203). However, interestingly, carotenoids show the opposite trend in 
Fig. 17. 
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Table 36 Tentative assignments of peaks in the Raman spectra of colon tissue 
Peak 
No 
Centre 
(cm−1) 
Vibrational 
mode 
Major Assignments 
   
1 1003  Ring breathing   Phenylalanine 
ρ(C-CH3)   Carotenoids  
 
2 1125 ν22-ν(Pyr ½ ring)as Myoglobin (haeme core)  
  ν(C–C)   Phospholipids          
  ν(C–N)   Proteins  
 
3 1155  ν(C–C)   Carotenoids  
 
4 1244   Amide III, ß sheet    
     
5 1307  τ(CH2)   Phospholipids, lipids  
    Adenine  
ν21-δas(CmH) Myoglobin (haeme core)  
 
6 1368  ω(CH2),  δ(CH) Tryptophan  
Guanine  
Thymine  
ν4-ν(Pyr ¼ ring)s Myoglobin (haeme core)  
 
7 1395  ν20-ν(Pyr ¼ ring) Myoglobin (haeme core)  
    Uracil  
 
8 1440  δsc(CH2)   Phospholipids, lipids  
  δ(CH2), δ(CH3) Collagen    
 
9 1518  ν(C=C)  Carotenoids  
 
 
10 1549 ν11-ν(CαCß)as Deoxy-Myoglobin (haeme core)   
11 1585  δ(C=C)  Phenylalanine  
    Hydroxyproline  
  ν37-ν(CαCm)as Oxy-Myoglobin (haeme core)  
 
12 1641  ν10-ν(CαCm)as Oxy-Myoglobin (haeme core)  
 
13 1690   Amide I, ß sheet  
 
14 1709 ν(C=O)  Phospholipids, triglycerides  
 
15 2762 ν(C-H)  Phospholipids 
 
16 2854 νs(CH2)  Lipids  
 
17 2892 νas(CH2)  Lipids, proteins  
 
18 2936 νs(CH3)  Lipids, proteins  
 
19 2969 νas(CH3)  Lipids, proteins  
 
ν – stretching vibration; νs – symmetric stretch; νas – antisymmetric stretch; δ – bending vibration; δsc – in-plane 
bending (scissoring); ρ – in-plane bending (rocking); τ – out-of-plane bending (twisting); ω - out-of-plane 
bending (wagging). 
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Figure 17 Characteristics of beta-carotene 
This figure shows the plot of frequency of C = C (ν1) versus C-C stretching vibration (ν2) for beta-
carotene isomers (black squares), colonic mucosa showing endoscopic MH (grey circle, our data), 
colonic mucosa showing endoscopic inflammation (red circle, our data), cancerous colon tissue (blue 
diamond), cancerous breast tissue (pink triangle), cancerous lung tissue (green triangle [37],). Figure 
adapted from(203). 
 
This may be due to the presence of CH3 groups which disturb the C-C stretching modes 
[53]. From Fig. 17 we suggest, that in both our colonic mucosa which showed endoscopic 
MH and in those with endoscopic inflammation, the carotenoid found may be of 
canthaxanthin and lycopene types. The carotenoid present in cancerous colon tissue also 
appears to be of these types. 
 
Statistical analysis of data 
In Fig. 18 we compare the average Raman peak intensities of the endoscopically assessed 
biopsy samples which showed endoscopic MH with those of the samples which showed 
endoscopic inflammation. The p values, obtained in the non-parametric Mann Whitney U test 
for this group of endoscopically assessed samples, are also shown in Fig. 18. It can be seen 
from Fig. 18 that in the endoscopically inflamed tissue the average intensity of the carotenoid 
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peak at 1003 cm−1 is ~75% greater than in the endoscopic MH tissue, whilst the carotenoid 
peaks at 1155 cm−1 and 1518 cm−1 are almost double those in the endoscopic MH tissue. 
The standard deviation of the peak intensities is substantial, which reflects the 
inhomogeneity of the tissue samples. Differences in the peak intensity between endoscopic 
MH and endoscopically inflamed tissue with a significance level of p ≤ 0.05 are found for 
peaks 1 (1003 cm−1), 3 (1155 cm−1), 9 (1518 cm−1), 14 (1709 cm−1) and 15 (2762 cm−1). 
Differences with a significance level of 0.10 ≥ p > 0.05 are obtained for peaks 6 (1368 cm−1) 
and 8 (1440 cm−1). These statistics clearly indicate that the Raman spectral differences 
between endoscopic MH and endoscopically inflamed colon tissue are significant and are 
consistent with previous reports(190, 191). 
Figure 4 presents the same information as Fig. 3 but for the group of histologically assessed 
samples. The p values come from the non-parametric Mann Whitney U test for this group. 
 
 
Figure 18 Histogram of Raman peaks in endoscopic assessment of UC activity 
This figure is a Histogram displaying average Raman peak intensities, standard deviations and p 
values for endoscopically assessed colonic mucosa which showed either a) endoscopic MH (N = 24) 
or b) endoscopic inflammation (N = 36). No asterisk represents p > 0.10, a single asterisk * 
represents 0.10 ≥ p > 0.05 and two asterisks ** represent p ≤ 0.05. Abbreviations: Car = carotenoids; 
Myo = myoglobin, Oxy-Myo = oxy-myoglobin, Deoxy- Myo = deoxy-myoglobin, P-lipid =phospholipids. 
 
The peak intensities are very similar to those in Fig. 18, with the carotenoid peaks much 
greater in the samples which showed HA than in the samples which exhibited histological 
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healing. Differences in the peak intensity between histologically healed samples and 
samples which showed HA with a significance level of p ≤ 0.05 are again observed for peaks 
1, 3, 9, 14, 15 and also 19 (2968 cm−1). Just as for the endoscopically assessed group, Fig. 
19 indicates that there are significant differences in the Raman spectra of histologically 
healed and histologically active samples. 
 
 
Figure 19 Histogram of Raman peaks in histological assessment of UC activity 
This figure shows the Histogram displaying average Raman peak intensities, standard deviations and 
p values for histologically assessed colonic mucosa which showed either a) histological healing (N = 
27) or b) HA (N = 33). The same key and abbreviations as for Fig. 18 apply. 
 
The non-parametric analysis is extended to a multivariate analysis, which has been shown to 
be more accurate and reliable when analysing multiple peaks over a large Raman spectral 
range, as is the case for our colon tissue spectra. The results of the multivariate analysis are 
presented in Table 37. 
In the multivariate model peaks 1, 3, 8, 9 and 15 turn out to be significantly different between 
endoscopic MH and endoscopically inflamed samples. All of these except peak 8 are also 
significantly different between histologically healed samples and samples which showed HA. 
A visual comparison is presented in the 3D scatter plots in Figs. 20(a) and 5(b) which show 
the distribution of the intensity of the important peaks 1, 3 and 15 in the groups assessed 
endoscopically and histologically. In both figures, the separation between the two 
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populations (the quiescent population and the inflamed population) is clearly visible. Both 
figures suggest that in a Raman spectrum where peaks 1 and 3 are high, whilst in 
comparison peak 15 is medium to low, the sample is more likely to be inflamed than 
quiescent. The strong likeness between the distributions in both figures is to be expected in 
view of the close match between the endoscopy and histology grades for the vast majority of 
samples. 
 
Table 37 Multivariate analysis of the patients included in Raman spectroscopy study 
Peak no. MH: absent versus present  
OR (95% CI) 
HA: histologically active versus inactive (quiescent) 
OR (95% CI) 
1# 3.71 (1.79-7.67) 1.92 (1.28-2.87) 
3# 1.50 (1.19-1.89) 1.22 (1.07-1.39) 
6 0.68 (0.05-9.48) n/a 
8 0.05 (0.004-0.55) n/a 
9# 1.36 (1.14-1.61) 1.17 (1.09-1.30) 
11 0.82 (0.32-2.07) n/a 
14 0.68 (0.15-3.04) 0.48 (0.08-2.80) 
15 0.24 (0.09-0.64) 0.40 (0.19-0.84) 
19 n/a 0.65 (0.21-2.04) 
Multivariate analysis for the a) endoscopically assessed group and b) histologically assessed a group of colonic 
mucosa 
# inputted separately into the model as they were highly correlated (rho > 0.6). Significant differences 
are in bold. N/A implies the p-value of the peak in the Mann Whitney U test was > 0.10 and therefore 
was not included in the multivariate analysis. 
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Figure 20 Scatter plot  
This figure shows Scatter plot of intensities of peaks 1, 3 and 15 for a) endoscopically assessed 
colonic mucosa which showed either endoscopic MH (open squares) or endoscopic inflammation 
(filled circles) and b) histologically assessed colonic mucosa which showed either histological healing 
(open squares) or HA (filled circles). 
 
 
Biomolecular explanation for differences between quiescent and inflamed Raman 
spectra 
We attempt to explain the similarities and differences between the Raman spectra of colonic 
mucosa showing endoscopic MH and of colonic mucosa showing endoscopic inflammation 
in terms of the biomolecular composition of the mucosa, based on the peak assignments. 
The fact that the same set of peaks occurs in both the endoscopic MH and endoscopically 
inflamed tissue indicates that their biochemical composition is very similar. This is consistent 
with the common understanding of inflammation. Inflammation does not introduce new 
metabolites to the system but rather leads to overproduction or overuse of the existing 
metabolites. One would thus expect the same peaks to be found in the two tissue types. 
Variations in peak intensities between the two tissue types are due to differences in the 
concentrations of biomolecules in the two. The endoscopically inflamed tissue contains very 
high amounts of carotenoids. Carotenoids are known to act as anti-oxidants(184) in the 
defence mechanism of tissue against inflammation. Beta-carotene, for instance, has been 
shown to suppress the activation of nuclear factor kappa-beta and thereby inhibit pro-
inflammatory gene expression(204). Carotenoid compounds could thus be expected to be 
strongly present in the endoscopically inflamed tissue, as observed. Additionally, we found 
that the phospholipid components (peak 8 at 1440 cm−1 and peak 15 at 2762 cm−1) were 
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markedly higher in samples where endoscopic MH had occurred. This observation would 
reflect the fact that when, endoscopically, the tissue is visibly inflamed, there is a marked 
loss of tissue integrity, characterised by ulceration or erosion of the mucosa with loss of the 
cell membrane. Phospholipids are well known to be a major component of the colonic cell 
membrane and if the tissue is disrupted, as is the case when it is inflamed, their levels would 
be expected to decrease. 
 
Conclusion 
An emerging goal of gastroenterology is to establish whether mucosal healing (MH) has 
occurred in patients treated for UC, as MH appears to lead to favourable outcomes for the 
patient. To this end, a spectroscopic tool which could assist current techniques such as 
endoscopy and histopathology in examining colonic mucosa for evidence of MH would be of 
great benefit. In this study, we thus employed Raman spectroscopy to evaluate its potential 
for such a tool. 
60 biopsy samples were taken from areas of the colon which showed endoscopic MH and 
from areas which showed endoscopic inflammation, snap frozen at −80°C in order to 
preserve their metabolic content and their Raman spectra were obtained. Simultaneously, 
we collected a second group of 60 samples from these areas of the colon and assessed 
them histologically. 
We analysed the Raman spectra of the colonic mucosa, assigned the peaks to vibrations of 
biomolecules and performed Mann Whitney U analyses and multivariate statistical analyses 
on the spectral peak intensities. The essential findings can be summarised as follows: 
 
1. A similar set of Raman peaks corresponding to vibrations of proteins, amino acids, 
lipids, nucleic acids, myoglobin and carotenoids was observed in the endoscopic MH 
and the endoscopically inflamed tissue, indicating that similar biomolecules are 
present in each. This suggests that inflammation can be thought of as a state of 
activity where greater or lower quantities of existing biomolecules are produced by 
the body’s response. 
2. The major visual difference between the Raman spectra of the biopsy samples 
which showed endoscopic MH and those which showed endoscopic inflammation 
was found to be in three carotenoid peaks. Carotenoid levels were found to be very 
high (almost double) in the inflamed compared to in the quiescent tissue. This finding 
is consistent with the role they play as anti-oxidants in fighting inflammation. 
Significant differences were also observed in two phospholipid peaks. Phospholipid 
levels were found to be lower in the inflamed tissue. This is also consistent with 
124 
 
studies which indicate that phospholipids are a key component of the colonic cell 
membrane. Their levels may thus be expected to decrease when tissue is inflamed 
and thus damaged. 
 
3. Using multivariate analysis, the intensities of these five peaks (the three carotenoid 
and the two phospholipids) were found to be statistically significantly different 
between the Raman spectra of the endoscopic MH and the endoscopically inflamed 
tissue. A similar result was obtained for the histologically assessed samples with four 
of the same five peaks (three carotenoid and one phospholipid) also significantly 
different between the spectra of the histologically healed and the histologically active 
tissue. 
 
This study shows that Raman spectroscopy can be used to discriminate between quiescent 
and inflamed colon tissue, as assessed either endoscopically or histologically, and thus 
illustrates its potential as a diagnostic tool for the evaluation of MH in patients with UC. 
Possible applications of Raman spectroscopy could thus be as an in-vivo adjunct during 
endoscopy or for rapid assessment of tissue samples taken in endoscopy units. Larger 
studies to look at whether using these spectral biomarkers can help predict patients at risk 
for adverse outcomes like a relapse of disease activity or lack of response to medical 
therapy are required. 
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7 The utility of routine chromoendoscopy for the 
detection of dysplastic lesions during surveillance 
colonoscopy in patients with Ulcerative Colitis. Does 
research translate into clinical practice?  
Introduction 
There is an increased risk of cancer in patients with ulcerative colitis (UC). The risk 
increases with the duration of the disease and reaches approximately 18% after 30 years of 
disease(111). The dysplasia in UC is usually flat and difficult to detect. Random colonic 
biopsies have been the mainstay of detecting the dysplasia in UC. However, random 
sampling method can easily miss the dysplastic areas. It is estimated that approximately 33 
biopsies are needed to achieve 90% confidence interval for detecting dysplasia(205). The 
other main feature that renders this method somewhat ineffective is that the dysplasia in UC 
is multifocal and it is difficult to map them to a particular colonic segment(206). And besides 
being ineffective, it is time-consuming, laborious and expensive. In a retrospective analysis 
of 167 patients undergoing 466 colonoscopies over a period of 10 years (1998-2008), 
dysplasia was detected on random colonic samplings on only 5 colonoscopies in 4 patients. 
Only one of these patients had advanced neoplasia confirmed on the proctocolectomy 
specimen(207). The quality of surveillance colonoscopies is variable among colonoscopists 
and could also be dependent on factors influencing day to day running of endoscopy lists 
like the timing of the list and involvement of fellows.  
New generation High definition (HD) endoscopes have shown to be superior in the 
identification of dysplastic areas in IBD surveillance compared to the standard definition (SD) 
endoscopes(208). Contrast enhancement is used to improve the detection of abnormalities 
in the gastrointestinal tract. Non-dye based contrast enhancement methods, also called 
virtual chromoendoscopy (VCE) involves optical filters or software-based technologies to 
provide contrast enhancement without the use of dyes. Narrow band imaging (NBI), Fujinon 
intelligent colour enhancement (FICE) and iSCAN (are examples of VCE in clinical use. 
There is, however, no convincing evidence to support their routine use in surveillance 
colonoscopies in colonic IBD and this view has been endorsed by the international SCENIC 
consensus guidelines(209)  Dye based contrast enhancement, also called as 
chromoendoscopy (CE), refers to application of diluted indigo carmine or methylene blue to 
the colonic mucosa to highlight subtle mucosal abnormalities. By providing a rim of contrast 
around the lesions, CE helps in detection, delineation, and characterisation of dysplastic 
tissue. There is growing evidence to suggest CE is superior in detecting dysplasia in UC 
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surveillance compared with the standard white light examination (WLE). A Meta-analysis 
including 665 patients from 6 studies in 2013 confirmed that CE detects more dysplastic 
lesions compared to random biopsies obtained from standard WLE(118). CE is 
recommended by British Society of Gastroenterology(119) and European Crohn’s and Colitis 
Organisation(120) as a preferred method of surveillance in colonic IBD. However, the uptake 
of CE among the colonoscopists has been variable. It may be due to the steep learning 
curve involved, time constraints on endoscopy lists and the common perception that this is a 
‘messy’ time-consuming procedure.  
We aimed to look at the practice among the endoscopists in our hospital who offer 
surveillance colonoscopies for patients with UC to see if CE improves the detection of 
dysplasia in routine clinical practice and audit the uptake of this technique in routine clinical 
practice. 
Methods 
All patient undergoing surveillance colonoscopy for long-standing UC (>7 years) between 
January 2012 to December 2013 in Leeds teaching hospitals were included in this 
retrospective cohort study. This study was conducted as an audit on local practice of 
surveillance procedures. This study was approved by the local audit governance committee 
and used for quality assurance and improving local practice. The study protocol conforms to 
the ethical guidelines of the World Medical Association Declaration of Helsinki- Ethical 
Principles for Medical Research Involving Human Subjects" (adopted by the 18th WMA 
General Assembly, Helsinki, Finland, June 1964, as revised in Tokyo 2004). All procedures 
were done as a part of routine patient care. There has been no extra tests or procedures 
done as a part of the study.  
Data was collected using electronic records for endoscopy reports and the subsequent 
clinical care. Demographic details of the patients were recorded along with the duration and 
extent of the disease, medications (current and past), and colonoscopy outcomes.  
Inclusion criteria: All adult patients (Age ≥18 years) who underwent colonoscopy for 
surveillance of UC with a disease duration of ≥7 years were included in the study.  
Exclusion criteria: Patients were excluded from the study if they were having severe colitis or 
undergoing surveillance of only rectal stump or pouch.  
Equipment: High definition and High-resolution endoscopes (CF HQ260DL, CF Q260SL, 
PCF Q260AL colonoscopes from Olympus Keymed®) with Lucera series processors (CV 
260) were used for all the procedures. Biopsies were obtained using single-use Radial 
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Jaw™ biopsy forceps from Boston Scientific®. Standard equipment available in the 
department were used for resecting polyps when identified.  
Biopsy materials were processed according to standard procedures and read by an expert 
gastrointestinal pathologist. When there was dysplasia or cancer the consensus opinion of 
two pathologists was reported. Histology was classified according to the Vienna criteria of 
gastrointestinal epithelial neoplasia ranging from no intraepithelial neoplasia to invasive 
neoplasia(210)  
Statistics  
Numeric variables are summarized with the sample mean and standard deviation and 
categorical variables with the number and percentage. The primary endpoints of interest 
were the number of patients with any dysplastic lesion detected and the number of patients 
with endoscopically visible dysplastic lesions. The secondary endpoints were the number of 
high-grade dysplasia’s/cancers detected and the number of patients with endoscopically 
visible flat non-polypoid dysplastic lesions. The risk of association between the outcome 
variables of interest and type of endoscopy (HD or SD) was estimated using Poisson 
regression with robust standard errors rather than a more commonly used logistic 
regression(211, 212)The choice of the Poisson model, which provides a prevalence ratio 
(PR), was based on the fact that the outcomes were relatively common. The Poisson model 
provides a more conservative estimate of the relative risk that is closer to its sample value 
than when logistic regression is used in cross-sectional studies. Potential confounders that 
were included in multiple regression models included age, gender, duration of disease, 5 
amino-salicylate use, the extent of disease, exposure to immunomodulators or biologics, the 
experience of colonoscopist, adequacy of bowel preparation and a total number of biopsies 
taken. A two-sided significance level was set at p < 0.05. The statistical software’s SPSS 
version 20 (SPSS Inc, Chicago, Illinois) and Stata version 16 (Stata Corp, College Station 
Texas) were used in all analyses. 
Results 
Total of 10831 colonoscopies was performed in Leeds teaching hospitals during the study 
period. We selected the procedures undertaken for the surveillance of UC for this study.  A 
total of 336 patients were included in the study after applying our exclusion criteria (5 
pouchoscopies) and removing wrongly coded procedures (n=3). 120 patients underwent 
surveillance colonoscopy with CE and 216 patients underwent WLE alone.  
Table 38 provides the summary of the patient demographics, disease characteristics, 
equipment used and the grade of endoscopist for the colonoscopies included (120 CE and 
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216 WLE).  The groups were well matched for age, gender, diagnosis, extent of disease, 
disease duration and drug therapy (5-Aminosalicylates and Immunomodulators). There were 
significantly more patients who had their procedures performed by consultants among CE 
(89%) than WLE group (55%). Significantly more colonoscopies in the WLE group (21%) 
were done by trainees compared to CE group (2%). Significantly more CE procedures 
involved HD scopes (34%) compared to the WLE group (19%). 
9 dysplastic lesions (all low-grade dysplasia) were detected in 7/216 colonoscopies in the 
WLE group. Of these 2 lesions were detected outside the extent of colitis leaving 7 
dysplastic lesions detected in 5/216 colonoscopies in the WLE group. 27 dysplastic lesions 
(all low-grade dysplasia) were detected in 20/120 colonoscopies in the CE group. Of these 3 
lesions were detected outside the extent of colitis leaving 24 dysplastic lesions noted in 
17/120 colonoscopies in the CE group. There were 2 patients in the WLE group with 
endoscopically visible non-polypoid flat dysplasia and 11 in the CE group. Table 39 provides 
details of the number and characteristics of lesions detected by the two modalities. 
Table 40 provides the adjusted and unadjusted prevalence ratio of picking up any dysplastic 
lesion, and endoscopically visible non-polypoid flat dysplastic lesions with CE compared to 
WLE. Significantly more dysplastic lesions and non-polypoid endoscopically visible flat 
dysplastic lesions were detected by CE compared to WLE even after adjusting for age, 
gender, diagnosis, duration of disease, extent of disease, 5 amino-salicylate use, 
immunomodulator or biologic drug exposure, number of biopsies taken experience of 
colonoscopist, previous dysplasia, high definition scope use and bowel preparation score.
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Table 38 Details of patients include in the study 
Variable WLE  (n=216) Chromoendoscopy  
(n=120) 
Age (mean ± SD) years 48.8 (15.2) 49.7 (14.8) 
Gender:              Male (%) 
                           Female (%) 
122 (56.5%) 
94 (47.3) 
72 (60%) 
48 (40%) 
Disease extent: Pancolitis (%) 
Left sided UC (%)                 
104 (48.1%) 
112 (51.9%) 
66 (55%) 
54 (45%) 
5-aminosalicylate use (%) 167 (77.3%) 92 (76.6%) 
Immunomodulator or biological 
drug exposure (%) 
48 (22.2%) 28 (23.3%) 
Disease duration (mean ± SD) 19.9 (9.8) 20.3 (12.1) 
Adequacy of bowel preparation# 
                        Poor (%) 
                        Adequate (%) 
                        Good (%)            
 
42 (19.4%) 
43 (19.9%) 
131 (60.7%) 
 
13 (10.8%) 
49 (40.9%) 
58 (48.3%) 
Completion rate* 200 (92.6%) 119 (99.2%) 
Grade of colonoscopist** 
               Consultant (%) 
               Nurse Endoscopist (%) 
               Trainee (%) 
 
118 (54.6%) 
53 (24.5%) 
45 (20.9%) 
 
107 (89.2%) 
11 (9.2%) 
2 (1.6%) 
High Definition endoscope use** 41/216 (19%) 42/120 (34%) 
Mean number of biopsies (SD)** 22 (10) 13 (9) 
 # p=0.004,* p=0.008 and ** p<0.001 
Table 39 provides comparative details of the total number of dysplastic lesions in each group 
along with the patients with dysplasias, site of the lesions and the number of flat dysplastic 
lesions.  
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Table 39 Characteristics of dysplastic lesions detected 
 WLE (n=216) CE (n=120) 
Total number of dysplastic 
lesions#  
7 24 
Number of patients with 
dysplasia# 
5 17 
Anatomic location of lesions: 
Right Colon             
Sigmoid/Descending 
 Rectum 
 
3 
3 
1 
 
8 
11 
5 
Number of patients with non-
polypoid dysplastic lesions# 
(endoscopically visible) 
2 7 
Location and number of dysplastic lesions within the colitic area detected according to modality.  
WLE: White light endoscopy, CE: Chromoendoscopy5 adenomatous polyps in 5 patients outside the 
segment of colitis (3 in chromoendoscopy arm and 2 in WLE arm).  
# all lesions were low-grade dysplasia noted on targeted biopsies. No dysplasia was noted on random 
biopsies. 
Table 40. Multiple regression analysis  
 Prevalence 
ratio 
(95% CI) 
P 
value 
Adjusted 
prevalence ratio* 
(95% CI) 
P 
value 
Any Dysplasia 6.12(2.25-
16.58) 
<0.001 5.43 (1.3-17.55) 0.004 
Flat dysplastic lesions 
detected by targeted 
biopsies 
7.19 (1.52-
33.9) 
0.01 4.30 (1.02-18.16) 0.04 
Multiple regression analysis of the association between type of colonoscopy (WLE or CE) and 
detection of any dysplastic lesions and endoscopically visible non-polypoid dysplastic lesions on a per 
patient basis. 
* Adjusted for age, gender, diagnosis, duration of disease, extent of disease, 5 amino-salicylate use, 
immunomodulator or biologic drug exposure, number of biopsies taken the experience of 
colonoscopist, previous dysplasia, high definition scope use and bowel preparation score. 
Discussion 
Our study demonstrates that CE improves detection of dysplastic lesions during surveillance 
colonoscopy of patients with ulcerative colitis even in routine clinical practice. CE was found 
to be superior to WLE in detecting all dysplastic lesions and the detection of endoscopically 
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visible flat non-polypoid lesions. This is a significant finding as dysplastic lesions in long-
standing UC are usually non-polypoid and flat. 
This study was conducted after the guidelines by British Society of Gastroenterology 
recommending the use of CE for surveillance colonoscopies in long-standing UC(119) and 
we aimed to understand the uptake among the colonoscopists in our centre. Despite being 
an active academic centre with robust IBD service, CE was performed only in 1/3rd of the 
study population, and the remaining patients underwent standard WLE with random colonic 
biopsies. Among those who underwent CE, 89% of procedures were performed by the 
consultants and 54% of the WLE were also performed by the consultants who opted not to 
perform CE for reasons we have been able to capture from our study. This highlights the 
lack of a uniform approach for endoscopic surveillance even in academic units. Our results 
are very similar to a recent physician survey from Canada looking at the practice of 
surveillance colonoscopy in patients with UC among the academic gastroenterologists (121). 
This study showed results similar to ours with only 26.5 % of Canadian Gastroenterologists 
routinely using CE, despite the fact that the majority (71%) of the participants were 
physicians with IBD as their subspecialty.  
Although there is ample evidence in favour of CE and targeted biopsy over WLE and random 
biopsies, results from a retrospective study from the Netherlands found contrasting 
findings(213). In their retrospective study, the authors collected data from 2000 to 2013 and 
included 401 and 772 patients in CE and WLE arm respectively. The rate of dysplasia in the 
CE group was 11% and that in WLE group was 10%. These findings must be interpreted 
with caution as the study spanned a 13 year period with historical controls as the WLE arm. 
All the surveillance procedures in the initial part of the study were done with WLE and CE 
was introduced only in the later years of the study period. Factors that could have influenced 
these results could be the decreasing incidence of dysplasia over time and the relative in-
experience of colonoscopists with the technique of CE when it was first introduced.  
A much larger retrospective study from St Mark’s Hospital(214) reported outcomes of 
colonoscopic surveillance in UC over a period of forty years and included 1375 patients 
followed up for 15,234 patient-years. They reported a 2.5 fold increase in dysplasia detection 
with CE compared to WLE. In their time-trend analysis, they also report a significantly 
reduced incidence rate of colorectal cancer among patients who had at least one or more 
CE procedures (2.2 per one thousand patient-years) compared to those who never had CE 
(4.6 per one thousand patient-years). In this study mainly, standard definition endoscopes 
were used and the study was spread over a long period of time with different technological 
advancements like video endoscopy and ever-improving image resolution. We have 
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previously shown that new generation High definition (HD) endoscopes with over 1 million 
pixels image density improve the detection of dysplastic lesions during routine surveillance 
colonoscopies in colonic IBD(208). Results of a recent randomised controlled trial by our 
group comparing the outcomes of HD-WLE and HD-CE has shown a significant increase in 
detection of dysplastic lesions by HDCE(215). This present study confirms that CE during 
routine clinical care with modern endoscopes does increase the detection rate of all 
dysplastic lesions. This increase appears to be driven by the increased detection on non-
polypoid flat endoscopically visible lesions which may be missed by WLE alone. 
We understand that the retrospective nature of our study is an important limitation with the 
potential to introduce bias. Standardisation of data collection between the two groups was 
not possible as there was lack of information on factors such as reasons for not performing 
CE, withdrawal time and the procedures were performed by endoscopists of varying grade 
and expertise. We used appropriate statistical tests to exclude confounding factors in our 
study. The retrospective design could also be considered a strength as we aimed at 
capturing data in routine clinical practice outside of randomized trials. It has been argued 
that randomized controlled studies in endoscopy could also be considered biased as 
endoscopists perform the procedure more diligently than in routine clinical practice. The 
Institute of Medicine has issued recommendations and priorities on “comparative 
effectiveness research” to include colorectal cancer screening strategies to be done on 
routine clinical practice(216). A prospective study design would have potentially introduced 
researcher bias by influencing the endoscopist’s decision to perform CE. This would not 
have represented real-world practice. We did not have data on smoking status and family 
history of colorectal cancer as these could not be reliably confirmed by the patient records. 
The mean number of biopsies taken in this study was 22 in the WLE group and 13 in the CE 
group. This is less than the recommended 33 biopsies that are needed to achieve 90% 
confidence to detect dysplasia(205). A survey of UK gastroenterologist revealed that 57% 
take fewer than 10 biopsies per patient(217). The figures we observed in this audit are 
similar to the UK clinical practice. This could have led to the lower identification of dysplasia 
but many studies have shown an extremely low yield of dysplasia from random biopsies 
suggesting that the incremental benefit from multiple random biopsies is small(209).  
However, we felt that major limitation of our study was the inability to perform a more 
qualitative work to identify the reasons of not performing CE when it was clinically indicated. 
Further research in this area will enhance our understanding in a challenging aspect, which 
is the behaviour of endoscopists affecting their performance and outcomes.     
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In conclusion, CE picks up significantly more dysplastic lesions especially non-polypoid flat 
lesions even when performed in routine clinical settings. However, the uptake for CE among 
endoscopists is poor with only 1/3 of the procedures in our tertiary centre being done using 
CE. Increased time taken, lack of training, the perception that CE is a messy procedure 
could be speculated to be among the reasons. Further work is needed to understand the 
reasons for the poor utilization of CE in routine clinical practice and make innovations to the 
procedure that can increase the uptake of this technique to improve surveillance outcomes 
in this high-risk population.
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8 High definition white light endoscopy versus high 
definition chromoendoscopy in detecting dysplasia in 
Ulcerative colitis  
Background  
Patients with ulcerative colitis (UC) have an increased risk for colorectal cancer (CRC) 
compared to the general population(111). Cancer in UC occurs at a younger age and 
increases with time, approaching 18% after 30 years of disease(111). This increased risk 
has prompted both the North American and UK gastroenterology societies to recommend 
cancer prevention strategies(218, 219). Random sampling throughout the colon has been 
the mainstay of conventional surveillance practice. Surveillance colonoscopy requires 
multiple biopsies, to be taken and processed which is tedious, expensive and time-
consuming. It has been estimated that at least 33 biopsies are needed to achieve 90% 
confidence to detect dysplasia if it is present(205).  Surveillance colonoscopy practices are 
not uniform and less than 10 biopsies were noted to be taken based on gastroenterologists 
self-reported practices for colonoscopic surveillance for UC(217). The focus of dysplasia in 
UC is flat and multifocal and can be easily overlooked with conventional white light 
endoscopy(206).  There is growing evidence that the yield of surveillance can be improved 
by the addition of newer endoscopic methods that enhance the detection of subtle mucosal 
abnormalities like chromoendoscopy (CE) and autofluorescence with narrow band 
imaging(106). CE refers to the topical application of dyes or pigments to improve detection 
and delineation of surface abnormalities and is an inexpensive adjunct to conventional 
endoscopy. It has been shown to be useful in the detection of flat adenomas in the sporadic 
setting as well as in patients with familial polyposis syndromes(220, 221).  There is 
increasing evidence that most dysplasia in UC is associated with visible mucosal 
abnormalities(222, 223). This has, in turn, led to increasing use of endoscopic resection 
techniques to treat areas of raised, visible dysplasia in patients with UC, without the need for 
colectomy.  There is, therefore, a need to improve detection techniques during surveillance 
endoscopy and CE has been advocated as a promising method. A recent meta-analysis has 
shown that CE is better than the standard white light endoscopy in detecting dysplasia in 
UC. However, despite several studies showing the utility of CE in detecting subtle mucosal 
abnormalities in CE, this technique has not been widely accepted in routine clinical practice.  
CE is time consuming increasing the extubation time by 9-26 minutes, and even when 
performed with specially designed dye-spray catheters, complete and even mucosal dye 
coverage is not guaranteed(112). CE has only been compared in clinical trials with standard 
definition endoscopy rather than the currently available high definition endoscopes with 
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better resolution and picture. High definition (HD) endoscopy uses a high definition (1080 
lines of vertical resolution) monitor and a high resolution CCD (charge coupled device) with 
up to a million pixels which provides much better images than standard video endoscopy. A 
recent meta-analysis showed that HD colonoscopy was better than standard endoscopy in 
polyp detection but not in the detection of high risk adenomas(113). HD colonoscopy 
promises therefore to provide an alternative to chromoendoscopy in UC surveillance without 
the need for the extra time and experience required for dye spraying for both endoscopists 
and nursing staff. 
At the time we started this study there were no trials comparing these 2 modalities. The 
recent SCENIC guidelines endorsed the view that HDCE was the preferred modality for 
surveillance in these patients based on one study from the Mayo Clinic on 75 patients which 
showed a more than 2 fold increase in dysplasia detection (9.3% vs 21.3%) with HDCE 
using a 0.2% indigo carmine solution. A subsequent randomized trial from Canada showed 
no differences in detection rates between HDWL and HDCE using a 0.03% methylene blue 
solution 
The aim of study was to a randomized trial to compared HDWL colonoscopy alone 
compared to HDWL with chromoendoscopy (HDCE) for dysplasia detection during 
surveillance for extensive ulcerative colitis.  
Methods  
This was a parallel group randomized controlled trial (clinicaltrials.gov number 
NCT02138318) in a single tertiary centre in the UK. Ethical approval for the study was 
obtained from the UK National Research Ethics Committee (Reference number 
12/YH/0228). 
Patients with extensive colitis on a surveillance program at the Leeds Teaching Hospital 
NHS trust (150 patients per year) and those referred for a surveillance colonoscopy from the 
outpatient clinics at the Leeds Teaching Hospital NHS trust were screened by a research 
nurse/ fellow and were invited to join the study by letter along with their colonoscopy 
appointment if they meet the inclusion and exclusion criteria. A patient information leaflet 
(PIL) explaining the study was sent to the patient. On arrival in the endoscopy reception 
area, they were given the opportunity to ask questions to the endoscopists/member of the 
research team and be invited to participate and sign the written consent form. Preparation 
prior to colonoscopy including bowel preparation and dietary restriction were according to 
local unit protocol.  
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Consecutive eligible patients undergoing surveillance colonoscopy for long standing 
ulcerative colitis were approached for inclusion in this trial. Patients were reassured that 
participation in the trial would ensure they have a thorough procedure with a possible chance 
of increased detection rates. The increased procedure time of around 10 minutes with the 
use of chromoendoscopy was explained beforehand.  
Inclusion criteria 
1. Patients with longstanding (more than 8 years of disease), extensive (extending 
proximal to splenic flexure) colitis attending for surveillance colonoscopy  
2. Patients aged over 18 years of age. 
Exclusion criteria 
Pre-intubation 
1. Pregnancy 
2. Unwilling or unable to give informed consent 
3. Severe active colitis (as assessed by endoscopists) 
Pre-randomization 
1. Poor bowel preparation (solid stool or <90% of mucosal area cannot be visualized 
even after jet washing using the Aronchik scale score of > 3) 
8.1.1.1 Standardisation for colonoscopy 
All efforts were made to standardise every step of the patient journey. A standard split dose 
polyethylene glycol based bowel preparation was used as per unit protocol. Colonoscopies 
were performed in the standard manner till caecum or terminal ileum as appropriate. Hand 
pressure, position changes, sedation and antispasmodics were used as per unit protocol. 
The Olympus Lucera spectrum processor, with an Olympus CFH260 DL scope and high 
definition monitor, were used for all procedures. After informed consent for the trial and 
procedure patients had an intravenous cannula sited. Sedation and antispasmodics were 
used as per unit protocol at the discretion of the endoscopists. As much fluid residue was 
washed out at insertion as possible, using a jet wash system (Olympus or Mediavators). 
Caecal intubation time was recorded and caecum was identified by IC valve, appendicular 
orifice and tri-radiate fold. Bowel preparation quality was noted as per the Aronchick 
scale(224) which is score as 1. Excellent > 95% of mucosa seen, 2. Good: clear liquid 
covering <25% of mucosa but > 90% mucosa seen, 3. Fair semisolid stool could be 
suctioned off but > 90% of mucosa seen, 4. Poor: semi solid stool could not be suctioned off 
and < 90% of mucosa seen, 5. Inadequate, repeat preparation required.  
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Randomization 
Patients were randomized to withdrawal with either high definition white light endoscopy or 
chromoendoscopy when caecum is reached. A closed envelop randomisation with block 
sequence was used and minimization techniques were utilized to ensure a balance between 
groups on known risk factors like family history, primary sclerosing cholangitis and previous 
dysplasia.  
8.1.1.2 Withdrawal 
Withdrawal was also standardised for every patient. The colon was examined in segments 
with at least 2 targeted biopsies per suspected lesion noted or snare resection of lesion 
detected if deemed appropriate by the endoscopists. Suspicious areas were defined as 
mucosal irregularities not consistent with chronic or active ulcerative colitis. Quadrantic 
biopsies were taken from around each suspicious lesion to look for field change. Random 
biopsies from each segment were taken as per the guidelines. 
In patients randomized to the CE arm, dye spraying was performed using 0.2% 
Indigocarmine solution via a spray catheter inserted via the biopsy channel of the 
colonoscopy and sprayed from a 50cc Luer lock syringe prefilled with dye solution. 
Extubation time (excluding time for resection and biopsies) was calculated and a minimum of 
8 minutes were used to examine mucosal surface. If there was marked psuedopolyposis 
then representative biopsies of any atypical looking psuedopolyps were taken. Sizes of 
lesions were measured against an open biopsy forceps. Segment of lesions, type (according 
to Japanese Research Society classification) and endoscopic diagnosis (hyperplastic, 
adenoma, carcinoma, DALM) were recorded. Figure 21 shows assessment of polyps with 
HD-WLE and HD-CE. Where possible all lesions had still and video images recorded.  
Endoscopists made an assessment of mucosal inflammation of each segment as per the 
Mayo score 
 0= normal or inactive disease 
 1= mild (erythema, decreased vascular pattern, mild friability) 
 2= moderate (marked erythema, absent vascular pattern, friability, erosions) 
 3= severe (spontaneous bleeding, ulceration) 
Endoscopist also commented on the presence of tubular colon, featureless colon, strictures, 
scarring, psuedopolyps and backwash ileitis. Figure 22 shows the assessment of active 
disease with HD-WLE and HD-CE. 
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Histology 
All specimens were fixed in 10% formalin. Slides were read by an experienced 
gastrointestinal histopathologist with confirmation of any equivocal cases with a second 
experienced gastrointestinal histopathologist. Lesions were graded as 1-Normal, 2- indefinite 
for dysplasia 3-Low grade 4-High grade 5-Invasive cancer(210).  
Non-targeted biopsies were additionally assessed for inflammation:  0= normal, 1=mild 
chronic inflammation only 2= mildly active (cryptitis but not crypt abscess) 3= moderately 
active (few crypt abscesses) and 4= severely active (numerous crypt abscesses) 
Statistical analysis 
At the time of study initiation there were no data available on the potential incremental yield 
with HDCE. Hence a sample size calculation prior to starting the study was not possible; 
instead we agreed to perform an interim analysis to guide us estimate the number needed 
for completion of study. Based on our preliminary results after the first 103 patients were 
recruited we showed a 9.4% yield with HD and 22.4% yield with HDCE. With this yield, for a 
once sided (HDCE unlikely to be worse than HD alone) test of significance, with a power of 
80% (beta error 0.2, alpha error 0.05) we estimated 79 patients in each group had to be 
enrolled. 
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Primary Outcomes 
1. Number of lesions with at least low grade dysplasia detected by targeted biopsy  
2. Total number of patients with dysplastic lesions in each group 
Both primary outcomes were analysed on a superiority basis. For the detection of dysplasia 
on a per patient basis the chi square test was used with the confidence intervals (CI) for the 
relative difference based on the standard error of the log relative risk. For the number of 
lesions detected the data did not follow a Poisson distribution because of over-dispersion 
(variance greater than the mean) and therefore negative binomial regression was used to 
compare the means in this group.  
 
  
      
             
            
            
            
            
            
             
 
Figure 22 Active UC assessed using HD-WLE (left) and HD-CE (right) 
 
Figure 21 Assessment of polyp assessed using HD-WLE (left) and HD-CE (right) 
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Results 
From 23/08/2013 to 31/08/2015, 297 patients with ulcerative colitis underwent surveillance 
colonoscopy at Leeds Teaching Hospital NHS trust. Of these 137 were not included (110 did 
not have extensive colitis, 4 did not consent to trial, 13 had active disease in the 
endoscopists opinion). In all 160 patients consented to the trial of which 2 were excluded (1 
was noted to have a subtotal colectomy and the other had Mayo Grade 3 colitis). The 
remaining 158 were randomly assigned by block randomization with 79 in each arm and 
were analyzed on an intention to treat bases. No patient was excluded due to poor bowel 
preparation as the endoscopists made every attempt using a jet wash system to achieve 
adequate mucosal visualization. Figure 23 provides an overview of the study enrollment. 
Flowchart  
 
Figure 23 Flowchart of patient selection-RCT 
HDWLE- High definition white light endoscopy, HDCE-High definition chromoendoscopy 
297 patients underwent 
surveillance colonoscopy and 
assessed for eligibility                               
160 patients recruited 
79 patients included in 
HDCE arm 
137 excluded patients: 
120 did not have 
extensive colitis 
4 did not consent 
13 had active disease 
as per endoscopists 
assessment  
1 for severe active 
disease 
1 for a subtotal colectomy 
79 patients included in 
HDWLE arm  
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Baseline characteristics 
Table 41 provides information on the baseline characteristics of the population enrolled. 
There were 79 patients in each arm and no significant differences were noted between the 
two groups. The mean age was around 55 years in each group with predominantly male 
patients 62%). There were slightly more patients with PSC in the HD group compared to the 
HDCE group but this was not statistically significant, but overall 17% of our cohort had PSC. 
Characteristic of the study procedures is shown in Table 42.  The caecum was reached in 
99% of patients in each group. A completion CT-Colonography done in both patients in 
whom the caecum was not intubated did not show any additional polyps. Both have been 
included in the analysis on an intention to treat basis. The median time taken for the 
procedure was significantly higher in the HDCE group which was mainly due to a difference 
in about 9 minutes in withdrawal time which was a combination of the additional time taken 
to spray the dye and the time taken for additional targeted biopsies or polyp resections. The 
median number of biopsies taken was similar (32) but more targeted biopsies were taken in 
the HDCE group.  
Table 41 Patient characteristics  
 High Definition alone (n=79) High Definition with 
chromoendoscopy (n=79) 
Mean age in years 55.5 (14.2) 55.0 (14.0) 
Male 49 (62) 49 (62) 
Female 30 (38) 30 (38) 
Current or previous 
smoking history** 
34 (43) 31 (39) 
Median disease duration 
(years) 
17 (9-25) 20 (12-28) 
Previous dysplasia 5 (6.3) 6 (7.6) 
Primary sclerosing 
cholangitis 
16 (20.2) 11 (11.5) 
Family history of colorectal 
cancer 
5 (6.3) 4 (5.1) 
Previous or current 
immunomodulator use* 
27 (34.2) 34( 43.0) 
Previous or current 5 
aminosalicylate use 
75 (94.9) 68 (86.1) 
Data are mean (SD), n (%) and median (IQR). *immunomodulator therapy is thiorpurines, 
methotrexate or biologics. **only 2 patients in the HD group and 1 patient in the HDCE group were 
current smokers 
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Primary end points 
47 dysplastic lesions were identified in 30 patients. The overall dysplasia detection rate was 
19%. 10 patients (12.6%) in the HD arm had dysplasia compared to 20 patients (25.3%) in 
the HDCE arm. This gave HDCE an incremental yield of 12.7% (p=0.04). The mean number 
of dysplastic lesions detected in the HDCE arm (0.37) was also significantly higher than the 
HD arm (0.16). Table 43 provides an overview of these results. 
Histological and morphological characteristics of detected lesions 
Table 44 provides details of the detected lesions and their characteristics. Of the 47 lesions 
detected using HD colonoscopy, 13 had dysplasia (27.6%) and of the 103 lesions detected 
using HDCE, 29 had dysplasia (28.1%). There were 64 targeted biopsies taken in the HD 
group (mean 0.81 ±1.5) and 176 targeted biopsies taken in the HDCE group (mean 2.2 ± 
2.7). This difference was statistically significant (p <0.01). A total of 2305 random biopsies 
were taken in the HD group of which one showed low grade dysplasia and a total of 1937 
random biopsies were taken in the HDCE group of which none had any dysplasia noted. No 
dysplasia was noted on random biopsies taken from the mucosa surrounding each 
suspicious lesion. Agreement between the blinded histopathologists (OR and PP) for the 
presence of dysplasia was excellent with disagreement in only 1 polyp in a patient who had 
an additional dysplastic lesion and therefore was included in the per patient detection 
analysis. 
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Table 42 Colonoscopy characteristics 
 High Definition 
alone (n=79) 
High Definition with 
chromoendoscopy 
(n=79) 
P value (two 
sided) 
Post inflammatory 
polyps 
16 19 0.28 
Mayo 1 colitis 12 9 0.41 
Tubular shortened 
colon 
6 4 0.36 
Bowel preparation ** 
1. Excellent  
2. Good 
3. Fair 
 
47 
24 
8 
 
53 
21 
4 
 
0.38 
Caecal intubation 78$ 78$ 1.00 
Total time of 
colonoscopy 
26 (21-31) 32 (24-36) <0.01 
Withdrawal time 
(minutes)  
15 (10-20) 24 (20-28) <0.01 
Number of biopsies 
taken 
32 (29-35) 30 (24-36) 0.36 
Number of targeted 
biopsies taken 
64 176 <0.01 
Data are n (%) or median (IQR) 
** The Aronchick bowel preparation scale was used to assess the quality of bowel preparation $ In 
both cases the ascending colon was reached but caecum was visualized but not intubated, 
completion CTC done showed no additional polypoid lesions beyond the point of insertion. 
Table 43 Outcome measures of the trial 
 High Definition alone 
(n=79) 
High Definition with 
chromoendoscopy 
(n=79) 
P value (2 sided) 
Proportion of 
patients with ≥ 1 
dysplastic lesions 
10 (12.6%) 20 (25.3%) 0.04 
Mean number of 
dysplastic lesions 
per patient 
0.16 (0.5) 0.37(0.7) 0.04 
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Table 44. Characteristics of detected lesions and details of histology 
 High Definition alone (n=79) High Definition with 
chromoendoscopy (n=79) 
Total number of lesions 
detected  
47 103 
Total number of dysplastic 
polyps/lesions 
13 29 
Number of patients with >1 
dysplastic polyp/lesion 
2 7 
Location of dysplastic 
polyps 
1. Caecum 
2. Ascending 
3. Transverse 
4. Descending 
5. Sigmoid 
6. Rectum 
 
 
 
1 
4 
3 
2 
2 
1 
 
 
4 
6 
10 
6 
1 
2 
 
Median size of polyp in mm 
(IQR) 
3.5 (3-4.5)  4 (3-8) 
Morphology of dysplastic 
lesions by Paris 
classification 
1. Subpedunculated 
(Isp) 
2. Sessile (Is) 
3. Flat or flat elevated 
(IIa or IIb) 
4. Flat and Depressed 
component (IIa + IIc) 
 
 
 
 
1 
4 
8 
 
0 
 
 
 
 
3 
8 
16 
 
2 
Histology of dysplastic 
lesions detected 
a. Adenocarcinoma 
b. HGD/adenocarcinoma 
c. LGD 
 
 
0 
0 
13* 
 
 
0 
1 
28 
Mean number of targeted 
biopsies 
0.81 ±1.5 2.2 ± 2.7 
Total number of random 
biopsies 
2305 1937 
* One patient with a dysplastic adenoma in ascending colon also had low grade dysplasia 
noted on a random biopsy from the descending colon with no visible endoscopic lesion.  
Discussion 
In this randomized controlled trial we detected a significant difference between HD 
colonoscopy and HDCE for the detection of colitis associated neoplasia in patients with 
extensive long standing ulcerative colitis in remission. We used a standard 0.2% 
indigocarmine spray introduced via a spray catheter for all patients in the HDCE arm. This is 
the first parallel group randomized controlled study to compare HD and HDCE. The only 
other published study on this was a three arm study comparing HD, HDCE and ISCAN 
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technologies(225). This study however used a 0.03% indigo carmine dye or 0.04% 
methylene blue sprayed using the jet wash system rather than a spray catheter. All the 
randomized studies comparing standard definition colonoscopy and CE in the literature have 
used concentration of methylene blue and indigocarmine of 0.1% and higher(112, 209). The 
validity of the use of the lower concentration of dyes used in the Canadian study have never 
been shown previously to improve neoplasia detection in IBD surveillance in any published 
study to date. 
We found that HDCE has an incremental yield of about 12.7% with a NNT of about 8, 
suggesting that HDCE would detect one additional patient with a dysplastic lesion for every 8 
patients on whom this procedure is done. Studies on the use of CE with standard definition 
technology showed an incremental yield of 7% with a NNT of about 14(118). Our overall 
detected rate for dysplasia in this study was 1 in 5 which is higher than that found with 
standard definition technology where around 1 in 12 patients had dysplasia(209). This 
increase in yield may partly be due to the higher risk patients enrolled in this trial (extensive 
long standing colitis with 17% having concomitant PSC). The majority of lesions detected 
were however small (median size 4 mm) and it is unclear if these small lesions have the 
same malignant potential and if removal of these lesions would improve long term outcomes. 
Our detection rates are however similar to two recent studies comparing HDCE with 
NBI(226) and AFI(107) respectively. HDCE had a detection rate of 19% in the Vleugels et. 
al. AFI study and 21.2% in the Bisschops et.al. NBI study. The median size of dysplastic 
lesions detected was 3 mm in both studies.  
The withdrawal time with HDCE was on average 9 minutes longer. This is similar to studies 
comparing standard definition colonoscopy with CE(112, 209). The withdrawal time with 
HDCE in our study (24 minutes) is in between those in the 2 recently published studies 
comparing AFI with HDCE(107) where the withdrawal time with HDCE was 16 minutes and 
in that comparing NBI with HDCE(226) where the withdrawal time with HDCE was 27 
minutes. One of the reasons for the shorter withdrawal time in the AFI study may be 
because they separated the time for inspection (16 minutes on average) and dye application 
and lesion removal (7 minutes on average). Like in the Bisschops et.al study we did not 
attempt to separate these out as it would be impractical and difficult to measure accurately in 
a busy standard clinical endoscopy list and the total time taken would be a more accurate 
reflection of the costs involved with the procedure. 
As expected CE detected more lesions overall (103) compared to HD alone (47). However 
the proportion of lesions that were dysplastic was similar with 28.1% of lesions being 
dysplastic with HDCE and 27.6% with HD. This was slightly higher than the 17% of lesions 
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detected that were dysplastic in the Bisschops et.al. study(226). This difference may be due 
to the relative experience of the endoscopists involved in this single tertiary academic centre 
study who performed the study procedures (NM, VS and JH) compared to the 3 centre, 5 
endoscopist (4 inexperienced) study by Bisschops et. al(226). However, a Spanish study on 
the role of routine CE in dysplasia detection did not find a learning effect for CE with less 
experienced endoscopists nor a difference in detection rates between experts and non-
experts(227). 
In addition to targeted biopsies we took random biopsies from each segment with a median 
number of 30 and 32 biopsies per patient in the HDCE and HD arm. NICE guidelines in the 
UK do not recommend taking random biopsies when CE is used and the recent SCENIC 
guidelines(209) have been equivocal on their use with no consensus reached. Interestingly 
more random biopsies were taken in the HD arm in our RCT than the HDCE arm perhaps 
reflecting an unconscious bias on the part of the endoscopists in this trial feeling that HD 
was not detecting enough suspicious lesions. The lack of random biopsies have been a 
criticism of several recent trials including the Canadian study comparing HD,HDCE and 
ISCAN(225) and Bisschops et al(226) comparing HDCE and NBI. We had included the 
addition of random biopsies in both arms apriori to deflect this criticism that lesions may 
have been missed in either arm that might have been noted on random biopsy and also 
because random biopsies were part of routine clinical practice when this study was designed 
and an application for ethical approval made. Reassuringly only 1 of the 2305 random 
biopsies taken in the HD arm had a focus of low grade dysplasia and the patient was offered 
colectomy as he had an additional dysplastic polyp in the ascending colon, but declined this. 
On follow up colonoscopy 6 months later no lesion was found and no dysplasia noted on 
random biopsies from the same or other segments. Additionally no dysplasia was noted on 
biopsies taken from around each suspicious lesion in this study. These findings support the 
view that when using HD colonoscopy, taking routine 10 cm, 4 quadrant biopsies is not likely 
to increase yield. 
There are several limitations to our study. Firstly we used a randomized parallel group study 
design and cannot make assumptions on the neoplasia miss rate of either modality. 
However no cancers have developed on follow up on any of these patients till date. We 
chose a parallel group study as back to back study designs where HDCE would have 
followed withdrawal in HD is also inherently biased as it assumes all lesions noted on white 
light would be visible with chromoendoscopy. Due to our selection criteria these results are 
only valid for patients with extensive ulcerative colitis with long standing (> 8 years) disease 
and in endoscopic remission. As this was done in a tertiary academic centre the proportion 
of high risk patients was more than average with 17% of the cohort having PSC and 7% 
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having previous dysplasia. Finally the power calculation of our study was done on a 
superiority design based on our interim results. As the majority of studies using CE with 
standard definition colonoscopies had shown superiority of CE over white light endoscopy 
we felt this was a reasonable assumption to make. A total sample size of 158 patients with 
extensive long standing ulcerative colitis makes this one of the largest RCT’s to date to 
include such a high risk cohort where surveillance is presumed likely to have the greatest 
benefit.  Nevertheless, the results of this study need to be confirmed in larger multi-centre 
trials with a more inclusive group of patients and endoscopists of varying experience.  
In conclusion this RCT shows that chromoendoscopy should remain the preferred 
surveillance technique especially in high risk groups (extensive colitis, PSC and previous 
dysplasia) and validates the recommendations of the SCENIC guidelines(209). Further 
studies comparing HDCE with HD in multiple centres including a wider cohort of patents 
(both low and high risk) are needed before this approach can be advocated all for patients. 
Clinical societies (like the AGA, ASGE, BGS and ECCO) should facilitate the adoption of 
chromoendoscopy as the preferred surveillance method in daily practice while we await the 
results of this large multi-centre study. 
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Appendix D: Patient information leaflet for NBI prospective trial 
 
 
 
PATIENT INFORMATION SHEET 
 
Project title: Utility of narrow band imaging endoscopy in assessment of colonic 
inflammation and prediction of relapse in patients with Ulcerative colitis: a pilot study 
 
 
Invitation  
You are being invited to take part in a research study.  Before you decide we would like to explain 
why the research is being done and what it will involve.  Please take time to read the following 
information carefully and discuss it if you wish. Ask us if there is anything that is not clear or if you 
would like more information. Take time to decide whether or not you wish to take part. 
 
1. What is the purpose of the study? 
It is known that flare up of disease activity in people with ulcerative colitis is unpredictable. It is also 
known that inflammation can persist in the deeper lining of bowel wall despite the normal 
endoscopic appearance. This resistant inflammation contributes for further flare up of the disease. 
Flare ups cause health and economic burden to both the patients and carers. If the intestinal 
inflammation can be accurately assessed endoscopically and if we are able to predict future flare ups 
of the disease, this would improve health related quality of life of patients.  
 
The usual way to look at the inflammation in the colon is by Flexible sigmoidoscopy (examination of 
left side of the bowel) or colonoscopy (examination of whole colon) using a flexible endoscope. This 
uses standard white light to look at the inner lining of the bowel wall. Technological advances in 
endoscopy help explore options to improve assessment of intestinal inflammation using different 
modalities. Narrow band imaging technology is one such advancement. We wish to see if this 
correlates well with intestinal inflammation and if this could predict future flares in ulcerative colitis. 
This could potentially help us treat colitis better using the predictive capabilities of NBI endoscopy. 
  
2. Why have I been chosen? 
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We are currently inviting all patients with ulcerative colitis who are scheduled to have 
routine surveillance colonoscopy or flexible sigmoidoscopy for assessment of disease 
activity.  
 
3. Do I have to take part? 
NO. It is up to you to decide whether or not to take part.  If you do decide to take part you 
will be given this information sheet to keep and be asked to sign an extra consent form in 
addition to the one just before your procedure. If you decide to take part you are still free to 
withdraw at any time and without giving a reason.  A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care you receive. 
 
4. What does the study involve? 
You will undergo examination of the bowel with a flexible endoscope (camera). The endoscope has 
an ability to look at the inner lining of the bowel with different colours. Normally we perform the 
test with a white light, but in this study we would examine with white light first followed by blue 
light (called as Narrow band imaging or NBI). The blue light examination is only limited to lower left 
side of the bowel called sigmoid and rectum. If you agree, we would take digital images and videos 
of the lining of the gut during the NBI endoscopy before biopsy samples are taken. The NBI 
endoscope is a standard endoscope with all the functions of regular endoscopy, but can additionally 
visualize the lining under NBI light. This additional examination will only take 3-4 minutes more than 
standard examination. 
 
5. What do I have to do? 
There are no restrictions, other than the usual advice for flexible sigmoidoscopy or 
colonoscopy. This study involves no extra visits to hospital before or after the procedure. 
 
6. What are the possible disadvantages and risks of taking part? 
Taking NBI endoscopic images or videos is painless but will prolong your endoscopy by about 3-4 
minutes.  
 
7. What are the possible benefits of taking part? 
This research is being done to try to make scientific progress. This study could potentially help 
improve our understanding about the flares in ulcerative colitis and help treating the disease better. 
The NBI endoscopic images and videos obtained may help improve our knowledge to treat your 
condition (colitis) better. 
 
8. What if something goes wrong? 
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If you have a concern about any aspect of this study, you should ask to speak to the researchers who 
will do their best to answer your questions [contact Dr V Subramanian, Tel 01132067575]. If you 
remain unhappy and wish to complain formally, you can do this through the NHS Complaints 
Procedure or PALS. Details can be obtained from either your doctor or the Leeds Teaching Hospitals 
NHS Trust PALS centre at Tel: 01132067188.  
 
9. Will my taking part in this study be kept confidential? 
If you consent to take part in the research, your own GP will be notified.  This means that other 
doctors in the same practice may be aware of your participation in the study. If you give permission, 
your medical records may be looked at by responsible people involved in this research. All 
information that is collected about you during the course of the research will be kept strictly 
confidential. Any information about you which leaves the hospital will have your name, address and 
other identifiers removed so that you cannot be recognised from it.   
 
When your samples are analysed in the laboratory, they will be identified only by a code so 
that your name will not be known to laboratory staff. Samples will also be stored in a secure 
laboratory for future studies. Only the research team and your usual doctors will be able to 
link your tissue samples to your personal and medical details. 
 
10. What will happen to my samples after the study is complete? 
Samples will be stored in a secure facility at Leeds Teaching Hospitals and University of Leeds, known 
as the research tissue bank. The samples may be used for further projects in the future after 
successful application for permission has been made from ethics committees for specific projects. 
Personal information will not be stored therefore you will not be identified in any future projects. 
 
11. What will happen to the results of the research study? 
The results of the research may be published in a scientific journal when the study is complete. This 
means that results may not be published for a couple of years from now. If you would like a copy of 
the published results, you should contact us on following address; Department of Gastroenterology, 
4th Floor, Bexley Wing, St James’s University Hospital NHS Trust, Leeds LS9 7TF. 
Please note that you will not be personally identified in any report or publication. 
 
12. What will happen if I don’t want to carry on with the study?  
Your participation is voluntary and you are free to withdraw at any time, without giving any reason, 
and without your legal rights being affected. If you withdraw then the information collected so far 
cannot be erased and that this information may still be used in the project analysis. 
 
13. Who is organising and funding the research? 
This study is organised and funded by Department of Gastroenterology, Leeds Teaching Hospitals 
NHS Trust.  
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14. Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a Research 
Ethics Committee, to protect your interests. This study has been reviewed and given 
favourable opinion by National Research Ethics Committee. 
 
Contact for further information 
If you would like further information about this study at any stage, please contact: 
 
Dr. N Mohammed 
Endoscopy Research Fellow,  
St James’s university Hospital,  
4th Floor, Bexley wing,  
Leeds LS9 7TF.  
07886577132  
 
Dr Venkat Subramanian  
Consultant Gastroenterologist 
St James’s university Hospital,  
4th Floor, Bexley wing  
Leeds LS9 7TF.  
 0113 2062288 (secretary) 
 
15. Your consent 
In order to obtain images and videos for research we need to ask your permission: 
• To take them. 
• For your medical records to be looked at by responsible people involved in this research. 
You are free to give or withhold permission for all, or some of these activities, without 
prejudice to your medical care.  People not involved in your care or in the research will not 
gain access to your notes as a result of your giving this consent. 
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If you decide to participate in the study, you will be given a copy of this information sheet 
along with a signed consent form to keep. Finally, we would like to thank you for reading 
this information sheet and considering participation in our study. 
 
Yours Sincerely, 
 
Dr Noor Mohammed 
Dr Venkat Subramanian 
Dr John Hamlin 
Professor Mark Hull 
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Appendix E: Consent form_NBI observational study 
            
       
Title of Study: Utility of narrow band imaging endoscopy in assessment of colonic 
inflammation and prediction of relapse in patients with Ulcerative colitis: a pilot study 
 
Name of Participant: 
 
DOB 
 
1. I confirm that I have read and understood the information sheet for the above study. 
I have had the opportunity to ask questions about the study, and to discuss with 
family and friends.  
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, and without my medical care or legal rights being 
affected. I understand that should I withdraw then the information collected so far 
cannot be erased and that this information may still be used in the project analysis. 
 
3. I understand that relevant sections of my medical notes and data collected in the 
study may be looked at by authorised individuals from the Leeds teaching Hospitals, 
University of Leeds, the research group and regulatory authorities. I give permission 
for these individuals to have access to these records.  I understand that my personal 
details will be kept confidential. 
 
4. I agree that digital images and videos of the lining of the bowel will be taken during 
the endoscopy and stored for research analysis. 
              
5.          I understand that tissue samples are used to asses inflammation under microscope. 
These will be stored anonymously, identifiable only to the research team and my 
usual clinical team using coded sequence. No extra samples will be obtained for 
research purpose.         
   
Please initial box to confirm 
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6. I agree to my GP being informed of my participation in this study.  
 
7. I agree to take part in the above study. 
 
 
 
______________________ ______________     ____________________ 
Name of Participant   Date          Signature 
 
________________________ ______________     ____________________ 
 Name of Person taking consent Date          Signature 
 (If different from Principal Investigator) 
 
________________________ ______________     ____________________   
Name of Principal Investigator Date          Signature 
 
3 copies: 1 for participant, 1 for the project notes and 1 for the medical notes 
 
 
 
 
 
 
 
 
NREC ref No 12/yh/0228   
High definition colonoscopy versus chromoendoscopy for dysplasia detection in ulcerative colitis. 
Dr Venkat Subramanian (P.I.) 
Version 3. 12.11.2012 
 
178 
Appendix F: Patient information leaflet_HDWLE v/s HDCE 
           
  
High definition colonoscopy versus chromoendoscopy for dysplasia 
detection in Ulcerative colitis. 
 
You are being invited to take part in a RESEARCH study. Before you decide, it is important for 
you to understand why the research is being done and what it will involve. Please take time to 
read the following information carefully and discuss it with friends, relatives and your GP if you 
wish.  Ask us if there is anything that is not clear, or if you would like more information. Take 
time to decide whether or not you wish to take part. 
 
Thank you for reading this. 
 
What is the purpose of the study? 
It is known that people with ulcerative colitis have a higher risk of developing bowel cancer 
than healthy people. For this reason it is recommended that you undergo regular checks on 
the health of your bowel by having a colonoscopy. Often bowel cancer develops from small 
patches of bowel lining which become abnormal and unstable. The aim of having a 
colonoscopy is to try and find these patches and to remove them before they can turn into a 
cancer. The higher the chance of finding these abnormal patches, the better the chance of 
picking up early bowel cancer and removing it.  
The usual way that we look for these patches is by colonoscopy. To help highlight early 
abnormalities, it is recommended that applying a special blue dye to the bowel lining can 
improve their chance of detection. This has the disadvantage of being more time consuming 
and occasionally messy. There are now newer more advanced instruments available which, 
using high-definition technology gives much clearer images of the bowel lining. We wish to 
investigate whether these new instruments are as good at picking up abnormal patches 
without the need for the additional blue dye. If this is the case, then these procedures can be 
performed quicker, be more comfortable for the patient, yet still pick up early abnormalities.  
 
Why have I been chosen? 
We are currently inviting all patients with ulcerative colitis who are scheduled to have routine 
surveillance colonoscopy.  
 
 
 
 
 
 
NREC ref No 12/yh/0228   
High definition colonoscopy versus chromoendoscopy for dysplasia detection in ulcerative colitis. 
Dr Venkat Subramanian (P.I.) 
Version 3. 12.11.2012 
 
179 
Do I have to take part? 
No, participation is entirely voluntary and is completely separate from your usual care. If you 
do decide to take part you will be given this information sheet to keep and be asked to sign an 
extra consent form in addition to the one just before your colonoscopy. If you decide to take 
part, you are still free to withdraw at any time and without giving a reason. This will not affect 
your usual medical care.  If you decide not to take part, this will also not affect you in any 
way. 
 
What will happen to me if I take part? 
The study doctor may have already explained the study at your clinic appointment. If not, you 
will be contacted soon by the research team to ask you if you are interested in taking part and 
will arrange to see you on the day of your colonoscopy, before the test. On the day, you will 
have an opportunity to ask any questions you may have about the study to the study doctor 
who will also be performing your colonoscopy. At this time, if you are willing to participate, you 
will be asked to sign a consent form. 
You will then have the colonoscopy in the same way and offered the usual choice of 
painkillers and sedatives. The colonoscopy tube will be inserted in the usual manner all the 
way to the caecum (the end of your large bowel). We then aim to look for abnormalities as we 
slowly bring the tube out. Just before we do this, we will decide whether we do this using the 
blue dye or not. The decision will be made using a special computer code.  
If you are to receive blue dye we will slowly pull the tube back 10 cm at a time, spraying the 
blue dye down the colonoscope, onto the lining and closely inspecting the lining for any 
abnormalities. If any abnormalities are found, we will take samples from them for further 
analysis. If any polyps are found, these may be removed. We will also take a series of 
samples from the bowel lining which looks normal. The tube will be gradually removed and 
this procedure will be repeated every 10 cm.  
If we decide not to use the blue dye, we will gradually pull back the tube 10 cm at a time and 
closely inspect the bowel lining. We will again be looking for abnormal patches, from which we 
will take samples and also a round of samples will be taken from the normal looking lining.  
At the end of the procedure you will receive the same care you would usually receive after a 
colonoscopy and be allowed to go home shortly after the procedure if you are well enough. 
   
 
Is there anything else I have to do? 
No, this study involves no extra visits to hospital either before or after the 
colonoscopy.  
 
What are the possible benefits of taking part in the study? 
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There will be no direct benefit to you from participating in this study. However, determining 
whether the new high-definition colonoscopies are as good on their own, compared with using 
the additional blue dye to detect abnormal patches, will help improve our understanding of the 
best way of looking for these abnormalities.  
 
Are there any risks in taking part? 
Having any form of colonoscopy test for any reason carries a very small risk of making a hole 
in the bowel. This risk is less than 1 in 1,000. The new colonoscopes carry no additional risk 
and are in widespread use for many endoscopy procedure of both the stomach and the large 
bowel. The use of the blue dye is entirely safe and is recommended by all the international 
gastroenterology societies. A very small amount is absorbed into the bloodstream and may 
make your urine or stool and light shade of green just for a day or so. This is entirely harmless 
and will return to normal. 
 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements. If you are harmed due to someone’s negligence, then you may have grounds 
for a legal action but you may have to pay for it. 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions [contact Dr Prashant Kant 
(07753659893). If you remain unhappy and wish to complain formally, you can do this through 
the NHS Complaints Procedure or PALS. Details can be obtained from either your doctor or 
the Leeds Teaching Hospital NHS Trust PALS centre at Tel: 0113 2067168  
 
Will my taking part in the study be kept confidential? 
If you consent to take part in the research, your own GP will be notified.  This means that 
other doctors in the same practice may be aware of your participation in the study. If you give 
permission, your medical records may be looked at by responsible people involved in this 
research on them. All information that is collected about you during the course of the research 
will be kept strictly confidential.  Any information about you which leaves the hospital will have 
your name, address and other identifiers removed so that you cannot be recognised from it.   
 
When your samples are analysed in the laboratory, they will be identified only by a code so 
that your name will not be known to laboratory staff. Samples will also be stored in a secure 
laboratory for future studies. Only the research team and your usual doctors will be able to link 
your tissue samples to your personal and medical details. 
We will aim to publish the results of the study in a specialist research journal so that other 
health care professionals can see the results. You will not be identified in such a report. 
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What will happen to my samples after the study is complete? 
Samples will be stored in a secure facility at Leeds Teaching Hospitals and University of 
Leeds, known as the research tissue bank. The samples may be used for further projects in 
the future after successful application for permission has been made from ethics committees 
for specific projects. Personal information will not be stored therefore you will not be identified 
in any future projects. 
Who has reviewed the study? 
The way that this study is being carried out was reviewed and given a favourable ethical 
opinion by the Bradford Research (Ethics) Committee. All research in the NHS is looked at by 
independent group of people, called a Research Ethics Committee, to protect your interests. 
This study has been reviewed and given favourable opinion by The Leeds  Research Ethics 
Committee. 
Who to contact for further information 
If you have any questions, please either ask the study doctor when you come for your 
colonoscopy. Alternatively, please contact either; 
Dr Noor Mohammed, Specialist Registrar in Gastroenterology, Leeds Teaching Hospitals on 
0113 3925811 or 07886577132 
Dr Venkat Subramanian, Consultant Gastroenterologist, Leeds Teaching Hospitals on 0113 
2062288 (secretary) 
If you decide to participate in the study, you will be given a copy of this information 
sheet along with a signed consent form to keep. Finally, we would like to thank you for 
reading this information sheet and considering participation in our study. 
 
Yours Sincerely, 
Dr Noor Mohammed 
Dr Prashant Kant 
Dr Venkat Subramanian 
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Appendix G: Consent form_HDWLE v/s HDCE 
CONSENT FORM 
 
Comparison of high definition colonoscopy versus high-definition 
chromoendoscopy in the detection of dysplasia in UC 
 
Name:                                                    DOB: 
Patient Identification No: 
 
  Please 
initial to 
confirm 
 
• I have read the information sheet for the above study. 
I understand that relevant sections of medical records/data collected during 
the study may be looked at by individuals from the University of Leeds, from 
regulatory authorities or from the NHS Trust, where it is relevant to my taking 
part in this research. I give permission for these individuals to have access to 
my records. 
___ 
•   
 
 
___ 
• I have had the opportunity to ask questions about the study, and to discuss it 
with family and friends. 
 
___ 
• I understand the purpose of the study, and how I will be involved. ___ 
• I understand, and accept, that if I take part in the study I will not gain any 
direct, personal benefit from it 
 
___ 
• I understand, and accept, that as is explained in the information sheet the  
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procedures which will be carried out may possibly have some side effects. ___ 
• I understand that all information collected in the study will be held in 
confidence and that, if it is presented or published, all my personal details will 
be removed. 
 
___ 
• I understand that my samples will be stored anonymously, identifiable only to 
the research team and my usual clinical team using a coded sequence, and 
may be used in future studies. No information regarding my personal details 
will be stored. 
 
___ 
• I confirm that I will be taking part in this study of my own free will, and I 
understand that I may withdraw from it, at any time and for any reason, 
without my medical care or my legal rights being affected. 
I give permission for my GP to be informed about my inclusion in this study 
 
 
___ 
___ 
 
 
I agree to take part in the above study. 
 
 ______________________
Signed 
_________________
_Date 
 ______________________ 
Person taking consent 
_________________
_ 
Date 
 ______________________ 
Researcher (if different  
from above 
_________________
_ 
. 
